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Summary
The aim of this project was to develop and introduce an MLST system for all 
meningococci causing invasive disease in Scotland starting in 1999, and subsequently 
throughout 2000, 2001 and 2002, MLST was introduced because strains within the 
electrophoretic type 37 (ET-37) complex, particularly those of ST ll, are often 
indistinguishable by traditional methods.
Nucleotide sequencing was performed on seven housekeeping genes and one outer 
membrane protein gene, porA. Data was analysed using databases and software 
available through the MLST website (www.mlst.net) and the porA websites 
(neisseria.org/nm/typing/porA/ and http://www.show.scot.nh8.uk/smprl/).
The introduction of MLST in Scotland was used as a routine method for the 
characterization of Neisseria meningitidis isolates in 1999. Coincidentally this is just 
prior to the introduction of the MenC vaccines in November 1999.
All N. meningitidis isolates fi-om invasive disease were analysed. This has given 
valuable data highlighting the effect the MenC has on Serogroup C disease and its 
decline over the length of the vaccination campaign. At the same time, the overall 
numbers of cases were monitored including the effect on serogroup B between 1999 
and 2002. This has been linked with historical data such as the typical cyclical pattern 
seen with serogroups B and C over the past decade. The incidences of ET-37 strains in 
serogroup C disease were assessed along with ET-37 strains of other serogroups. The
XXI
number of different ST’s isolated were monitored from the introduction of the MenC 
vaccine and this has been linked with their corresponding serogroups and subtypes.
A decrease in serogroup C disease was observed, however this has been accompanied 
by an increase in serogroup B disease. The occurrence of capsule switch has been 
assessed and applied to the whole data set for subsequent conclusion. This thesis 
clearly shows that MLST is extremely important for the surveillance of 
meningococcal disease over a period of years and, and that this study, has been 
effective not only in monitoring the impact of the MenC vaccines, but also providing a 
detailed genotypic representation of strains now commonly associated with disease.
In addition to enhanced sequence based characterisation, development of a fluorescent 
-based PCR protocol using N. meningitidis specific probes has been developed to 
markedly improved sensitivity and specificity of meningococcal DNA detection. 
Using an automated platform employing Taqman chemistiy, a detection system 
employs fluorescence-based chemistry that eliminates post PCR processing and has 
provided accurate real-time quantitative PCR. This development has identified 
previously undetectable quantities of meningococcal DNA, which have been 
subsequently used in a modified MLST system to produce genotypic results, which 
would not normally be created.
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Chapter 1 
Introduction
1.1 Developments in Molecular Biology
When a patient is suspected of having a life-thi*eatening infectious disease it is 
important to obtain as much microbiological information as possible. The pace with 
which developments have occuned in molecular diagnostic and characterisation tools 
makes it seem increasingly likely that molecular techniques will play an even larger 
role in the diagnosis of diseases such as meningitis and septicaemia. It is important to 
utilise molecular methods and realise their tremendous value not only in the 
investigation of basic scientific questions, but also in application to a wide variety of 
problems and limitations affecting all agents that can affect the human condition.
Such stimuli have helped this area progress and develop so that investigators can 
adequately address the genetic basis of biological function. This had slowly emerged 
over the latter half of the twentieth centuiy and has continually gathered pace over the 
last decade (Tait 1999; Boxer 2000). The development of genetics, specifically 
molecular genetics, has incorporated newly-evolving techniques and resulted in the 
start of the genetic revolution, which has led to a greater understanding of basic 
mechanisms of disease-causing pathogens (Boxer 2000; Pitt 2000). The primaiy 
motivation behind this unprecedented growth of molecular genetics was initially to 
benefit the understanding of human genetics. This has ultimately benefited other areas 
of molecular science including bacterial genetics (Pitt 2000). Virtually all major 
scientific disciplines will find molecular techniques increasingly necessary in areas
1
such as research, diagnosis, prognosis, and clinical management. This introduction 
will provide an up-to-date review on the molecular methods used in the laboratory 
confirmation of meningococcal disease (MD). It attempts to highlight the constant 
evolution and continual need for diagnostic procedures and molecular typing methods. 
Techniques required for the laboratory confirmation and characterisation of 
meningococci and the future prospects for the role of new technologies in such 
enviromnents are described. In addition, it provides a background for the description 
of the research project undertaken for this thesis.
1.2 Historical Perspectives of Meningococcal Disease
hr 1919, long before the introduction of antibiotics, Hemck famously described MD 
with the words “no other infection so quickly slays”. After more than 80 years of 
major developments in detection, characterisation and treatment, it still holds tme in 
recent times. (Knapp 1988a; Ellis-Pegler 2003).
Neisseria meningitidis (the meningococcus) is a causative agent of septicaemia and 
meningitis. Meningitis is classically described as inflammation of the meninges 
(membranes covering the brain and spinal cord). The symptoms typically include a 
severe throbbing headache, photophobia, accompanied by a stiff neck, fever and can 
lead to delirium and coma. Meningococcal meningitis may be rapidly fatal (Ferguson 
et al. 2002). It is notable for its rapid progiession and sometimes sporadic or epidemic 
presentation in both industrialised and developing countries. The unexpected 
appearance in previously healthy children and young adults has resulted in a gieat deal 
of public as well as medical attention. This has lead to a large amount of research
concerning diagnosis, characterisation, therapy and vaccine design (van der Ende et al. 
1995; Moiling et a l 2000; Riclimond et a l 2001; Pollard and Moxon 2002; Riordan et 
a l 2002; Tunkel and Scheld 2002; Welch and Nadel 2002; Wildes and Tunkel 2002). 
The symptoms mentioned above have been associated with disease as far back as 400 
BC, and subsequently recognised as possible meningitis (Fomara 1968). The cause of 
these conditions remained unloiown until the late 19^  ^century (Vieusseux 1806; Bovre 
1984). The development of bacteriology and science in general over the late 19^ '^  
centuiy culminated in microbiologists making repeated attempts to isolate organisms 
from patients who had died from suspected meningitis (Knapp 1988b). hr the 1870s 
the Italian physician, pathologist and neurologist Ettore March!afava in collaboration 
with Angelo Cell, identified and described micrococci within the cytoplasm of 
leukocytes, but they failed to culture any identifiable organisms (Marchiafava 1884). 
hr Vienna, seven years later, Airton Weichselbaum made a breakthrough with the 
isolation of a coccoid bacterium from meningeal exudates. There was initial caution 
however, given the previous isolation of pneumococci from other cases of meningitis 
(Weichselbaum 1887; Kiefer 1896). Nevertheless this coccoid bacterium was later 
tenned Diplococcus intracellularis meningitides and then Neisseria meningitidis 
(Figure 1.1).
Further investigations of small epidemics of meningitis were reported, with the same 
intracellular bacterium being isolated resembling the coccoid bacterium described by 
Weichselbaum. These investigations yielded a gram-positive chain of cocci similar to 
streptococci (Weichselbaum 1887). Because of low discrimination techniques 
between cultures at that time there was confusion over what was isolated and this 
continued for some time. The association between the meningococcus and meningitis
Figure 1.1 A pair of meningococci {Neisseria meningitidis) showing their pili 
and expressed capsules (With kind permission from Dr. Muhamed-Kheir Taha, 
National Reference Centre for Meningococci Unite Neisseria, Institute Pasteur).
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was eventually defined by a series of publications from Weichselbaum’s findings. It 
was only eight years after these initial findings that meningococci were isolated from 
lumbar punctures for the first time from patients clinically confirmed with meningitis 
(Knapp 1988b). Isolation of N. meningitidis and the introduction of techniques to 
obtain suitable clinical samples, such as the lumbar puncture, became routine clinical 
procedures and led the way for intraspinal immunotherapy in the early 20^ Centuiy. 
hnportantly, at about the same time it was hypothesized that patients suffering from 
meningococcal meningitis could also carry the organism in the oropharynx (Knapp 
1988b).
1.3 Meningococcal Disease
Since the isolation of meningococci over 115 years ago, studies have slowly 
highlighted the inten*elationships between meningococci and the host (Peltola 1983). 
Meningococci employ complex mechanisms involving molecular mimicry and 
immune evasion and subsequent circumventation of immune responses to elicit 
disease (van Deuren and Meis 2001). The three principal stages involved in MD will 
be discussed, namely mucosal colonization, adhesion and penetration causing 
systemic disease and inflammation of the meninges (meningitis).
1.3.1 Mucosal Colonization
MD starts invariably with the colonization of the upper respiratory tract, mainly the 
mucosa of the nasopharynx and the tonsils. Meningococci are transmitted via droplets 
fi'om a carrier of N. meningitidis. It is unloiown as to the exact parameters pertaining 
to the successful transmission of meningococci from one person to another (Townsend
et al. 2002). Concentrated numbers of people can facilitate transmission, and this is 
one factor considered to contribute to successful acquisition of N. meningitidis (hnrey 
et al. 1995; Cardenosa et al. 2001; Round et al. 2001; Simmons et al. 2001; Taha et al.
2002). Invasive disease has been observed quickly after the pathogenic clone has been 
transmitted to a new host. This can be in the form of upper respiratory symptoms days 
prior to the development of generalized disease however most individuals are 
asymptomatic during colonization of the nasopharynx (Faoagali 1995; Townsend et 
al. 2002). There are many risk factors associated with the onset of disease. These 
include general social and environmental factors (Krause et al. 2001; Nelson et al. 
2001), smoking (Fischer et al. 1997; Dobson 2000), passive smoking (lies et al. 2001), 
socioeconomic deprivation (Kriz et al. 2000; Stuart et al. 2002), viral infections 
(Harrison et al. 1991) and even snoring and speech problems (Robinson et al. 2001) 
although contradictory reports debate correlations between respiratory infections and 
its association with the onset on MD (Yusuf et al. 1999; Robinson et al. 2001)
In the absence of globally effective vaccination progi'ammes, meningococcal disease 
remains a major public-health problem worldwide. In Europe, North America, and 
Australasia most cases occur in young children and adolescents and are caused by 
group B or C meningococcal bacteria. The UK was the first countiy to introduce 
vaccination against meningococcal group C disease in November 1999 with a take-up 
assessed a year later at around 80-85% (Anon. 1999b; Miller et al. 2001; Ramsay et al. 
2001; B aimer et al. 2002; Finn and Lakslunan 2002).
As a consequence of this vaccination campaign a multi-centre collaborative study 
involving centres from around the UK compared the carriage of meningococcal
bacteria from around 14,000 students aged 15-17 years at the start of vaccination in 
1999, with around 16,500 students of the same age surveyed one year later (Maiden 
and Stuart 2002). The investigators report a two-thirds reduction in the carriage of 
group C meningococci after vaccination. This carriage study in combination with the 
implementation of the meningococcal C conjugate vaccines have highlighted its effect 
on meningococcal carriage and potentially protecting unvaccinated members of the 
population (Maiden and Stuart 2002).
1.3.2 Mucosal Adherence
Studies on human nasopharyngeal tissue cultures found that encapsulated, piliated 
meningococci adhere selectively to the microvilli on non-ciliated epithelial cells 
(Rayner et al. 1995) (Figure 1.2). To facilitate attachment to the epithelial cell layer, 
pathogenic meningococci possess class I and class II pili. Non-capsulated stains have 
a greater ability to adhere to these cell lines than capsulated strains (Rayner et al. 
1995; Virji 1996). They also down-regulate the ciliary activity and one reason 
explaining this is that local inflammatory response mediators such as tumor necrosis 
factor oc (TNF-oc) and/or interleukin-1 p (IL-lp) could be responsible for some or all 
the effects caused by colonization (Virji et al. 1996). It has also been noted that the 
class 3 outer membrane proteins tenned opacity proteins (Ope) may facilitate 
adherence to endothelial cells in vitro (Virji et al. 1995; McNeil and Virji 1997). In 
general the major attributes of pathogenic neisseriae for interaction with 
nonphagocytic cells are:
Figure 1.2 Neisseria meningitidis interaction with human epithelial cells. (With 
kind permission of Prof. Mumtaz Viiji, School of Medical Sciences, University of 
Bristol).
t Neisseriameningitidis
• Pilus mediated adhesion factors
• Pilin antigenic variation and modulation of adhesiveness through the 
formation of bundles of pili for cell-binding specificity including pilC proteins 
pilCl which are likely candidates as adhesions
• Opacity proteins including opa/class 5 proteins and opc, which are involved in 
adhesion and invasion. These are known to be very efficient in endothelial 
cells
• Capsule
• Lipo-oligosaccharide (LOS).
1.3.3 Mucosal Penetration
After the initial interaction of the meningococcus with the mucosal layer, there is a 
period of localised adaption and proliferation, hiterestingly, there are a number of 
routes by which meningococci can penetrate the mucosal layer (Pujol et al. 1997; van 
Deuren et al. 2000; Tinsley and Nassif 2001). Non-capsulated strains can enter by 
endocytosis tlnough non-ciliated epithelial cell lines without the use of membrane- 
bound phagocytic vacuoles (Nassif 1999). Alternatively, capsulated meningococci are 
transported via phagocytic vacuoles through the mucosal layer only 24 hours after 
initial colonization (Eugene et al. 2002). Although adhesion to endothelial cells is 
facilitated by pili, once the meningococci migrate from the upper mucosal layer these 
are down-regulated (Nassif 1999). Previous studies have highlighted a third route of 
entry through M cells present in the nasopharynx at the tonsillar sites. These could be 
used as a “mode of transport” as they continually endocytose material from the lumen 
and deliver it to a pocket formed by the basal plasma membrane consisting of 
lymphocytes and macrophages (Nassif 1999).
These stages can be summarized in several parts, the meningococcal subpopulation 
that expresses high levels of adhesive pilin and pilCl would have an advantage and 
therefore have the capacity to colonise the host. Following the production of high 
levels of Opc/Opa the organism is likely to access the epithelial bamer and cause 
disease. These processes require the down regulation of the capsule so that the outer 
membrane proteins (OMPs) are available for interaction. The expression of either 
pilin or opacity proteins could explain why a small population can harbor colonizing 
meningococci without causing disease. The high regulation of pilin can encourage 
colonization of the mucosal surface, but expression of Opc or an appropriate class 5 
variant is required for the meningococcus to cross the epithelial barrier (Figure 1.3) 
(Nassif 1999). Thus, production of adhesions without invasions could result in 
colonization, and the host would become one of approximately 10-20% of the 
population that carry K  meningitidis as a commensal organism on the nasophaiynx 
(Verdu et al. 2001).
Once in the bloodstream the meningococcus can multiply and cause systemic 
infection, which clinically displays as a rash on the skin where the blood vessels have 
ruptured causing hemonhaging. Patients who develop systemic meningococcal 
disease have a high risk of tissue damage, usually around the extremities, including 
the hands, fingers, feet and toes. Severe cases can result in amputations where lack of 
oxygen from damage to blood vessels has caused gangrene (Mele et al. 1997; Nolan 
and Sinclair 2001; Oostenbrinlc et al. 2002; Wheeler et al. 2003).
hiteraction of meningococci with the blood-brain barrier (BBB) can be achieved 
thi’ough the initial interaction with the cerebrospinal fluid (CSF) via the bloodstieam.
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Figure 1.3 Neisseria meningitidis interaction with the host (Adaptation from the 
WHO website: http://www.who.org/).
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This has been demonstrated with recovery of N. meningitidis from CSF after 
inoculation into the blood stream of animal models. It is also well established that 
after clinical presentation of classic meningitis, N. meningitidis can often be cultured 
from blood samples (Nassif et al. 2002). From the blood, the meningococcus can gain 
access to the meninges by crossing the capillaries of the meninges (Figure 1.4), either 
by transcytosis or by passage after disruption of tight junctions between cells (Hardy 
2000). After entry, the meningococcus can cause inflammation of the local site that 
clinically causes a whole range of symptoms including, as mentioned before, 
headaches, photophobia, stiff neck and nausea (van Deuren et al. 2000).
1.4 Historical Trends in Meningococcal Disease
During the early 20^  ^Century there were large epidemics of MD described thi'oughout 
the world, in New York between 1904-1905 (Counts and Petersdorf 1980), East 
Germany between 1905-1907 (Ballada 1990), Brazil between 1971-1972 (Barata Rde 
1988) and India in 1985 (Sarkar et al. 1987). Over thirty major epidemics of 
meningococcal meningitis also occurred throughout the world between 1971 and 1997 
(WHO 1998). Because of these large epidemics, European microbiologists developed 
agglutinating antibodies by immunising rabbits and horses with meningococci. 
Consequently, this led to the first human trials of anti-serum for the treatment of 
meningococcal meningitis. These initial human trials involved primary subcutaneous 
injections followed by further doses administered by intra-spinal injections. 
Preliminary reports showed a 67% survival rate compared with 70-80% mortality rate 
at the time (Rockowitz and Tunkel 1995). By 1908, several groups working in both 
the USA and Europe reported over 400 cases, which had been treated with
12
Figure 1.4 Neisseria meningitidis crossing the capillaries of the meninges
(With kind permission from Dr. Xavier Nassif, Faculté’ Necker Enfants Malades, 
Paris, France).
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meningococcal anti-serum and the mortality rate was reduced to approximately 25%. 
Although there were many side effects to this treatment and its mode of application, 
such as artirritis and skin emptions, this therapy remained in use until the 1930s 
(Schwartz et al. 1989).
Within the African Continent, epidemic meningitis has been laiown to occur for as 
long as within other areas of the world. It was reported from the West Coast of Africa 
by G. William in 1909 and has been present consistently since that time (Greenwood 
et al. 1984; Greenwood et al. 1985; Molesworth et al. 2002). From the early 1940s 
meningococcal disease has constituted a pennanent public health problem in many 
countries throughout the world however, by the 1960s it was no longer considered a 
serious problem in most European and North American countries. Unfortunately, this 
was not a trend miirored in some tropical countries, particularly those located in the 
African meningitis belt (Figure 1.5). During the 1970s epidemics were again 
commonplace throughout the world and meningococcal disease increased in a number 
of countries of the Americas, Asia and Europe. This pattern was characterised by 
recurrent epidemics and persistent sporadic disease. Significant increases in disease 
were observed in Mongolia and in the former USSR between 1973-1974 (Hjetland et 
al. 1990; Tsend et al. 1992), Argentina in 1974 (Anon. 1998a), Vietnam and Rwanda 
between 1977-1978 (Oberti et al. 1981; Vimont-Vicaiy and Rogerie 1983), Algeria 
and Chile in 1979 (Anon. 1998a), and in Brazil since 1971 (Anon. 1998a). From the 
early 1980s, epidemics of meningococcal disease have occurred in Chile in 1986, 
Faroe Islands between 1980-1981, but mainly tlnoughout Africa, from Ethiopia in 
1989 in the East, to the Côte d’ Ivoire in 1983 and 1985 in the West, including Sudan 
in 1988. This culminated in more than 30,000 reported cases during 1988 in Sudan
14
Figure 1.5 The “meningitis belt” of Central Africa.
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and over 40,000 reported cases in Ethiopia in 1989 (Anon. 1998a). In the 1990s the 
epidemic spread in West Africa, with more than 25,000 reported cases in Niger during 
1995 and more than 16,000 cases the following year, hr total an estimated 800,000 
cases have been observed during a 20-year period between 1970 and 1992 and over a 
further 200,000 cases were obseiwed during 1995 and 1997 (Anon. 1998a). This level 
has had significant effects on the spread of the disease outside its normal boundaries, 
and if this is a true reflection, it could be due to increased mobility of the population, 
or the introduction of a new meningococcal strain into susceptible populations.
1.5 Global Trends in Meningococcal Disease
Meningococcal disease was described as far back as 1805 with an outbreak in Geneva, 
Switzerland. The causative agent was not identified for a further 82 years. The 
documentation of meningococcal disease has highlighted major global outbreaks at 
the time of both World Wars One and Two. Epidemics have been periodically 
reported on the African continent since the turn of the 20^ ’’ centuiy (Norheim et al. 
2000; Anon 2001a; Lewis et al. 2001; Pollard and Maiden 2003). In Asia, major 
epidemics have been documented during the past 30 yeais in China, Vietnam and 
Mongolia (Skalova 1984; Achtman et al. 2001). There have also been epidemics in 
Europe and in both North and South America during the past 30 years, but these have 
not reached the high incidence levels of epidemics documented in sub-Saharan Africa 
(Pollard and Maiden 2003). The characterisation of meningococci from different 
continents shows trends that are closely associated with these regions of the world. 
The major epidemics in the meningitis belt are commonly associated with serogroup 
A disease, whereas in recent years the most common cause of meningococcal disease
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in the United States of America has been serogroup Y (Lingappa et al. 2001; 
Rosenstein et al, 2001b). hi Europe, a fluctuation between two serogroups, namely 
serogroup B and serogioup C meningococci, has been well documented (Cartwright et 
ai. 2001).
1.6 European Trends in Meningococcal Disease
In many European countries, serogroup B predominates, while in others such as the 
Czech Republic, United Kingdom and the Slovak Republic, serogroup C has been 
more common (Noah 2001). Serogroup C has been known to be responsible for case 
clusters and outbreaks, with a high morbidity and mortality rate, especially among 
certain age gioups such as 16-24 years of age (Round et al. 2001). This, combined 
with its ever-increasing responsibility in causing MD prompted the development and 
implementation of a UK national vaccine campaign. This campaign involved the 
administration of a meningococcal serogi'oup C conjugate vaccine (MenC) in 
November 1999 initially to high-risk groups (under 17 year old) and then to all ages 
less than 24 years of age (Miller et al. 2001). Serogroup W135 has recently emerged 
as a potential source of outbreaks, and vaccination against this serogi'oup is now 
mandatory for all persons traveling from European countries to high-risk regions, such 
as Saudi Arabia for the annual Hajj pilgrimage (Hahne et al. 2002; Wilder-Smith et al.
2003).
Meningococcal disease incidence rates in Europe can be giouped into three main 
categories, categoi-y 1 containing incidence of 3.0 cases/ 100,000, category 2 
containing incidence of 1.0-2.9 cases/100,000 and category 3 containing incidence of
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<1.0 cases/100,000 (Cartwright et al. 2001) (Table 1). Due to the variation in 
individual specimen culturing and disease reporting practices, the amount of data that 
can be compared and interpreted is limited. However there are efforts in place to 
construct a pan-European infrastructure for the investigation and surveillance of 
meningococcal disease (EuMenNet), which will be built up for the analysis of the 
meningococcal population structure and the dynamics of the spread of the causative 
organism, K  meningitidis, this now includes the European Meningococcal MLST 
Centre (EMMC) part of the European Meningococcal Epidemiology Centi e (EMEC). 
In addition, the European Union Invasive Bacterial Infections Surveillance (EU-IBIS) 
project has established surveillance networks within the European Union (EU) for 
invasive H. influenzae and N. meningitidis disease in 2000. The overall aims of this 
project are to improve epidemiological information and laboratory capacity to 
characterise isolates of these two invasive bacterial infections within the EU. These 
networks were established with the assistance of existing networks within Europe. 
Specialist microbiologists and epidemiologists from each of the 15 EU countries, and 
the Czech Republic, Iceland, Israel, Malta, Norway, and Australia are collaborating to 
achieve the sui-veillance network aims, including improvements to the laboratory 
capacity to characterise accurately the isolates of H. influenzae and N. meningitidis 
using standardised methods and to evaluate the impact of vaccination with conjugate 
vaccines on the epidemiology of H. influenzae and N, meningitidis. From recent 
literature the epidemiology of meningococcal disease during 1998/1999 was chosen as 
a suitable overview. The incidence of disease was highest in the Republic of Ireland 
(7.9 cases/100,000) with Malta and Scotland above 6.0 cases/100,000. In contrast, 
Poland and Romania had the lowest incidence (0.1 cases/100,000). The degi'ee of 
variation could be due to underreporting, and coimtries that are classified as category
18
Table 1.1 Incidence of meningococcal disease in Europe, during 1998-1999
(adapted Jfrom Cartwright et al, 2001).
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3, could have a high underreporting rate compared with countries within category 2 
and 1 (Kremastinou et al. 1999a; Achtman et al. 2001; Cartwright et al. 2001; Alcala 
et al. 2002).
1.7 United Kingdom Trends in Meningococcal Disease
Meningococcal disease trends within Scotland are similar to those experienced by 
England and Wales (Fallon et al. 1984; Fallon 1988; Smart and O'Brien 1997; Clarke 
2002b; Kyaw et al. 2002c). However, Scotland has a different laboratory 
infrastructure compared with England and Wales and surveillance has been conducted 
in Scotland on an ad hoc basis from the early 1970s. Since 1993 funding for a 
Scottish Meningococcus Reference Laboratory has been made available to provide a 
national service relating to the laboratoiy confirmation of meningococcal disease and 
characterization of meningococci. Between 1993 and 2002, there have been a total of 
2552 notified cases of meningococcal disease in Scotland (Figure 1.6) compared to 
over 1446 clinically notified cases in just five regional health authorities in England in 
1998 (Clarke 2002b; Clarke et al. 2002; Davidson 2002).
From 1999 to 2002 there has been a decline in the number of meningococcal 
septicaemia notified cases in England and Wales. In 1999 there were 1822 cases 
compared to 842 in 2002 a decrease of over 50% over four years. Within Scotland, 
culture based methods have provided a laboratory confirmation of 1051 cases. Since 
1993 there has been a steady increase in notified cases; this peaked in 1999 with 349 
cases, and subsequently deceased to fewer than 100 by 2002. Within England and 
Wales the number of notified cases can be observed from as far back as 1912 when
20
Figure 1.6. Meningococcal infections in Scotland from 1993 - 2002 (adapted 
ftom Smait et al, 1995,1996,1998, Clarke et al 1999,2001,2002),
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cerebrospinal fever was made statutorily notifiable. Coincidently, this monitoring 
system was in place to obsei-ve the gi'eat outbreaks during World War One when there 
were 3496 notified cases of MD in England and Wales alone. This level of notified 
cases remained high for the duration of both World Wars One and Two. Throughout 
World Wars One and Two many countries experienced large outbreaks of MD 
including Australia, Canada, Germany, New Zealand and the United Kingdom. The 
outbreaks were confined mainly in military troops whose over-crowded living 
conditions were ideal for the spread of MD (Gordon 1915; Abbott et al. 1985). After 
World War Two the number of notified cases decreased hom over 12,000 cases in 
1940 to over 300 cases in 1966, during this time there was a slight increase between 
1950 and 1952. This level remained constant until 1967 when the number of cases 
increased dramatically with over 1200 in 1974. With enlianced suiweillance systems 
in place present day levels are over 11,000 clinically diagnosed cases within England, 
Wales and Northern h'eland. This coirelates to 8.0-9.2 per 100,000 people 
(Shigematsu et al. 2002) (Figure 1.7).
Over the past 30 years, the UK has observed a cyclical pattern of dominance in the 
meningococcal disease population between serogroup B and serogroup C 
meningococci. Thi'oughout the 1990s there was a significant increase in serogroup C 
disease. This was more commonly observed in older teenagers with a much higher 
case fatality rate than with other age gioups. This continuing increase in serogroup C 
disease prompted the development and introduction of a serogroup C conjugate 
vaccine (MenC). This was successfully introduced to the UK population in November 
1999. Subsequent effects of the MenC have shown a decrease in serogroup C disease
22
Figure 1.7 Number of notified cases in England and Wales from 1912 -  1983
(adaption from Abbott et al 1985).
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with the meningococcal disease population in the UK in 2003 predominantly 
serogroup B meningococci.
1.8 Periodicity and Seasonality of Meningococcal Disease
The temporal distribution of meningococci has been shown in the increased number of 
cases observed over the winter period in developed countries such as the UK (Wylie et 
al. 1997; Clarke et al. 2002). Climatic factors seem to play an important role in the 
occurrence of meningococcal disease, hi tropical and temperate regions such as South 
America and central regions of Africa the transition from rainy to diy seasons are 
thought to be influential (1996; Weiss et al. 2001). This has been observed with an 
increase in incidence in the early di*y season, when the climate is hot, diy and dusty. 
The incidence of MD peaks at the end of the dry season and virtually disappears at the 
start of the rainy season (Lapeyssonnie 1963; Peltola 1983; Achtman 1995; Riedo et 
al. 1995). In Africa this central region relating to high incidences of disease is called 
the “meningitis belt” (Figure 1.5) (Molesworth et al. 2002). Within this area, 
epidemics can last for as long as two to thiee dry seasons each lasting several months, 
separated by the intermittent rainy seasons. However, in small towns and villages, 
these epidemics can recede within a few weeks of initial onset (Hart and Cuevas 1997; 
Greenwood 1999; Norheim et al. 2000; 2001b; 2001a).
Within England, Scotland and Wales, doctors and medically trained staff have been 
required by statute since 1969 to notify clinically diagnosed cases of meningococcal 
meningitis and since 1989, cases of meningococcal septicaemia, to the proper officer 
of the local authority. In England and Wales this is the Consultant in Communicable
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Disease Control (CCDC) and, in Scotland the Consultant in Public Health Medicine 
(CPHM). hiitial detection is perfonned at the hospital laboratories. Subsequent 
characterisation including serogrouping, typing, sub-typing and antibiotic resistance 
profiles are conducted at the national reference laboratories, such as the 
Meningococcal Reference Unit for England and Wales (MRU) or the Scottish 
Meningococcus and Pneumococcus Reference Laboratoiy (SMPRL). Data on such 
cases are sent each week to the Office for National Statistics in England and Wales or 
the Scottish Information and Statistics Division (ISD) in Scotland and the 
Communicable Disease Surveillance Centre (CDSC) in England and Wales or the 
Scottish Centre for Infection and Enviromnental Health (SCIEH) in Scotland. This 
data is published in the Communicable Disease Report Weekly (CDR Weekly), from 
the Health Protection Agency (HPA) in England and Wales and Scottish Centre for 
Infection and Environmental Health (SCIEH) weekly Report from SCIEH in Scotland.
This infi'astructure provides an excellent representation of meningococcal disease and 
its distribution tliroughout the year (Figure 1.8). With coordination between 
laboratories and communicable disease surveillance centres, the confinnation of 
disease along with the identity and characterisation can be correlated with detailed 
patient data. Trend analysis can then be undertaken and meningococcal disease 
distribution data tliroughout the country can be produced. From these surveillance 
systems, England and Wales, Scotland and Europe (tlu'ough the European 
Surveillance Network (EU-IBIS)) display repeated patterns of meningococcal disease 
tliroughout each year, and within a single year a significant increase in incidence 
during the cooler, dryer months. This pattern is similar in other countries such as 
Australia, Canada, Italy and New Zealand (Fallon et al. 1984; Ballada et al. 1991;
25
Figure 1.8 Management of meningococcal disease notifications in Scotland.
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Jackson and Wenger 1993; Squires et al. 2000; Cartwright et al. 2001; Pollard and 
Scheifele 2001; Kyaw et al. 2002b; Lindsay et al. 2002; Moura et al. 2003).
1.9 Meningococcal Vaccines
N. meningitidis (the meningococcus) remains an important cause of meningitis and 
septicaemia worldwide and, in many countries, serogi'oup B meningococci account for 
a large percentage of disease for which there is no effective vaccine (Rosenstein et al. 
2001a; Vermont and Van Den Dobbelsteen 2003). In the 1960s, vaccines consisting 
of purified polysaccharide antigens were developed against four of the five pathogenic 
serogi'oups (A, C, Y and W135) (Gotschlich 1985). These vaccines were highly 
effective in adults but are not efficacious in infants and young children. Although 
plain polysaccharide or conjugate vaccines are now available against serogi'oups A, C, 
Y and W135 (Rappuoli 2001a) there is an urgent need for a conjugate vaceine against 
the serogroup B meningoeoccus (Vermont and Van Den Dobbelsteen 2003; Zagursky 
et al. 2003; Capecchi et al. 2004). However, there are problems with the design of a 
capsule-based vaccine because the meningococcal polysaccharide is identical to a 
human carbohydrate (a(2^8) W-acetyl neuraminic acid or polysialic acid and is 
therefore poorly immunogenic and induces only a transient antibody response (Finne 
et al. 1987; Hayrinen et al. 1995). The development of a serogi'oup B vaccine 
therefore requires a different approach, perhaps based on an essential virulence gene 
from data gained through the genome sequencing projects (Rappuoli 2000; Rappuoli 
2001b; Zagursky et al. 2003; Capecchi et al. 2004; Newcombe et al. 2004). Dining 
sueh development, there is the option to develop vaccines based on other antigens, the 
most studied of which are those based on outer membrane proteins (OMP) (Ala'
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Aldeen et al. 1996; Rosenstein et al. 2001a). Although OMP-based vaceines are not 
the final solution for combating serogi'oup B meningococcal infection, they may 
provide a short-term solution and have shown gi'eat promise for the control of 
serogi’oup B meniningococcal infection (Rappuoli 2001a). OMP’s of classes 1 to 5 
have been studied as potential vaccine candidates (Tsai et al. 1981). The class I PorA 
and class 2 PorB proteins have been studied most because they are used as phenotypic 
markers in the characterisation of meningococci, for the sero subtype and serotype, 
respeetively. These proteins are variable because they are antigens exposed on the 
meningococcal cell surface; some regions of the proteins are hypervariable.
A two-dimensional structural model has been predicted for the meningococcal PorA 
protein. It consists of eight exposed surface loops (I to VIII) (van der Ley et al. 1991). 
Most variability is thought to occur in variable regions 1 and 2 (VR’s 1 and 2) whieh 
correspond to loops I and IV, respectively (Maiden et al. 1991; van der Ley et al. 
1991; McGuinness et al. 1993). Serosubtype-specific monoclonal antibodies react 
with peptide epitopes located in these loops and therefore serosubtyping is used to 
identify these PorA VR epitopes. A widely-recognised nomenclature is used which 
has been recently updated to take into account new data now available thi'ough DNA 
sequence typing. A novel subtyping nomenclature has also been proposed (Sacchi et 
al. 1998a; Maiden et al. 1999).
Experimental vaccines based on OMV’s have demonstrated that bactericidal 
polycloncal antibodies are mainly directed against PorA. Over the last decade, single 
and mutli-valent vaccines have therefore been developed (Wedege and Michaelsen 
1987; Rosenqvist et al. 1995; Peeters et al. 1996; van der Voort et al. 1996). These
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have been based on the most prevalent serosubtypes eirculating in distinct 
geographical areas (Van Der Ley and Poolman 1992; Peeters et al. 1996; Perkins et al. 
1998; Cartwright et al. 1999; Tappero et al. 1999; de Kleijn et al. 2000a) because such 
proteins are antigenically highly variable and an OMP vaccine cannot protect against 
all types and subtypes of N. meningitidis. For example, the reeombinant hexavalent 
PorA OMV vaccine developed by the Institute for Public Health and the Environment 
(RIVM) in the Netherlands is comprised of P I.7, 16; P I.19, 15; P I.5, 2; PI.5c, 10; 
PI. 12, 13 and PI.7, 4 (Rouppe van der Voort et al. 2000). This composition accounted 
for over 80% of UK meningococcal case isolates in 1996 (Cartwright et al. 1999). The 
vaecine has shown promising results in phase I and phase II clinical trials (Peeters et 
al. 1996; Cartwright et al. 1999). Therefore, selected OMV’s must be used based on 
the prevalent types and subtypes in a given country.
To develop such vaccines, high quality data must be gained to determine such 
prevalence. Although it is thought that VRl and VR2 are the most variable regions 
within PorA, there is little data to support this. A number of new VR3 serosubtypes 
have been described (Aiiiin et al. 1998; Moiling et al. 2000; Riesbeck et al. 2000; 
Moiling et al. 2001; Clarke et al. 2003) which suggest that more data is required to 
deteiinine the importance of this variable region for both disease suiweillance and 
vaccine development. As most laboratories use monoclonal antibodies for the 
characterisation of meningocoeei to serotype and serosubtype level, new types and 
subtypes are missed unless nucleotide sequencing is performed.
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1.10 Identification of Meningococci -  The Gold Standards
Historically, culture has been used for the characterisation of meningococci. Once 
successfully isolated and cultured, the meningococcus can be examined by 
microscopy after Gram-staining as well as for oxidase production and sugar 
degradation profiles. Meningococcal characterisation can be obtained with subsequent 
sero-grouping, sero-typing and sub-typing of the capsule and outer membrane proteins 
respectively (Anon 1998d; Anon 1999a). This is accompanied by other tests sueh as 
antibiotic susceptibility profiles (Wall 2001). These clinical samples for culture are 
usually taken from either a non-invasive site such as the nasopharynx or invasive sites 
such as CSF and blood.
Culture has long been the “gold standard” of diagnosis and confirmation for MD, but 
with the advent of antibiotics and rapid and effective treatments, it is not always 
possible to obtain a culture for characterisation. Cultures are often negative due to the 
rapid administration of antibiotics before hospital administration. There are many 
reasons why isolation of meningococci could fail, including the transport media used, 
the isolation media used and the techniques used for culture isolation. These are a few 
reasons why non-culture detection and characterisation is being recognised as an 
increasingly important tool for reference laboratories to maximize the chances of 
confirmation followed by characterisation (Diggle et al. 2001a; Diggle 2003).
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1.11 Laboratory Confirmation of Meningococcal Disease
Molecular biology by its veiy nature embraces modem molecular teclmiques. These 
include detection, isolation, identification and characterisation of pathogens such as N. 
meningitidis (van Deuren et ah 2000). Only five of the thirteen recognised serogroups, 
A, B, C, W135 and Y are at present considered clinically important worldwide (Horby 
et ah 2001; Clarke et ah 2002). Control of all these serogi'oups by methods such as 
immunisation has yet to be accomplished (2000b; 2000a; Pizza et al. 2000; Morley 
and Pollard 2001) consequently, modem laboratories utilize a wide range of 
teclmiques to provide infoi*mation relating to the diagnosis and monitoring of 
infections caused by meningococci (Ragunathan et ah 2000; Clarke et al. 2001a; 
Diggle et ah 2001b; Clarke et ah 2002).
Typing of microorganisms has traditionally involved the subdivision of a single 
species utilising a standard set of characteristics. Historically these have included 
culture, microscopy, biochemical characterisation, antibiotic susceptibility and antigen 
characterisation (Pitt 2000). These typing methods are usually based on phenotypic 
markers, biological and biochemical pathways and some can be species speeific. This 
can be a limitation because environmental pressures may adversely affect these 
fundamental criteria and compromise the reliability and reproducibility of the different 
methods (Williams 1999). A good example of this is the effect on the expression of 
outer membrane genes, whieh can be used for the characterization of meningococci 
(Urwin et ah 1998a; Urwin et ah 1998b; Vogel et ah 2000; Arreaza et ah 2001; 
Meyers et ah 2003). The necessity for molecular procedures based around DNA 
analysis can offer a more stable and universal approach to typing N. meningitidis.
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These new approaches are used increasingly in microbiology laboratories, and can 
complement the historical phenotypic methods (Yakubu et al. 1999; Diggle et al. 
2001b). In the not too distant future, genotypie typing methods will not only 
supplement but may also replace existing typing methods (Olive 1999; Diggle et al. 
2001b). The basis of DNA typing methods is the differentiation in nucleotide 
variations. The only drawback from providing greater discrimination is the vast 
amount of information DNA typing methods inevitably provide.
1.12 Phenotypic Analysis of Neisseria meningitidis
The laboratory confinnation of MD is veiy important as it provides valuable 
information for therapy, short-temi management of case clusters and eontacts, and 
long-teim epidemiological data. This can be complemented by the use of entranced 
surveillance schemes and are particularly useful for monitoring important situations 
such as epidemics or national vaccine programmes (Clarke 2002d). The laboratoiy 
confinnation of MD is usually achieved using antigen detection, culture and 
serological methods. Traditionally, the characterisation of N. meningitidis has 
involved the analysis of phenotypie markers such as the capsule and outer membrane 
proteins using latex agglutination, co-agglutination and enzyme-linked 
immunosorbent assays (ELISA) methods (Clarke et al. 2002). However, these 
methods are not universally applicable to all circumstances when attempting to 
eharacterise meningococci. Recent developments in DNA analysis, together with the 
natural limitations of phenotypic methods, have resulted in a natural evolution 
towards genotypic procedures (Stmelens 1996; Ragunathan et al. 2000; Clarke 
2002a).
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1.12.1 Specimens
In patients with suspected meningococeal disease, specimens from various sources 
such as blood, cerebrospinal fluid (CSF), eye and throat can be obtained (Demina and 
Orlova 1981). Skin scrapings and post mortem samples can also be obtained where 
lesions are present but this is not commonly practiced (Barker et al. 1999; Fischbacher 
et al. 2001; Anon 2002b). Isolation of different strains from different areas of the host 
is uncommon. It is therefore unlikely that a nasophai*yngeal isolate from a suspected 
case of meningococcal disease will be attributed to their nomial nasopharyngeal flora 
and is more likely to be attributed to causing meningococcal disease, if all invasive 
samples are negative. Usually a number of different sites are used to isolate 
meningococci and this is considered sufficient to limit attributing commensal strains 
as disease causing within the same patient (Olcen 2001). National guidelines are 
available in most countries explaining the protocols required for successful isolation 
of A. meningitidis (Anon 1998d; Anon 1999a; Anon 2002b).
1.12.2 Bacterial Culture
N. meningitidis are less nutritionally fastidious than other Neisseria species sueh as 
N. gonorrhoeae but are still likely to be present only in comparatively smaller 
quantities in clinical samples (Hackett et al. 2002). It is eommon for isolates of 
N. meningitidis or Neisseria species, required for serological characterisation to be 
transported on heated blood (chocolate) agar slopes or transport swabs. Subcultures 
are taken from organisms on these transported slopes or swabs to obtain fresh colonies 
for testing. Neisseria species are usually sub-cultured onto different types of agar 
plates, such as Columbia agar with 5% horse blood and heated Columbia blood agar 
(Isenberg 1992; Anon 1998d; Anon 1999a; Mun*ay 1999). Inoculated plates are
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commonly incubated at 37°C for greater than 18 hours air mixed with a final 
concentration of 5-10% carbon dioxide. Isolates taken from areas such as the 
nasopharynx can be inoculated onto selective media, which inhibit the growth of a 
large number of unrelated residing commensal species (Olcen 1979; Anon 1998b). 
After incubation colonies are characteristically pale grey and approximately 1mm in 
diameter (Olcen 2001). Furthermore all isolates can also be stored for future analysis 
in self-contained storage systems at -70^C (Anon 1998d; Anon 1999a).
1.12.3 Antimicrobial Susceptibility
The search for antibiotics began in the late 1800s, with the growing acceptance of the 
geim theory of disease, a theory which linked bacteria and other microbes to the 
causation of a variety of ailments. As a result, scientists began to devote time to 
searching for drugs that would kill these disease-causing bacteria (Wainwright 1990).
Penicillin along with the discovery of sulphonamides in 1932 both were widely used 
for bacterial infections (Braude 1953). This success led scientists to intensify the 
development of new antibiotics that could treat other bacterial diseases. 
Sulphonamides, first used in epidemics in World War II, were given as a two-day 
course of treatment which was very effective in eliminating carriage strains (Scheld 
and Mandell 1984). Eventually, resistance to sulphonamides became commonplace 
(Abbott et al. 1985) and to combat antibiotic resistance, chemical modifications and 
derivatives were produced to prevent widespread resistance (Wainwright 1990). By 
early 1945, in an inteiwiew with The New York Times, the British scientist and the 
discoverer of penicillin, Alexander Fleming warned of the misuse of antibiotics such 
as penicillin that could lead to selection of resistant forms of bacteria (Anon 1945).
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Antimicrobial susceptibility testing is also important so that effective therapies can be 
used for patients and their contacts. The sulphonamides introduced in the late 1930s 
prompted a decline in the meningococcal mortality rate (Scheld and Mandell 1984) 
until significant resistance was noticed in the 1950s and 1960s. This increase in 
antibiotic resistance necessitated the switch to new antibiotics such as penicillin 
derivatives and chloramphenicol. Nevei-theless, in recent years increased resistance 
has been reported in both penicillin and chloramphenicol (Van Esso 1987; Sutcliffe 
1988; Jackson 1994; Galimand 1998; Kyaw et al. 2002a). In the United Kingdom in 
the early 1990s over 36% of sero group B and 42% of sero group C strains were 
resistant to sulphonamides (Oppenlieim 1997). Therefore, imless an antibiotic 
susceptibility profile has been carried out on the causative organism, sulfonamide is 
not considered the first choice antibiotic treatment (Oppenheim 1997). Several 
different laboratory methods can be used for meningococcal antibiotic susceptibility 
testing (Hughes et al. 1993; Gomez-Hemiz et al. 1995). These methods are based on 
the evaluation of minimal inliibition concentrations (MIC) by methods like the E-test 
(Hughes et al. 1993; Marshall et al. 1997), agar dilution, and disc diffusion (Il'ina 
1992). In addition, slight decreases in penicillin and rifampicin susceptibility have 
also been observed in other countries throughout Europe and North America. (Bellete 
et al. 1994; Ringuette et al. 1995; Enting et al. 1996; Richter et al. 2001; Kyaw et al. 
2002a). For cases involving penicillin-resistant strains, broad-spectmm 
cephalosporins such as ceftriaxone are recommended because of the resistance 
reported in both penicillin and chloramphenicol (Van Esso 1987; Sutcliffe 1988; 
Jackson 1994; Galimand 1998; Kyaw et al. 2002a). As a prophylatic in contacts with 
meningococcal disease (Richter et al. 2001) rifampicin is the most widely used 
chemoprophylactic agent at present, as many studies throughout the world have shown
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little resistance to date. A standard course will eradicate carriage in over 70% of 
contacts (Begg 1995; Simmons et al. 2000).
In recent years, the primary treatment for meningococcal disease has been penicillin G 
or ampicillin in invasive cases (Anon 2003). Chloramphenicol is an alternative in 
developed countries because it is inexpensive and stable. The most frequently 
recommended antibiotics used where contact has been noted between persons and an 
invasive case(s) are ciprofloxacin or rifampicin (Green and Tillotson 1997; WHO 
1998; Wall 2001). There has been a long-standing debate as to whether bactericidal 
antibiotics may increase the levels of LPS thus up-regulate inflammatory reactions 
(Shenep 1986). Treatment of meningococcal meningitis is similar to that of patients 
presenting with meningococcal septicemia (Anon 2003).
It is not uncommon to give broad-spectrum treatment for all meningeal pathogens 
including K  meningitidis before identification and characterisation is known. The 
most widely used combination of antibiotics remains penicillin and chloramphenicol. 
Over the past few years, third generation cephalosporins such as cefotaxine and 
ceftriaxone are considered on eases as first-line treatments due to the increased 
resistance of H. influenzae strains to chloramphenicol and the increased resistance of 
meningococci to penicillin (Oppenheim 1997; Wilcox and Modi 2000). The 
advantage with third generation cephalosporins is the high activity towards all 
common meningeal pathogens except Listeria monocytogenes, good penetration into 
the cerebro-spinal fluid (CSF) and ease of administration either once, twice or tliree 
times a day depending on the particular cephalosporins. They can also be used with 
pregnant women and young children (Tunkel and Scheld 2002). A, meningitidis was
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previously considered extremely susceptible to penicillin, with most isolates showing 
minimal inliibitoiy concentrations of 0.06pg/mL. However, meningococcal isolates 
with decreased susceptibility to penicillin were reported from carriers over 30 years 
ago (Martin 1964). Since then, clinical meningococcal isolates with decreased 
susceptibility to penicillin have been widely described in many countries (Sutcliffe 
1988; Saez Nieto et al. 1990; Tzanakaki et al. 1992; Woods et al. 1994; Blondeau et 
al. 1995). If a meningococcus is isolated and eharacterised as penicillin resistant, 
treatment can be easy tailored to suit the susceptibility profile of the organism and 
other antibiotics such as cephalosporins can he administered.
Seven days is generally considered adequate parenteral therapy of both meningococcal 
meningitis and septicemia, although this is dependent on several factors including the 
severity of the disease and patient response to treatment (Anon 2002b; Singhi et al. 
2002). Therapy can therefore be shorter in the case of a good patient response and 
mild disease or of longer duration in cases where complications are evident including 
brain abscesses, prolonged fever or subdural empyaema (Anon 2002b). One 
drawback of third generation cephalosporins is the expense. They are still more 
expensive to administer than the older generation penicillin and chloramphenicol 
(Wall 2001; Singhi et al. 2002). This has ramifications on developing countries and 
thus in poorer countries penicillin remains the common treatment for meningococcal 
meningitis and septicemia (Molesworth et al. 2002). Chloramphenicol is not as 
coimnon even though it is considered the choice antibiotic when clinical presentation 
without the charaeteristic rash is observed (Tondella et al. 2001). Chloramphenicol 
has other benefits including its flexibility of administration, either intravenously or 
intramuscularly, and in addition the oral route may be considered in improving cases
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(Tondella et al. 2001). Several antibiotics can be used for close contact and persons 
connected with meningococcal disease for suceessful eradication of nasophaiyngeal 
carriage as briefly stated earlier.
1.12.4 Biochemical Identification
In combination with biochemical techniques, basic teclmiques are still used in 
diagnostic laboratories. These make use of the specific biochemical composition of 
microbial structures, for example Gram staining using Gram and AO (acridine orange) 
stains according to defined protocols (Anon 1998d; Anon 1999a). Further to this 
simple microscopy can identify meningococci on the basis of their characteristic 
biochemical Gram stain, which highlights the pink-stained gi'am-negative diplococci 
ananged in pairs (Isenberg 1992; Mun'ay 1999).
N. meningitidis utilizes glucose and maltose which is used as a standard biochemical 
identification of the bacterium using commercial or non-commercial reagents. These 
are common and simple carbohydrate utilization tests for identification based on the 
biochemical characteristics of acid production by the meningococcus. 
Simultaneously, use of other sugars such as lactose and sucrose can identify other 
Neisseria species like N. lactamica and N. gonorrhoeae. Spurious results can occur 
and commercially available tests such as API NH, which incorporate several specific 
biochemical reactions can be used to speciate and sub-speciate, identifying to genus 
and species level.
1.12.5 Capsular Grouping
Rapid tools for the non-culture diagnosis and serogrouping determination in cases of
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meningococcal disease are crucial for effective patient treatment, contact management 
and epidemic logieal surveillance. Sero grouping of meningococci is important and 
often relies on accurate and sensitive methods for the characterisation of all or part of 
the polysaccharide capsule (Figure 1.9). The main serogroups of interest within 
Europe (B, C, Y and W135) boast a polysaccharide capsule which is composed of 
polysialic acid and are biochemically considered similar (Lewis et al. 2003). For 
example the capsule chemical composition of serogroups B and C are a2-8 linked 
sialic acid and a2-9 linked sialic acid, respectively, and serogroups Y and W135 are 
A-acetylneuraminic acid and D-glucose, and A-acetylneuraminic acid and D- 
galactose, respectively. All these serogroups with the exception of B can be O- 
acetylated or de-O-acetylated.
The gene cassettes of all the capsules contain four open reading frames (ORFs), {siaA, 
siaB, siaC and siaD) which code for different sialytransferase genes. From extensive 
studies the siaD sequence of serogroups B and C are individually distinct but are 
considered genetically related. The nucleotide sequence differs significantly from 
serogroups Y and W135 which are highly homogenous with each other even though 
they encode a similar protein. The capsular nucleotide sequence of serogroup A 
differs from the other disease-associated serogi'oups B, C, Y and W135. The capsular 
polysaccharide of serogroup A isolate is composed of repeating units of (a 1-^6)- 
linked-A-acetyl-D-maimosamine-1-phosphate (Swartley et al. 1998). This is in 
contrast to the common capsule types containing sialic acid (Claus et al. 1997). The 
capsular polysaccharide of A. meningitidis serogioup A is encoded by an operon 
containing four genes (mynA, mynB, mynC, and mynD) (formerly known as open 
reading frames 1 to 4) (Swartley et al. 1998) (Figure 1.10). Confusingly, these have
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Figure 1.9 Schematic representation of the Neisseria meningitidis capsule
(adapted from Rosenstein et al 2001).
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also been refeired to as sacA, sacB, sacC and sacD. However, this operon appears to 
be unique to members of N. meningitidis serogi'oup A. The mynA gene produet is 
responsible for the first biosynthetic step in the production of the serogroup A capsule 
and is probably therefore the most consei'ved gene in the operon (Diggle et al. 2003b).
The usual methods for serogrouping are slide latex agglutination and co-agglutination, 
using serogi'oup specific rabbit antiserum. Agglutination denotes a positive reaction 
provided that it oceurs with only one of the antisera. Groups A, C, Y, W135 and B/Æ. 
coli are tested and further co-agglutination with specific A, C, Y, and W135 gi'oups 
can show specific serogroups (Eldridge 1978). E. coli K1 antisera is used for 
serogroup B detection due to the similarity between both A. meningitidis serogroup B 
and E, coli K1 antigens. More recently, ultrasound-enhanced latex 
immunoagglutination (USELAT) has been developed, which can provide enhanced 
sensitivity for the detection of capsular polysaccharide antigens from serogroups A, B, 
C, Y, and W135 in clinical samples without nonspeeific reactivity (Gray et al. 1999; 
Sobanski et al. 2002; Porritt et al. 2003). Such phenotypic methods have proved less 
effective on clinical specimens such as CSF and blood samples due to the small 
amount of antigen or DNA present. Several methods can be used for the genotypic 
serogi'ouping of phenotypically non-groupable culture strains and clinical samples 
(Taha 2000; Tsang et al. 2001; Probert et al. 2002; Diggle et al. 2003b). These 
methods have demonstrated both the value of obtaining characteristics when 
phenotypic methods have failed and the importance of obtaining definitive serogroups 
especially in potential clusters and possible outbreaks.
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Figure 1.10 The gene cluster containing four genes mynA, B, C and D.
a
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1.12.6 Porin Typing and Sub-Typing
OMPs that are expressed at high levels have been recognised for over 15 years (Frasch
1985). There are two OMPs which have been functionally characterised as porins. 
These are two different classes of protein from a collection of five different classes (1- 
5), isolated based on differences in molecular weight. Initial experiments revealed 
that the meningococcal class 1 porin protein (porA) and elass 2 and 3 porin proteins 
iporB) perfonn as selective channels, whieh permit the passage of cations and anions 
across the cell membrane. Recently the advent of sequencing has confirmed the porin 
nature f  these proteins with homology with well-characterised E. coli 
porins.
1.12.6.1 Class 2 and 3 Porin Proteins B (PorB). Meningococcal strains have the 
ability to possess either PorB2 (class 2) or PorB3 (class 3) OMPs that are predominant 
proteins of the outer membrane, mutually exclusively expressed by alternative alleles 
(porB2 and porBS) at the porB locus (Hitchcock et al. 1986; Denick et al. 1999). 
PorB topology models have been constructed on the basis of nucleotide sequence data 
(Maiden et al. 1991; van der Ley et al. 1991) and, more reeently, the structural 
similarity between previously described E. coli porins OmpF and PhoE, and Neisseria 
porins, have generated tliree dimensional homology models for these Neisserial 
porins. From these predictions eight surface exposed loops combined with consei'ved 
outer membrane-spanning sequences have been postulated (Figure 1.11). As would 
be expected, the antigenically variable epitopes targeted in the host immune response 
were found to reside in the most exposed loops (McGuiimess et al. 1990; Maiden et 
al. 1991).
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Figure 1.11 The amino acid topology of the class 2/3 porin protein B (PorB) 
variable regions (VR).
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1.12.6.2 Class 1 Porin Protein A (PorA). Virtually all meningococci possess the 
class 1 OMP (PorA) (Suker et al. 1994; van der Ende et al, 2003). The secondary 
structui'e of the elass 1 OMP has been formulated and subsequent construction of 
topology models was possible. These displayed highly conseiwed trans-membrane 
regions with eight strain-variable exposed loops, which play a crucial role in the host 
immune response. These surface exposed loops are the most prominent regions 
within the protein and thus most exposed to immune responses. There are three 
regions considered important in sero-subtype characterisation; variable regions at 
loops 1, 4 and 5 correspond with variable regions I, II and HI (VRl, VR2 and VR3) 
(Figure 1.12) (Moiling et al. 2000; Tondella et al. 2000; Moiling et al. 2002; Clarke et 
al. 2003).
Detection and characterisation of the outer membrane protein (OMP) genes porB and 
porA can be achieved by several methods (Frasch 1985; Diggle and Clarke 2003a). 
Typing may be performed on the basis of SDS-PAGE, specific monoclonal antibodies 
and whole cell ELISA typing methods (Hoelm 1990; Lehmann et al. 1999; Tondella et 
al. 2000; Wang et al. 2000). More recently, molecular characterisation of the 
meningococcal porins has included nucleotide gene sequencing of previously 
described variable regions or the whole gene (Ui-win et al. 1998a; Clarke et al. 2003). 
These porins have not only been used for sero-typing and sero-subtyping but also for 
epidemiologieal analysis of meningococcal carriage and disease (Poolman et al.
1986), although the variability of these proteins means they are not entirely accurate as 
epidemiological markers (Ui'win et al. 1998b).
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Figure 1.12 The amino acid topology of the class 1 porin protein A (PorA) 
variable regions (VR).
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The class 4 OMP are antigenically stable (Munkley et al. 1991), and appear to be the 
most highly conserved between meningococcal strains. Although its cellular function 
is unknown, it shares sequence homology with E. coli Omp A (Klugman et al. 1989). 
Antibodies directed against this protein are non-bactericidal and have the additional 
ability to block the lytic effect of antibodies directed against other outer surface 
antigens (Munkley et al. 1991). In contrast to the other major OMP the heat 
modifiable class 5 opacity proteins, Op a and Ope are hypervariable (Stephens and 
McGee 1983; Tinsley and Heckels 1986) both in qualitative and quantitative 
expression (Achtman et al. 1991; Aho et al. 1991) but may induce bactericidal 
antibodies (Danelli et al. 1995). This group of proteins also elicits strong but strain- 
specific antibody responses and confers important interstrain antigenic differences 
which may be detected by MAbs (Zollinger et al. 1984).
1.13 Other Diagnostic Methods
1.13,1 Polymerase Chain Reaction (PCR)
The PCR method has been available for over a decade (Mullis et al. 1986) and has 
been applied in many different ways for the detection of N. meningitidis. During the 
past decade, the PCR has provided an invaluable tool and is considered a key advance 
in molecular biology (Wright 1990; Markman 1993). There are a number of different 
methods available for the detection or amplification of specific DNA sequences 
(Southern 1975; Viscidi 1987; Livak 1995; Tyagi 1996). The fundamental PCR 
method has found a home in many areas which utilise molecular tecluiiques in 
research and non-research enviromnents including microbiology, animal and human 
genetics and clinical diagnostics. Traditionally, PCR products are amplified in a
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commercial thennocycler followed by visualisation of PCR products on a gel-based 
system (Sambrook 2000).
Some of these have disadvantages including low sensitivity, lack of specificity, high 
cost or their laborious methodology (Wright 1990). However, various teclmologies 
are now available to exploit the PCR method beyond its basic concept and this will be 
discussed in further sections.
Within routine microbiology laboratories it is still common to use gel-based PCR 
detection systems. The specific gene targets can vary in different laboratories, but the 
principle remains the same. Several genes are commonly used for the detection and 
characterisation of meningococci. The detection of the insertion element 1^1106 can 
be used to confinn the presence of N. meningitidis in suspected cases (Ni 1992; 
Newcombe et al. 1996). However, insertion sequences are genetically mobile with the 
ability to spread between species and even genera. The IS 1106 PCR has been 
evaluated and used for many years although recent studies evaluating the specificity 
have found a number of false positives caused by organisms other than N. 
meningitidis (Borrow 1998). As an alternative, the ctrA gene can be used for 
detection in clinical samples (Frosch et al. 1992). Although only present within the 
meningococcal genome as a single copy gene and compared to multiple copy genes 
such as the IS 1106, lacks the sensitivity that IS 1106 offers, it is at present thonght to 
be specific to N. meningitidis. \S1106 was initially reported as a PCR target designed 
for the specific and sensitive detection of N. meningitidis DNA within clinical 
samples (Newcombe et al. 1996). There have been numerous ways attempted to 
produce a highly sensitive and highly specific PCR assay, using more than one gene,
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and using species-specific genes. At present, it is true that PCR assays should not 
replace culture characterisation, but complement it as a valuable detection and 
surveillance system for meningococcal disease when culture fails to tield positive 
results.
1.13.2 Enzyme Linked Immunosorbent Assay (ELISA)
The ELISA method can be used to detect antibodies against meningococcal outer 
membrane proteins in serum from patients with suspected MD, or for the detection of 
specific meningococcal polysaccharide antibodies present within clinical samples 
taken from confirmed cases of MD (Rosenqvist et al. 1990; Scholten et al. 1994; Salih 
et al. 1995; Kremastinou et al. 1999b). This is based on the detection of 
immunoglobulin M (IgM) and immunoglobulin G (IgG) against meningococcal outer 
membrane proteins possessed by common serogroups such as B and C as a result of 
meningococcal infection. This type of teclmique can confirm MD when PCR or 
culture results are negative.
1.13.3 Latex Agglutination
Latex agglutination tests (LAT’s) for the detection of meningococcal antigens can 
offer a rapid diagnostic tool (Aguiar-Nogueira et al. 1989). This technique is more 
commonplace due to its relative low cost and low complexity (Coovadia et al. 1989), 
although recently PCR has emerged as the first-line investigation to confirm the 
presence of specific meningococcal antigens within clinical samples. LAT's are now 
usually performed in conjunction with PCR with attention focused on rapid, 
inexpensive easy to perform tests, which can be used during or after antibiotic 
treatment. The primary drawback of LAT’s is the lack of sensitivity (Tarafdar et al.
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2001) although recent developments have been made to improve and entrance the 
sensitivity of meningococcal antigen detection using modified LAT’s with ultrasound 
teclniology (Sobanski et al. 2002).
1.14 Molecular Typing ofN. meningitidis
Shortcomings in some phenotypic teclmiques for characterizing and typing 
meningococci have become more commonplace, an example being the increase in 
non-gioupable, non-typeable and non-subtypeable strains. There are a number of 
reasons including the introduction of antibiotics, selective pressures such as climate, 
sociological factors and immunological factors, which have altered different 
bioehemieal stmctures, and processes hindering phenotypic methods such as, 
availability of reagents and availability of new technologies. Consequently, this has 
had a constructive effect on the development of new techniques and the development 
of molecular typing methods for enlianced characterisation and suiweillance of 
microorganisms.
1.14.1 Selective Fragment Amplification Typing Methods.
hi recent years, a range of PCR-based approaches have been developed and used with 
vaiying degrees of success for detecting meningococci (Frosch 1992; Ni 1992; 
Newcombe et al. 1996; Taha 2000). These molecular methods tend to be relatively 
quick and can be sensitive and specific. A typical test can take only a few hours 
before a definitive result is known. Because of the nature of PCR detection within 
clinical samples, inhibitors can sometimes be present such as immunoglobulin G in 
human plasma, hemoglobin and lactofemn in erythrocytes and leukocytes,
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respectively (Hackett et al. 2002). They have been identified as major inhibitors of 
diagnostic PCRs, which can decrease their efficacy (Al-soud 2000; Al-soiid 2001). 
PCR-based detection and characterisation is especially useful when treatment has been 
given and culture has proven negative. The success of positive non-culture detection 
and characterisation ranges fi'om 31% to 40% of suspected cases of meningococcal 
disease (Newcombe et al. 1996; Taha 2000; Clarke 2002b; Clarke et al. 2002).
A limited number of methods for non-culture diagnosis, that detect and type 
meningococci, have been described. These are based on the amplification of the siaD 
gono, porB, porA and 16S rRNA genes (Saunders 1993; Greisen 1994; Borrow et al. 
1997; Sacchi et al. 1998b). With the exception of a few techniques, the majority of 
reported methods only identify the presence of N. meningitidis without serogroup or 
serotype prediction, and less can predict serogroups, serotypes and sero-subtypes.
There are initial trends towards the development of comprehensive non-culture 
characterisation methods based on PCR,-which can identify group, type and sub-type, 
and in some cases further analysis of the appropriate genes. A good example of the 
limited techniques available is the lack of a test to detect serogroup A meningococci 
which, although not prominent in the majority of countries outside of the meningitis 
belt, is the serogroup encountered in the major epidemics in Africa (WHO 1998; 
Diggle et al. 2003b).
1.14.1.1 Developments in Selective Fragment Amplification Typing Methods. The
initial growth in molecular techniques started with the first licensed kit using nucleic- 
acid based teclmology (Roche Diagnostics, hidianapolis, USA) and has continued
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with yet another important growth in molecular typing techniques including real-time 
detection of PCR prodncts (Guiver et ah 2000), and the move towards automation 
(Clarke 2002a). New chemicals, such as Taqman® and molecular beacons, have been 
developed commercially, to provide real-time PCR that is also more sensitive than the 
equivalent gel-based system because it is fluorescence-based (Livak 1995; Tyagi 
1996). These chemistries have also allowed the further expansion of the applications 
of PCR into areas such as single nucleotide polymorphism (SNP) analysis (Morin 
1999) whilst standard PCR has been developed into providing amplicons for 
microarray analysis (Shalon 1996). Automation has also recently become more 
affordable and therefore more accessible to standard laboratories. It is now used 
heavily in the pharmaceutical industiy and more recently in academic research and 
clinical diagnostics (Clewley 1999; Seward and Towner 2000).
The three probe chemistries currently used for real-time detection of PCR products 
are;
• Hybridization probes which use a process of hybridization of small 
oligonucleotide probes to specific target DNA,
• Hydrolysis probes which rely on the 5'-3' exonuclease activity of Taq 
polymerase, which degrades a hybridized non-extendible DNA probe during 
the extension step of the PCR
• Hairpin probes which contain a duplex region adjacent to a single-stranded 
target capture region.
The basis of these tlnee chemistries allows the elimination of post-PCR processing 
while allowing real-time analysis of PCR products produced during amplification.
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Hairpin probe chemistry includes molecular beacons, which are oligonucleotide 
probes that can report the presence of specific nucleic acid sequences (Tyagi 1996). 
Molecular beacons are molecules with an internally quenched fluorophore whose 
fluorescence is restored when they bind to a target DNA sequence. They are designed 
in a way that allows the loop portion of the moleeule to be the probe sequence for the 
target DNA.
The loop is attached to a stem formed by the annealing of complementary sequences 
of the probe sequence. On one aim of this stem is a fluorescent moiety and a 
quenching moiety is attached to the end of the other ann. The function of the stem is 
to maintain the close proximity of both the fluorescent and quencher moieties. The 
quencher prevents fluorescence by converting the absorbing fluorescent energy into 
heat. Only when the target probe encounters a complementary target molecule will it 
form a hybrid that is long and stable enough to maintain a conformational 
reorganization that forces the stem apart. This causes the two moieties to separate, 
leading to the re-establislnnent of fluorescence, which can be detected. This 
technology is very limited within the meningococcal field (Guiver et al. 2000; Diggle 
et al. 2001a; Diggle et al. 2003b), and given the value of this technology combined 
with the potential value of automation this should be further explored.
1.14.2 Gel-Based Typing Methods.
Systems which utilise various types of gels are commonly used for charaeterisation 
and population genetics, consequently isolates of meningococci can be resolved into 
limited numbers of genetically related types or clones each thought to contain strains 
with a common ancestry. A number of alternative techniques for the determination of
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the clonal types present in bacterial populations have been investigated and these 
include but are not limited to, pulse-field gel electrophoresis (PFGE) (Popovic et al. 
2001), restriction fragment length polymoiphism (RFLP) (Fox et al. 1991; Kertesz et 
al. 1993), multi-locus enzyme electrophoresis (MLEE) (Caugant et al. 1986; Selander 
et al. 1986; Olyhoek et al. 1987; Selander et al. 1987; Tondella et al. 1999), amplified 
fragment length polymorphism (AFLP) and fluorescent amplified fragment length 
polymorphism (FAFLP) (Goulding et al. 2000; Goulding et al. 2003).
1.14.2.1 Pulsed-Field Gel Electrophoresis (PFGE). Pulsed-field gel electrophoresis 
(PFGE) uses clnomosomal DNA isolated from strains of target organisms, in this case 
N. meningitidis, and is digested with restriction endonucleases that cut the 
clnomosome into 10-40 fragments which are resolved into fingerprint patterns by the 
process of PFGE (Yakubu and Pennington 1995; Popovic et al. 2001).
PFGE involves embedding N. meningitidis in agarose, lysing it and digesting the DNA 
with restriction endonucleases that cleave occasionally. The resulting DNA fragments 
are reloaded into agarose wells and the various fragments are resolved into a specific 
pattern within the gel by an apparatus which switches the direction of the current in a 
predetermined pattern. Consequently, it can be difficult when comparing similar 
strains from different laboratories. Patterns produced are interpreted relatively simply 
and quickly, and are stable for at least eight passages of the strain in vitro. PFGE is 
used for comparison of these fingeiprints, enabling distinction and identification of 
clonal subgroups of meningococcal isolates and allows evaluation of genetical 
relationships between strains belonging to the same clonal subgroup (Bygraves and 
Maiden 1992).
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1.14.2.2 Restriction Fragment Length Polymorphism (RFLP). Restriction 
Fragment Length Polymorphism (RFLP) is a technique in which organisms may be 
differentiated by analysis of patterns derived from cleavage of their DNA. If two 
organisms differ in the distance between sites of cleavage of a particular restriction 
endonuclease, the length of the fragments produced will differ when the DNA is 
digested with a restriction enzyme. The similarity of the patterns generated can be 
used to possibly differentiate strains fi'om one another.
An RFLP typing method was developed for N. meningitidis in which a cloned EcoBl 
fr'agment from a serogroup B strain was used to probe Southern blots of total 
clnomosomal DNA restriction fragments (enzyme Aval). A  group of 75 apparently 
umelated organisms gave rise to twenty-six different RFLPs and two different groups 
of epidemiologically related strains had RFLP patterns that were distinct for each 
group. The teclnhque was highly reproducible and discriminatoiy. The RFLP data 
were compared with the results of serotyping and subtyping and isoenzyme 
electrophoretotyping. This data was consistent with those from alternative typing 
methods (Swaminathan et al. 1996). The use of RFLP typing technology has proven to 
be of considerable epidemiological value (Speers and Jells 1997; Picard 2000; 
Stefanelli et al. 2001).
1.14.2.3 Multi-Locus Enzyme Electrophoresis (MLEE). Multi-locus enzyme 
electrophoresis (MLEE) has long been considered the gold standard for the molecular 
characterisation of N. meningitidis (Caugant et al. 1986). MLEE has been used for the 
genotyping of meningococci, to identify specific clones, and to study the genetic 
diversity of the meningococcus. Although the conelation between the electrophoretic
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migration of individual enzymes and the genotype may be disrupted by horizontal 
gene transfer (Fell et al. 1995), the use of multiple enzymes make MLEE a moderately 
robust typing method for meningococci (Bart et al. 1998).
MLEE was first described in 1966 as a molecular approach to the study of genetic 
variation in eukaryotic systems, and microbiologists have as described been able to 
incorporate MLEE as a highly useful molecular typing tool. MLEE is fundamentally 
based around the different electrophoretic mobilities of constitutive enzymes from 
different amino acid changes. These enzymes were chosen on the basis of their 
powers to discriminate and type all strains and therefore allow enhanced population 
and evolutionary studies. Although only a small number of variants are detected at 
each locus, analyzing twenty or more loci can obtain a high level of resolution 
(Caugant et al. 1986). MLEE does have many attractive features for global 
epidemiology and epidemic-associated strain characterisation. Nowadays this 
procedure is considered labour intensive, and it can be subjective, relying on 
uncharacterized genomie differences between isolates while producing results which 
are difficult to compare between different laboratories. Given the emphasis on global 
epidemiology, due to the ability of meningococci to spread over whole countries and 
continents, tools are now being developed which not only maintain the same level of 
discrimination but also are easy to compare between far reaching laboratories.
1.14.2.4 Amplified Fragment Length Polymorphism (AFLP). AFLP is based on 
the selective PCR amplification of restriction fragments from a total digest of genomic 
DNA. Fingeiprints are produced without prior sequence knowledge using a limited 
set of generic primers. This technique can be considered as a combination of the
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robustness and reliability of RFLP and the relative power of the PCR teclmique 
(Goulding et al. 2003). The genomic fingerprinting process can be separated into 
tlnee appropriate steps. Firstly, the restriction enzyme digestion of the DNA and 
ligation of oligonucleotide adapters. Secondly, selective amplification of sets of 
restriction fragments and, thirdly, gel analysis of the amplified fragments using semi­
automated scoring software of AFLP images (Myburg et al. 2001). Additionally, the 
PCR primers can be labeled fluorescently, and the dye-labeled fragments can be 
separated by capillary electorphoresis, which is cuinently considered one of the most 
suitable methods of fragment analysis. Using the capillary electrophoresis system 
with appropriate size standards enables fluorés cent-APLP (FAFLP) with a usual 
fragment accuracy of +/- Ibp. FAFLP can be used as a genotyping tool with a high 
resolution and accurate size determination (Goulding et al. 2000).
1.14.3 Sequence-Based Typing Methods.
Given the disadvantages of relying on nncharacterised genomic differences between 
isolates, sequence-based approaches have become the alternative to overcome this 
(Sun et al. 2000; Tinsley and Nassif 2001). DNA sequencing has many advantages 
over other methods that are used for national and global epidemiology as well as to 
distinguish apparently identical strains identified by other methods.
1.14.3.1 Multi-Locus Sequence Typing (MLST). MLST was envisaged as the 
“next-generation” typing tool developed from MLEE. As a consequence of utilising 
sequence technology MLST can successfully differentiate strains that appear identical 
by standard phenotypic typing methods (Maiden et al. 1998; Enright and Spratt 1999). 
The method can be used during outbreaks of MD (Leavers et al. 1999) and at a time
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when sequencing has become a valuable tool, already a number of laboratories have 
started using multi-locus sequence typing (MLST) as a method for characterising 
isolates of Af meningitidis (Jolley et al. 2000; Clarke et al. 2001b; Van Looveren et al. 
2001). MLST produces nucleotide sequence data of approximately 500 base-pair 
segments from seven house-keeping genes providing results that are digital and 
therefore highly portable between laboratories.
MLST was first validated on meningococci by Maiden and colleagues (Maiden et al. 
1998). This method was originally evaluated on N. meningitidis because it provides a 
good example in which genetic recombination events are considered common. 
Originally, MLST for meningococci centred on ten loci from isolates that had been 
previously eharacterised. The meningococcal MLST house-keeping genes were 
subsequently reduced to use seven loci on the basis of its discriminatory power. This 
unique method was applied to a collection of 107 N. meningitidis isolates from 
invasive disease and healthy carriers that had been previously characterised by MLEE. 
MLST has now been validated for a number of important bacteria and fungi including 
Bordetella pertussis (Van Loo et al. 2002), Campylobacter jejuni (Dingle et al. 2001; 
Dingle et al. 2002), Candida albicans (Bougnoux et al. 2002), Enterococcus faecalis 
(Nallapareddy et al. 2002), Enterococcus faecium (Homan et al. 2002), Escherichia 
coli (Noller et al. 2003), Haemophilus influenzae (Meats et al. 2003), Listeria 
monocytogenes (Salcedo et al. 2003), salmonella (Kotetishvili et al. 2002), 
Staphylococcus aureus (Enright et al. 2000a), Streptococcus pneumoniae (Enright and 
Spratt 1998), Streptococcus pyogenes (Enright et al. 2001), and Streptococcus suis 
(King et al. 2002). The method is based on the well-tested principle of MLEE which
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as mentioned, assigns a gel-based profile indirectly from the electrophoretic mobilities 
of gene products.
This can be incorporated with similar enhanced systems in most laboratories as a 
routine method and consequently can provide data which is useful for the public 
health management of clusters or outbreaks in institutions such as schools, and also 
for general disease surveillance on a national basis, thereby providing information to 
determine national vaccine policy. This, however, is not yet commonplace in all 
laboratories responsible for detection and characterisation of N. meningitidis.
1.14.3.2 Single-Stranded Conformational Polymorphism (SSCP) Analysis. Single­
stranded confonnational polymorphism (SSCP) was developed in order to obtain the 
sub-specific typing information on the meningococci present in elinical samples, such 
as blood and CSF. hiitially the gene used for SSCP was variable region 1 (VRl) of 
porA (Newcombe et al. 1997). This is a target used for many serotyping antibodies 
and, a vast amount of infonnation is known on the genetic variation at this locus 
(Poolman 1995). SSCP analysis of post PCR products allows detection of single 
nucleotide point mutations within target DNA. This has been used to demonstrate the 
identities and non-identities of meningococci between clinical specimens. This sort of 
method is not unlike a number of single-nucleotide polymorphism (SNP) methods 
available for identifying single-base variations in a DNA sequence, usually 
represented by two or three different bases at a single position and can occur in a 
population at greater than 1% allele frequency. SNP’s can be considered highly 
abundant within bacterial genomes and along with the tools available to deteimine the
59
exact variant present in a DNA target seqnenee, these are useful molecular typing 
tools,
1.14.3.3 Matrix-Assisted Desorption/Ionization Time of Flight (MALDI-TOF) 
Analysis. MALDI-TOF mass spectrometiy has become, in recent years, a tool of 
choice for large-molecule analysis (Beavis 1996). Essentially MALDI-TOF is a 
teclmique for measuring large molecular masses precisely and is accurate enough to 
detect the differences between single nucleotides. The principle, using bacterially 
identified reference strains as a marker, could be used to detect differences in specific 
DNA sequences, but teclmiques such as this have not been widely reported for the 
discovery of different DNA sequences with N. meningitidis (Lowe 2004).
1.14.3.4 Pyrosequencing. Fundamentally, Pyrosequencing ™ involves the synthesis 
of a number of different chemicals, which enables a fast and accurate analysis of DNA 
sequences. After DNA amplification and subsequent single stranded DNA formation, 
a sequencing primer is hybridised to its complementary sequence on the template prior 
to the sequence of interest. Incubated enzymes are added with substrates to catalyse 
the incorporation of deoxynucleotide triphosphates into the DNA strand if it is 
complementary. Each incorporation event is accompanied by release of pyrophosphate 
(PPi) in a quantity equimolar to the amount of incorporated nucleotide, a complex 
cascade reaction follows that results in the generation of visible light in amounts 
proportional to the amount of dNTP originally incorporated. This is detected by a 
charged coupled device (CCD) camera and finally represented as a peak in a pyrogmm 
displayed on a compnter screen (Ronaghi 2001). As the process continues, the 
complementary DNA strand is built up and the nucleotide sequence is determined
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Figure 1.13 The chemical cascade system of Pyrosequencing,TM
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fi-om the collection of signal peaks in the Pyrogi am. The reaction is simple and robust 
and the teclmology can be adapted to create dedicated tools for specific applications 
(Diggle and Clarke 2004b) (figure 1.13).
Pyrosequencing™ could be used to develop typing assays for the characterisation of 
N. meningitidis. This could involve developing methods for the nucleotide sequence 
analysis of important variable regions contained on capsule and outer membrane 
proteins responsible for grouping, typing and sub-typing N. meningitidis. These, as 
described previously, include siaD, porB and porA genes, respectively. To achieve 
this, one would have to successfully perform amplification of all three genes, siaD, 
porB, and porA, fi'om the four main serogi'oups B, C, Y and W135. To improve 
reliability and reproducibility the method could also be automated. Recent studies 
using over 700 strains isolated in Scotland during 1999, 2000 and 2001 have shown 
that Pyrosequencing can be used for the single nucleotide polymoiphic (SNP) and 
sequence analysis (SQA) characterisation of meningococci (Diggle and Clarke 
2003b).
1.14.3.5 Microarrays. Microarray expression analysis has become one of the most 
widely used functional genomics tools (Hegde 2000). Microarrays are DNA segments 
representing a collection of genes or the various combinations of a single gene to be 
assayed. These are amplified by PCR and mechanically spotted at high density on 
glass microscope slides using simple x-y-z stage robotic systems. This results in a 
microarray containing thousands of elements. These micro arrays can easily be 
constructed within a relatively short period of time. Using fluorescence-based 
technology, hybridisation of complementary DNA segments upon the microarray with
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target DNA can be detected and immediately identified. This has already been 
reported for the discrimination of six gene sequences, which are representatives of 
different bacterial identification assays for E. coli gyrA, Salmonella gyrA, 
Campylobacter gyrA, E. coli parC, Staphlococcus mecA, and Chlamydia ciyptic 
plasmid (Westin 2001). It was also reported to have the ability of discriminating 
strains carrying antibiotic resistance single-nucleotide polymorphism mutations. The 
evidence provided by several reports highlights micro an ays as simple characterisation 
processes, allowing minimal processing of samples and required practical experience 
after system set-up (Bavykin 2001). The limitations with such new teclmology 
include cost and the practicality within laboratories with limited resources and 
technical support. The challenge with such teclmology is to find ways in which this 
can be used to study different aspects of the bacterial population. For example, the 
comparison of selected genes expressed by a pathogenic strain compared with that 
expressed by a non- pathogenic stain by hybridization to an array made from the 
genome of the pathogenic strain (Clewley 2000). hi this way, this method could be 
used to develop DNA ainays that are suitable for both diagnosis and typing of bacterial 
species such as N. meningitidis (Borrow 2001).
Ultimately, the identification of meningococcal genes involved in meningococcal 
pathogenesis will provide an insight into the pathogenic mechanisms that underlie 
infection. These genotypic studies could eventually lead to the routine genome-wide 
analysis of N. meningitidis for complete genotypic characterisation, and thus provide 
all the attributes of N. fneningitidis required for disseminated infection and may lead 
to new interventions to prevent and treat meningococcal infection.
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1.15 Aims of The Project
The aim of this project was to develop and introduce an MLST system for all 
meningococci causing invasive disease in Scotland during years 1999 - 2002. MLST 
will be introduced because strains within the electrophoretic type 37 (ET-37) 
complex, particularly those of ST ll, are often indistinguishable by traditional 
methods.
Nucleotide sequencing will be performed on seven housekeeping genes and one outer 
membrane protein gene, porA. Data will be analysed using databases and software 
available through the MLST website and the porA websites.
The introduction of MLST in Scotland will be used as a routine method for the 
characterization of Neisseria meningitidis isolates in 1999. Coincidentally, this is just 
prior to the introduction of the MenC vaccines in November 1999.
All N, meningitidis isolates from invasive disease will be analysed. This will give 
valuable data highlighting the effect the MenC has on Serogroup C disease and its 
potential decline over the length of the vaccination campaign. At the same time, the 
overall number of cases will be monitored including the effect on serogroup B 
between 1999 and 2002. This will then be linked with historical data such as the 
typical cyclical pattern seen with serogroups B and C over the past decade. The 
incidence of ET-37 strains in serogroup C disease will be assessed along with ET-37 
strains of other serogroups. The number of different ST’s isolated will also be 
monitored from the introduction of the MenC vaccine and this will be linked with
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their corresponding serogroups and subtypes.
Hopefully a decrease in serogroup C disease will be obseiwed, but it remains to be 
seen if this is accompanied by an increase in serogioup B disease. Any occurrence of 
Capsule switch will be clarified and applied to the whole data set for subsequent 
conclusion. This will hopefully show that MLST is extremely important for the 
suiweillance of meningococcal disease over a period of years and, and that this study, 
will have been effective not only in monitoring the impact of the MenC vaccines, but 
also providing a detailed genotypic representation of strains now commonly 
associated with disease.
hi addition to enlianced sequence based characterisation, development of a fluorescent 
based PCR protocol using N. meningitidis specific probes will be developed to 
markedly improved sensitivity and specificity of meningococcal DNA detection. 
Using an automated platfonn employing Taqman chemistry, a detection system will 
employ fluorescence-based chemistry that eliminates post PCR processing and will 
provide accurate real-time quantitative PCR. This development will identify 
previously undetectable quantities of meningococcal DNA, which can subsequently be 
used in a modified MLST system and ultimately produce genotypic results, which 
would not normally be created.
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Chapter 2 
Materials and Methods
2.1 Handling of Hazardous Chemicals
All chemicals were handled with care and the necessaiy precautions taken according 
to health and safety guidelines such as guidance notes for the control of substances 
hazardous to health (COSHH), Clinical Pathology Accreditation (UK) Ltd. (CPA) and 
the Advisory Committee on Dangerous Pathogens (ACDP). Health and Safety 
guidance and protection is based on the recommendations of the “Code of practice for 
the prevention of infection in clinical laboratories and post-mortem rooms” -  1978,
H.M.S.O. (working party chainnan Sir James Howie). This was drawn up to fulfil the 
department’s obligations under the Health and Safety at Work, Act (1974) and 
associated health and safety legislation. Subsequent updated documentation has been 
based on these findings. Appropriate safety wear and extractor hoods were used when 
necessary. The guidelines require that no activity, (teaching or non-teaching), which 
is liable to expose employees, students or any other person to any substance that is 
hazardous to health may be carried out unless a suitable and sufficient risk assessment 
has been completed. In addition each risk assessment must be reviewed and, where 
necessary, changed where there is reason to suspect that it is no longer valid or there 
has been a significant change in the activity to which it relates (Anon 2002a). 
Chemical databases are available on-line and a material safety data sheet can be 
provided for most substances upon request. Sites include: http://hazard.com/msds/ 
and http://www.msdssearch.com/.
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2.2 Patients and Specimens
All invasive N. meningitidis isolates received by the SMPRL during the years 1999, 
2000, 2001 and 2002 were included. These were chosen as (i) notified cases with 
isolates and (ii) all isolates that had caused invasive meningococcal disease in 
Scotland during that time period. These isolates originated h'om blood, eye, CSF and 
throat, from patients with confinned meningococcal disease. All isolates were initially 
isolated from diagnostie microbiology departments tliroughout Scotland.
2.3 Routine Culture of Bacterial Strains
All isolates were giown on horse blood agar (Oxoid, Basingstoke, UK) at 37°C in an 
atmosphere of 5% CO2. Serogiouping of N. meningitidis was performed by latex 
agglutination, co-agglutination, mynA and siaD PCR as previously described (Boitow 
et al. 1997; Borrow et al. 1998; Clarke et al. 2002; Diggle et al. 2003b). Serotyping, 
sero-subtyping and antibiotic sensitivity profiles were perfonned as previously 
described (Clarke et al. 2001b; Clarke et al. 2002).
2.4 Genomic DNA Extraction
One fresh colony was inoculated into 0.5ml of 18MO distilled water and boiled for 1 
min. The suspension was centrifuged at 15 000 g for 2 min and the supernatant was 
used as a source for the detection of meningococcal genomic DNA.
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2.5 Storage of Bacterial Strains
A sweep of single colonies was taken using a sterile cotton bud. This was immersed 
into a vial containing protect beads in solution. The cotton bud was aggi'egated and 
bacterial colonies were displaced into the solution. The solution was mixed with the 
beads and then removed leaving behind the bacteria bound to the beads. The vial was 
marked with the appropriate strain designation and stored at -70°C until required. 
Bacterial strains were recovered by taking a sterile loop containing a single bead, 
plating it onto a horse blood agar plate and incubated as described in section 2.3.
2.6 Sterilisation of Buffers, Media, Solutions and Equipment
All buffers, media, solutions and equipment requiring sterilisation before use were 
either autoclaved at 121°C, 15psi for 15 minutes or washed with 70% alcohol and 1% 
Virkon solution (Antec International Limited, Sudbury, UK).
2.7 Media
Various different media were required for the isolation and characterisation of N. 
meningitidis that were not used in this study. These included chocolate blood agar, 
DST agar with 5% horse blood, horse blood agar, Mueller Hinton agar, Mueller 
Hinton agar with 5% lysed horse blood, lysed horse blood, Flymi Watkins sugars, 
Mueller Hinton broth, o-nitrophenyl-b-D-galacopyianoside (ONPG) medium, ONPG 
stock solution, 0.2% phenol red, 10% saponin and 10% sugar solutions.
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2.8 Miscellaneous Reagents
Various other reagents were required for the isolation and characterisation of N. 
meningitidis, that were not used in this study. These included 0.2M acetic acid, 
blocking buffer for outer membrane protein (OMP) ELISA, dilution buffer for OMP 
ELISA, dilution buffer for monoclonal antibodies, dilution buffer for protein A 
conjugate, 0.2M Di-sodium hydrogen orthophosphate, feme nitrate (0.5%), 1% 
glutamine, sodium deoxycholate buffer, TMB 3,3,5,5 tetramethylbenzidine solution 
and TMB 3,3,5,5 tetramethylbenzidine substrate.
2.8.1 Agarose Gel Loading Bnffer.
To make 20ml of DNA electrophoresis loading buffer, 2ml of 5Ox electrophoresis 
buffer and 4ml of 20% glycerol was added to 14ml of sterile distilled water. 
Bromothymol blue was added to give a final concentration of approximately 0.001%.
2.8.2 XI0 Annealing Bnffer.
The measurement of 24.2g of Tris and 10.7g of magnesium acetate-tetrahydrate was 
dissolved into 900ml of 18MQ water. The pH was adjusted to 7.6 (at room 
temperature) with the addition of 4M acetic acid. Finally, 18MQ water was added to 
make 1 litre.
2.8.3 XI Annealing Buffer.
The measurement of 100ml of X I0 Annealing buffer was mixed with 900ml 18MD 
water. There was no pH adjustment required.
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2.8.4 Production of 5% Carbon Dioxide Atmosphere.
Approximately 10ml of 15% hydrochloric acid was dispensed into a universal 
container. The universal container with the acid was placed in the plastic holder 
inside the jar. One sodium bicarbonate tablet was added to the acid in the container, 
and the lid was quickly place on the jar. The cultures were incubated within this 
enviromnent overnight at 37°C.
2.8.5 X50 ELFO Bnffer.
The measurement of 242g of Tris and 18.61g EDTA were added to 900ml of distilled 
water. The pH was adjusted to 7.7 with approximately 50ml of glaeial aeetic acid and 
then the final volume made to 1000ml with distilled water.
2.8.6 Ethidinm Bromide.
To make a lOmg/ml solution of ethidium bromide, Ig of ethidium bromide powder 
was added to 100ml of distilled water and mixed to ensure that the powder had 
completely dissolved. The container was wrapped with aluminium foil and stored at 
4*^0 ,
2.8.7 20% and 50% Glycerol.
20% glycerol was made by the addition of 20ml of glycerol to 80ml of distilled water. 
The solution was then mixed thoroughly and autoclaved. 50% glycerol was made by 
the addition of 50ml of glycerol to 50ml of distilled water.
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2.8.8 15% Hydrochloric Acid.
The measurement of 1,190ml of de-ionised water was added into a 2 litre flask. 
Concentrated hydrochloric acid (810ml) was measured in a 1 litre measuring cylinder. 
The acid was slowly added to the water, mixing gently and allowed to cool. This was 
transferred to a 5 litre plastic container.
2.8.9 Orange G.
The measurement of Ig ficol was dissolved in 1ml distilled water. A 0.1% solution of 
orange G in distilled water was prepared. A 1:10 dilution of 5Ox electrophoresis 
buffer was made.
2.8.10 Phenol Chloroform.
Equal amounts of phenol and DNA-gi'ade chloroform were mixed and equilibrated by 
extracting with O.IM Tris HCl pH7.6. The equilibrated mixture was stored under a 
layer of O.OIM Tris HCl pH 7.6 at 4°C.
2.8.11 Phosphate Buffered Saline.
One phosphate buffered saline tablet pH 7.2 was dissolved in 100ml de-ionised water 
in a glass bottle and autoclave at 115°C for 10 minutes.
2.8.12 Sterile Saline.
Approximately 8.5g -  8.7g of sodium chloride was dissolved in 1 litre of de-ionised 
water. It was distributed in 2ml amounts in bijoux bottles and sterilised by 
autoclaving at 121°C for 15 minutes.
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2.8.13 0.2M Sodium Acetate.
The measurement of 8.2g sodium acetate was weighed out and mixed in 500ml of 
distilled water. Distributed in 500ml glass bottle. The solution was then autoclaved.
2.8.14 3M Sodium Acetate.
The measurement of 408g of sodium acetate- BHiO was added to 800ml of distilled 
water and mixed well. The pH was adjusted to 5.2 using glacial acetic acid and the 
volume made to 1000ml with distilled water. The solution was then autoclaved.
2.8.15 5M Sodium Acetate.
The measurement of 116.9g of sodium acetate was dissolved in 300ml of distilled 
water. Once dissolved the final volume was made to 400ml with distilled water. The 
solution was then autoclaved.
2.8.16 10% Sodium Dodecyl Sulphate (SDS).
The measurement of lOOg of SDS was added to 900ml of distilled water, mixed well 
and heated to 60°C to aid the dissolving process and adjusted to 1 litre. The pH was 
then adjusted to 7.2 using concentrated HCl and autoclaved.
2.8.17 IM Sodium Hydroxide.
The measurement of 4g of sodium hydroxide was weighed and added to 90ml of 
distilled water. Mixed well and transfeiTed into a 100ml glass bottle and made upto 
100ml with distilled water.
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2.8.18 Substrate Buffer.
The measurement of 25.7ml of 0.2M di-sodium hydrogen orthophosphate was mixed 
with 24.3ml of O.IM citric acid, then added to 50ml of de-ionised water and dispensed 
into a sterile 100ml glass bottle.
2.8.19 2M Sulphuric Acid.
The measurement of 340ml of de-ionised water was measured and transferred into a 
litre flask and placed in a fume cupboard. 20ml of concentrated sulphuric acid was 
measured and transfeiTed into a 50ml measuring cylinder. The acid was slowly added 
to the water, mixing gently tliroughout the procedure. It was allowed to cool and 
transferred into 500ml bottles.
2.8.20 O.IM Tris-HCl Buffer.
The measurement of 50ml of 0.2M Tris was mixed with 12ml of 0.2M HCl and made 
up to 200ml with the addition of distilled water.
2.8.21 XI0 TBE Buffer.
The measurement of 9.3g of EDTA was mixed with 27.5g of boric acid and 162g of 
Trizma base and added to 1 litre of 18MQ water in a 2 litre conical flask. This was 
placed on a heated plate with a magnetic stiiTer at 56*^ 0 and mixed until dissolved. 
The pH at 56°C was maintained between 7.2 and 7.4. The buffer was transferred into 
two sterile 500ml Duran bottles and stored at 4°C.
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2.8.22 2%Virkon.
The measurement of 2g of virkon powder was weighed out and added to 100ml of 
distilled water in a glass bottle. The powder was mixed until dissolved.
2.8.23 Wash Buffer.
The measurement of 2.5ml of Tween 80 was added to 10 litres of water. This was 
mixed well and stored.
2.9 Pheuotypic Confirmation and Characterisation.
2.9.1 Biochemical Confirmation and Characterisation.
A number of biochemical methods were required for the characterisation of N. 
meningitidis, which were used by the SMPRL to perform tests outside of this study. 
These included acid production, antimicrobial susceptibility testing (E-Test), 
serogrouping by latex agglutination, serogrouping by co-agglutination and whole cell 
enzyme-linked immunosorbent assay (ELISA) for typing and in cases where 
identification was not conclusive confirmation, by API NH was carried out. 
(BioMérieux UK Ltd. Basingstoke).
2.10 Genotypic Confirmation and Characterisation.
A number of biochemical methods were required for the confirmation or 
characterisation of N. meningitidis, which were used by the SMPRL to perform tests 
outside of this study. These included, the IS1106 PCR (Knight et al. 1992; Ni et al. 
1992).
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2.10.1 Primer Design
Primers were designed using the GeneFisher computer program
(http://bibserv.techfak.uni-bielefeld.de/genefisher/). Primers specifically for N. 
meningitidis genes were confirmed using the BLAST program
(http://www.ncbi.nlm.nih.gov/BLAST/).
2.10.2 Primers
Specifically designed PCR amplification and DNA sequencing primers were used. 
Primer annealing temperatures were confirmed using the OligoCalc program 
(http://www.pitt.edu/~rsup/01igoCalc.html).
Table 2.1 PCR amplification and sequencing primers used for MLST
Associated Gene Primer Sequence Reference
Amplification Primers
porA~F 5’- ATGCGAAAAAAACTTACCGCCCTC -  3’ Suker et al 1994
porA-R 5’- AATGAAGGCAAGCCGTCAAAAACA -  3 ' Maiden et al 1992
abcZ-F 5’- AATCGTTTATGTACCGCAGG -  3’ Maiden et al 1998
abcZ-R 5’- GTTGATTTCTGCCTGTTCGG -  3’ Maiden et al 1998
adk-F 5 ’ - ATGGC AGTTTGTGC AGTTGG -  3 ’ Maiden et al 1998
adk-R 5 GATTTAAACAGCGATTGCCC -  3 ’ Maiden et al 1998
aroE-F 5 ACGCATTTGCGCCGACATC -  3 ’ Maiden et a / 1998
aroE-R 5 ATCAGGGCTTTTTTCAGGTT -  3 ’ Maiden et al 1998
fumC-F 5’- CACCGAACACGACACGATGG -  3’ Leavers et al 1999
fumC-R 5 ACGACCAGTTCGTCAAACTC -  3 ’ Leavers et al 1999
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gdh-F 5 ATCAATACCGATGTGGCGCGT -  3 ’ Maiden et al 199%
gdh-R 5’- GGTTTTCATCTGCGTATAGAG -  3’ Maiden et al 1998
pdhC-F 5’- GGTTTCCAACGTATCGGCGAC -  3’ Maiden a;/1998
pdhC~R 5’- ATCGGCTTTGATGCCGTATTT -  3’ Maiden et al 1998
pgm-F 5’ - CTTCAAAGCCTACGACATCCG -  3’ Maiden et al 1998
pgm-R 5’- CGGATTGCTTTCGATGACGGC -  3 ’ Maiden et al 1998
abcZ (OF) 5’- TTCTTTTGCCATCGGCCACGT -3' Diggle et al 2003a
abcZ (OR) 5 GGCATTGCCGTTCTGTTTGGT -3 ’ Diggle et al 2003a
adk (OF) 5 CCAAAAAGTTGCCGGCTTGTG -3 ’ Diggle et al 2003a
adk (OR) 5’- CTCAAGCCTCCGACAAACTGT -3 ’ Diggle et al 2003a
aroE (OF) 5 TTCAGACGGCATCGTTCCCAT -3 ’ Diggle et al 2003a
aroE (OR) 5’- GCCTGATGGCGTTTTGAATGC -3 ’ Diggle et al 2003a
fumC (OF) 5’- CCGTCTGAACGCTTTTCAGAC -3 ’ Diggle et al 2003a
fumC (OR) 5 GAGGGAAAGATTAGCGCGGAT -3 ’ Diggle et al 2003a
gdh (OF) 5’- TCACATATTCCCACGCGGCTT -3 ’ Diggle et al 2003a
gdh (OR) 5’- AATTCTTCGCGCAAGCCTGTG-3’ Diggle et al 2003a
pdhC(OF) 5’- AGCTACGCCAACAGCAACTTC -3 ’ Diggle et al 2003a
pdhC (OR) 5 ’ - TCGGGC ATTCGGTTTTCAGAC -3 ’ Diggle et al 2003a
pgm (OF) 5’- CGGACGCGGAGATTTTTAAGC -3 ’ Diggle et al 2003a
pgm. (OR) 5’- GTGCTATGCCGTCTGAAAACC -3 ’ Diggle et al 2003a
IS 1106-1 5 ATTATTCAGACCGCCGGCAG -3 ’ Newcombe et al 1996
IS1006-8 5 ’ - TGCCGTCCTGCAACTGATGT -3 ’ Newcombe et al 1996
NMPDIF 5’- CGTAAGCAGATTGGCAGTCAGAATTGC ~3’ Diggle et al 2003
NMPDIR 5 GAAGACATATCGGGTGTTTGCCCGAT -3 ’ Diggle et al 2003
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ctrAF 5’ - TTGTGTGGAAGTTTAATTGTAGGATGC -3 ’ Guiver et al 2000
ctrAR 5’- TCAGATTGTTGCCCTAAAGAGACA -3 ’ Guiver et al 2000
Sequencing Primers
porA-F 5’- AACGGATACGTCTTGCTC -  3’ Suker et al 1994
porA-R 5’- TCCGTACGCTACGATTCTCC -  3' Maiden et al 1992
abcZ-F 5 GAGAACGAGCCGGGATAGGA -  3 ’ Maiden et al 1998
abcZ-R 5 GAGAACGAGCCGGGATAGGA -  3 ’ Maiden et al 1998
adk-F 5’- AGGCTGGCACGCCCTTGG -  3’ Maiden et al 1998
adk-R 5’- CAATACTTCGGCTTTCACGG -  3 ’ Maiden et al 1998
aroE-F 5 GCGGTCAACYTACGCTGATT -  3’ Maiden et al 1998
aroE-R 5 ’ - ATGATGTTGCCGTAC AC ATA -  3 ’ Maiden et n / 1998
fumC-F 5’- TCGGCACGGGTTTGAACAGC -  3 Leavers et al 1999
fumC-R 5’- CAACGGCGGTTTCGCGCAAC -  3’ Leavers et al 1999
gdh-F 5’- CCTTGGCAAAGAAAGCCTGC -  3’ Maiden et al 1998
gdh-R 5’- GCGCACGGATTCATATGG -  3’ Maiden et al 1998
pdhC-F 5 TCTACTACATCACCCTGATG -  3 ’ Maiden et al 1998
pdhC-R 5’- ATCGGCTTTGATGCCGTATTT -  3’ Maiden et al 1998
pgm-F 5’- CGGCGATGCCGACCGCTTGG-  3’ Maiden et al\99%
pgm-R 5’- GGTGATGATTTCGGTTGCGCC -  3’ Maiden et al\99%
2.10.3 Preparation of Agarose Gel
The appropriate amount of powder was added to 100ml ELFO buffer to obtain the 
required percentage agarose. The usual concentrations used were 1% and 2% and 
therefore Ig and 2g of agarose powder were added to 100ml ELFO buffer 
respectively. The solution was heated with care until the agarose was fully dissolved.
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For each 100ml solution 5ul of ethidium bromide (lOmg/ml) was added. The agarose 
solution was then stored at 55°C until required.
2.10.4 Agarose Gel Electrophoresis
Appropriate amounts of amplified DNA were transferred to the appropriate wells of 
an agarose gel in an electrophoresis tank; this ranged from between 5 and lOpl. Each 
sample of amplified DNA already contained a dye and precipitant from the master 
mix, this facilitated gel loading and visualisation under UV light.
2.10.5 CtrA Dual End-Point Fluorescence (DEF)-PCR.
This was based on a procedure described by Diggle et al (Diggle et al. 2001a). DNA 
was extracted using the previously described method. After DNA extraction, samples 
were transferred into 1.5ml NCC tubes and placed in the sample rack of the Roboseq 
4204 SE robotic liquid handling system, possessing an integrated theimocycler and 
fluorescence reader (MWG Biotech, Milton Keynes, United Kingdom). All 
components of the system were in a 96-well microtiter plate format, allowing 
standardization and high-throughput methodology. Programming of the liquid 
handling robot was performed according to the manufacturer’s instructions. All PCR 
reagents were maintained at 4°C on the robotic platfonn. Each reaction was performed 
in a final volume of 25pi consisting of 20pl of l .lx  Reddymix PCR Master Mix 
(ABgene) containing 1.25 U of Taq DNA polymerase; 75 mM Tris-HCl (pH 8.8 at 
25°C); 20 niM (NH4)2S0 4 ; 1.5 mM MgCfr; 0.01% (v/v) Tween 20; a 0.2mM 
concentration (each) of dATP, dCTP, dGTP, and DTTP; Ipl of each primer (1 pmol) 
(MWG Biotech); Ipl of dual-labelled probe (0.5 pmol) (MWG Biotech); and 2pl of 
extracted DNA. Each reaction was set up automatically by the robot within a
78
refrigerated 96-well microtitre plate using disposable tips. Cross-contamination was 
avoided by the use of these tips, which were discarded automatically into a waste 
container. After PCR setup, optically clear disposable strips (ABgene) were manually 
placed over the wells to seal the contents. The microtitre plate was then automatically 
placed into the integiated theimocycler for the period of theimocycling. After 
amplification, the microtitre plate was automatically removed from the theimocycler 
into the integrated Bio-Tek FL600 fluorescence plate reader. Selected wavelengths of 
485 to 420 nm and 530 to 525 nm for excitation and emissions respectively were used 
to detect the fluorescence emissions caused by carboxyfluorescein. A total of 100 
endpoint readings were taken from each well, and the average was calculated using 
the KC4 software (MWG Biotech). The ICC4 software was progi'ammed to calculate a 
cutoff value based on the subtraction of the average of the three controls from the 
positive control. Serogiouping of cW-positive samples was perfonned using the 
siaD gene, as described.
2.10.6 PCR for Serogroups B and C
2.10.6.1. SiaD Gene Amplification. PCR grouping was performed on all 
phenotypically non-groupable meningococci and on all clinical samples which gave a 
positive result for the ctrA meningococcal PCR (Borrow et al. 1997). The PCR mix 
used 300pl of l .lx  Reddymix PCR Master Mix (ABgene) containing 1.25 U of Taq 
DNA polymerase; 75mM Tris-HCl (pH 8.8 at 25°C); 20mM (NH4 )2S0 4 ; 3.5mM 
MgCh; 0.01% (v/v) Tween 20; a 0.2mM concentration (each) of dATP, dCTP, dGTP, 
and DTTP, to each of six eppendorf tubes. 4pl of positive sense primer at 50pmol 
concentration and 4pi of negative sense primer at 50pmol concentration was added to
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each eppendorf (these primers are designed specifically for the amplification of 
serogroups B and C). This was mixed well and store at 4^C. A single tube of PCR B 
and C grouping PCR master mix and a single tube of both gi oup B and group C DNA 
extracted controls was removed fi'om storage. These were mixed well and an aliquot 
of 40pi of PCR master mix was transferred into the appropriate number of PCR tubes 
(one tube per test). lOpl of purified water was added to one tube (negative control) 
and lOpl of control DNA to a further two tubes (positive B and C controls). lOpl of 
test DNA was transferred into the remaining tubes. This was mixed well and the caps 
secured. Placed into the thermocycler and the specific program started. The PCR 
conditions were 95°C for 5 min, 40 cycles of 94°C for 25 sec, 53°C for 40 sec 
(temperature gradient of 2.0°C/sec), 72°C for Imin (temperature gi'adient of 2.0°C/sec) 
and finally 72°C for 5 min.
2.10.6.2. RFLP of the siaD Gene in Serogroups B and C. For each test 1 Ipl of 
purified water, 3pi lOx restriction buffer and Ipl of Taq 1 was added to a PCR tube. 
15 pi of the amplified siaD gene product was added h om the previous stage. This was 
mixed and placed into the thermocycler. The digest conditions were 65°C for 90 min. 
After digestion they were removed from the thermocycler and the products generated 
from the first stage and the second stage were loaded on a 2% agarose gel. A lOObp 
DNA molecular weight ladder was loaded alongside the samples. The electrophoresis 
conditions were 50 volts for 15-20 min. The gel was removed from the 
electrophoresis tank and place under UV light to examine the products. The products 
sizes were as follows, initial PCR product of 460 bp and digested products of 460 bp 
for serogroup B and 207 bp, 200 bp and 53 bp for serogi'oup C.
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2.10.7 PCR for Serogroups Y and W135
2.10.7.1. SiaD Gene Amplification. PCR grouping was performed on all 
phenotypically non-gioupable meningococci and on all clinical samples that gave a 
positive result for the ctrA meningococcal PCR (Borrow et al. 1998). To create the 
PCR mix, 300pl of l .lx  Reddymix PCR Master Mix (ABgene) containing 1.25 U of 
Taq DNA polymerase; 75mM Tris-HCl (pH 8.8 at 25°C); 20mM (NH4)2S0 4 ; 3.5mM 
MgCh; 0.01% (v/v) Tween 20; a 0.2mM concentration (each) of dATP, dCTP, dGTP, 
and dTTP, was added to each of 6 eppendorf tubes. Seven microtitres of positive 
sense primer at 50pmol concentration and 7pi of negative sense primer at 50 pmol 
concentration was added to each eppendorf (these primers are designed specifically 
for the amplification of serogi'oups Y and W135). These were mixed well and store at 
4°C. A single tube of PCR Y and W135 grouping PCR master mix and 1 tube of both 
gi'oup Y and gi'oup W135 DNA extracted controls were removed from storage. These 
were mixed well and 40pl of PCR master mix was transferred into selected PCR tubes 
(one tube per test). lOpl of purified water was added to one tube (negative control) 
and lOpl of control DNA to a further two tubes (positive Y and W135 controls). lOpl 
of test DNA was transferred into the remaining tubes. These were mixed well and the 
caps secured. The samples were placed in the theimocycler and the specific program 
started. The PCR conditions were 95°C for 5 min, 40 cycles of 94°C for 25 sec, 53°C 
for 40 sec (temperature gradient of 2.0°C/sec), 72°C for Imin (temperature gradient of 
2.0°C/sec) and finally 72°C for 5 min.
2.10.7.2. RFLP of the siaD Gene in Serogroups Y and W135. For each test 1 Ipl of 
purified water, 3pi lOx restriction buffer and Ipl of Abn/was added to a PCR tube.
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15 pi of the amplified siaD gene product from the previous stage was added. This was 
mixed and place into the theimocycler. The digest conditions were 37°C for 90 min. 
After digestion they were removed from thermo cycler and the products generated 
from the first stage and the second stage were loaded on a 2% agarose gel. A lOObp 
DNA molecular weight ladder was run alongside the samples. The electrophoresis 
conditions were 50 volts for 15-20 min. The gel was removed from the 
electrophoresis tank and placed under UV light to examine the products. The 
products sizes were as follows, initial PCR product of 460bp and digested products of 
460bp for serogl'oup Y and smaller fragments for sero group W135.
2.10.8 MLST DNA Amplification.
This was hased on a procedure described by Clarke et al. (Clarke et al. 2001b). 
Progi'amming of the RoboAmp-4200 ® liquid handling system was performed 
according to the manufacturer’s instructions (figure 2.1). All PCR reagents were 
maintained at 4°C on the platform. Each PCR reaction was performed in a final 
volume of 25 pi using l . l x  Reddymix™ PCR Master Mix, containing 1.25U of Taq 
DNA polymerase (Abgene ®, Surrey, UK), 75 mM Tris-HCl (pH 8.8 at 25°C), 20 mM 
(NH4)2S0 4 , 1.5 mM MgCh, 0.01% (v/v) Tween 20, 0.2 mM each of dATP, dCTP, 
dGTP and dTTP and red dye for gel electrophoresis. For a 25 pi reaction, 20pl of PCR 
master mix and Ipl of each MLST or porA  primer pair were added to produce a 
master mix volume of 22pl. These pre-prepared master mixes were placed on the 
RoboAmp-4200® refrigerated reagent rack and the DNA preparation samples were 
placed on the sample area. Within a refrigerated non-cross-contamination (NCC) 96- 
well plate, 22pi of master mix was automatically added to appropriate wells using a 
washable tip along with 3 pi of DNA preparation, making a final 25 pi reaction mixture.
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After each stage of the set-up, the washable tip was automatically washed with 2ml of 
18MQ distilled water. The NCC 96-well plate was automatically placed into the 
integrated MWG-Biotech Primus 96 thermocycler. The PCR conditions were altered 
from Maiden and colleagues to a step-down PCR method to ensure complete and 
reproducible amplification of all eight genes. The step-down PCR conditions were 
94°C for 2 min; 3 cycles at 94°C for 1 min, 60°C for 1 min and 72°C for 2 min; 3 
cycles at 94°C for 1 min, 58°C for 1 min and 72°C for 2 min; 3 cycles at 94°C for 1 
min, 56°C for 1 min and 72°C for 2 min; 20 cycles at 94°C for 1 min, 54°C for 1 min 
and 72°C for 2 min; and finally 72°C for 10 min. After PCR the NCC plate was 
automatically removed fiom the theimocycler to a refrigerated block.
2.10.9 Liquid Phase PCR Product Purification
A 5pi aliquot of each PCR product was subsequently transferred into another NCC 
96-well plate. 0.5U of Shiimp Alkaline Phosphatase (SAP) (USB Corporation, Ohio, 
USA) and O.IU of Exonuclease I (USB Corporation, Ohio, USA) were added to each 
PCR product and automatically placed in the integrated thermocycler. The cycle 
conditions were 37^C for 15 min followed by 80°C for 15 min. This process removed 
unused primers and dNTP’s that could interfere with sequencing.
2.10.10 Solid Phase PCR Product Purification
This was based on a procedure described by Clarke et al. (Clarke and Diggle 2002). 
A Millipore MultiScreeifi'^ 96 or 384-PCR plate (Millipore, Watford, UK) was placed 
on a vacuum manifold; this was done automatically onto the integrated vacuum
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manifold using the Roboseq liquid handling robot. The entire volume (range 25 ql - 
50|ul) of each post-PCR reaction was added, up to a maximum volume of lOOpl, to the 
appropriate well of the Multiscreen 384 well plate. The PCR product was purified by 
applying a vacuum at 350 millibars pressure for 15 min or until the wells were dry. To 
ensure full purification, the vacuum was applied for a further 1 min after the last well 
was dried. The PCR products were re-suspended by adding 20pl of 18MQ distilled 
water and repeated pipetting a volume of 15 pi 100 times slowly at 50% pipetting 
speed on the liquid handling robot. The purified PCR products for 24 MLST samples 
were redistributed into four 96-well micro titre plates.
2.10.11 Licor 4200 PCR Sequence-Labelling
This was based on a procedure described by Clarke et al. (Clarke et al. 2001b). A 3pi 
aliquot of each purified PCR product was automatically transferred using the 
washable tip into an open 96-well microtitre plate. From a refiigerated block on the 
platform, a pre-dilution was performed by adding 24pl of 18Mf) distilled water and
1.5pl of both positive and negative sense sequencing primer specific for each PCR 
product. All positive sense sequencing primers were 700nm infra red dye (ERD) 
tagged and all negative sense sequencing primers were 800nm IRD tagged. 4pl of 
each pre-diluted sequence mix was distributed into appropriate wells of another open 
96 well plate, containing 2pi A, C, G and T from a Themio Sequenase fluorescent 
labelled primer cycle sequencing kit (Amersham Pharmacia Biotech, Amersham, UK). 
Finally, 15 pi of Chill-out 14 liquid wax (Genetic Research histruments, USA) was 
added to each well. Appropriate washing of the washable tip occuiTed with 18MQ 
distilled water tlri’oughout the procedure. The plate was automatically placed into the 
integrated thermocycler. The sequence cycle conditions were 95°C for 2 minutes, 30
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cycles of 95°C for 15 seconds, 50°C for 30 seconds, 70°C for 30 seconds, and finally 
72'^ C for 10 minutes. Afterwards the plate was automatically removed from the 
thennocycler and placed onto a refrigerated block. A 4pl aliquot of fonnamide 
loading dye / stop solution (Amersham Phannacia Biotech, Amersham, UK) was 
automatically added to all 96 wells with the washable tip and subsequently placed into 
the integrated thermocycler at 65°C for 10 minutes. The process took approximately 8 
hours for full automation from start to finish (figure 2.0).
2.10.12 MegaBACE 1000 Sequence-Labelling
Sequencing was performed using dideoxy dye-labeled terminators. At the start of the 
sequence set-up procedure, sequence master mixes for positive and negative sense 
nucleotide sequences of each of the eight genes of N. meningitidis were made. This 
consisted of fourteen serum tubes contained within a refrigerated reagent rack of the 
liquid handling robot. Each sequence master mix was made up from 4pl of sequence 
mix (DYEnamic™ ET Terminator sequence premix, Amersham Biosciences, Little 
Chalfont, UK) plus Ipl of positive or negative sense primer (5pmol/pL concentration) 
per 10pi of reaction mixture. 5pi of master mix was automatically transferred into the 
wells of a 96-well plate containing 5pi clean PCR product. Once the transfer was 
complete the plate was transferred into a thermocycler contained within the robotic 
platform.
2.10.13 Solid Phase Sequence Product Purification
This was based on a procedure described by Clarke and Diggle (2002) (Clarke and 
Diggle 2002). After performing the cycle sequence labelling reaction, according to 
previously described protocols, a Millipore MultiScreen’’'^  96 or 384-SEQ plate was
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placed on a vacuum manifold; this was done automatically onto the integrated vacuum 
manifold using the Roboseq liquid handling robot. The volume was adjusted to 20pl 
with 0.3 mM EDTA (pH 8.0) prepared with 18MO distilled water. The entire volume 
of each post PCR reaction was transfeiTed, usually ranging between 25pi -50pl 
depending on the gene being sequenced, up to a maximum volume of 100pi, onto the 
appropriate well of the Multiscreen plate. The product was purified applying a 
vacuum of 850 millibars for 5 min or until the wells were dry. The purified sequence 
labelled products were re-suspended by adding 20pl of 18MQ distilled water and 
repeatedly pipetting a volume of 15pl 20 times, slowly at 50% pipetting speed using a 
liquid handling robot. The purified sequence-labelled products were redistributed into 
plates ready for DNA sequencing. Wlien using the Multiscreen SEQ-384 plates for 24 
MLST samples, the products were redistributed into four 96-well microtitre plates.
2,10.14 Single-Stranded DNA Sample Preparation for Sequencing.
This was based on a procedure described by Diggle and Clarke (2003c) (Diggle and 
Clarke 2003c). The liquid handling robot transfered a volume of 5 U/pl of lambda 
exonuclease (cloned) (Amersham Phannacia Biotech) into 25ul of PCR product 
contained on the robot within a non-cross contamination plate with a washable tip. 
After each stage of the set-up, the washable tip was automatically washed with 2ml of 
18MQ distilled water. After liquid distribution, the microtitre plate was automatically 
placed into the integrated MWG-Biotech Primus 96 thermocycler. The thennocycler 
incubation was 37°C for 30 mins. To achieve optimum conditions for DNA 
concentration all parameters were assessed and evaluated including, enzyme 
concentration and length of incubation (Diggle and Clarke 2003c). After the cycle, the 
microtitre plate was automatically removed from the thennocycler onto a refrigerated
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block. The single stranded DNA was then removed from each well and placed onto an 
open well plate and transferred onto another robot for the single stranded DNA clean­
up procedure (Diggle and Clarke 2003c).
2.10.15 Single-Strand DNA Sample Clean up for Sequencing.
This was based on a procedure described by Clarke and Diggle (2002) (Clarke and 
Diggle 2002). The liquid handling robot transferred each sample into a Millipore 
SEQ-384 clean-up plate (Millipore U.K. Ltd. Hertfordshire, UK). A vacuum was 
automatically applied and after 20 minutes the dry wells were re-eluted with 18mf] 
distilled water (Clarke 2002c). A vacuum was reapplied to the wells and again after 
20 minutes the dry wells were re-eluted with xl annealing buffer (made to 
Pyi'osequencing specifications).
2.10.16 Licor-4200 DNA Sequencing System
2.10.16.2 Preparation of Acrylamide Gel Mixture. 7.5ml of Rapid-Gel XL 
Solution was carefrilly measured out (40% concentrate) (USB, Ohio, USA) into a 
100ml Duran bottle. 4ml of formamide, 21g of molecular grade urea, 5ml of XIO Tris 
buffer (162g Tris Base, 27.5g boric acid, 9.3g EDTA in 1 litre of 18MQ distilled 
water) and 28mls of 18MO water was added. A magnetic pellet was placed into the 
bottle which was then sealed. This was placed onto a magnetic stirrer to dissolve the 
contents. Once dissolved, the pellet was removed and the bottle was placed into a 
sonicator bath for 3 minutes. This removed any air bubbles from the mixture. During 
sonication, 1.5ml of 18MO water was transferred into a specimen tube and a 150mg 
of ammonium persulphate was added and dissolved. After sonication, 350pl of the 
ammonium persulphate solution was added to the Duran bottle with 75 pi of Temed
solution. This solution was quickly poured using a syringe into the prepared gel plate 
at a 45-degree angle, as described further in section 1.10.21.3. Once the anmionium 
persulphate and Teined solutions have been added the mixture has a limited self-life 
before solidification occurs.
2.10.16.3 Pouring of Acrylamide Gel. Using a pouring gel block the sequencing 
plates were placed into position. Using a 100ml syringe, approximately 40ml of 
acrylamide gel rrrixture was removed from the corrtainer and the injection into the gap 
between the two plates was performed, the syringe was moved from side to side 
between the two edges of the plate to get an even distribution of gel between the two 
plates. The gel mixture subsequently flowed down the inside of the plates combined 
with sporadic tapping ensuring no air bubble formation. Orrce the gel had reached the 
bottom of the plates, they were lifted and placed into a horizontal positiorr. A Licor 
comb was inseiied into the top of the plate creating a well at the top of the plate. This 
trough was later to be used in conjunction with the teeth from a comb to create 
individual wells for loading sequerrced samples. Finally, an additional 350ml of 
ammonium persulphate solution and 75ml of temed solution were added into the 
remaining gel mixture and using the syringe, this was added to the top of the gel onto 
the comb to create an air-tight seal. The gel was left to set in a horizontal position for­
ât least two hours at room temperature.
2.10.16.4 Preparation of Acrylamide Gel for Sequencing. Using white paper 
towels, excess gel matrix from arourrd the Licor comb in place at the top of the gel 
plate was removed. Once the majority of the gel was removed, the comb was flooded 
with 18MO water. Once flooded, the comb was slowly removed from the gel plate
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leaving a well in place at the top of the plate. Any excess gel matrix was removed 
using clean white paper towels. The back and front of the gel plates were cleaned 
with 70% alcohol and left to dry before placing into the Licor sequencer.
2.10.16.5 Loading Gel Plate. With the Licor 4200 in sleep mode the sequencing 
door was opened. The bottom buffer tank was placed into position on the bottom of 
the Licor sequencer. The prepared gel plate was loaded vertically into the sequencer 
and the side arms were slotted into the catches on the sequencer. The top buffer tank 
was placed into position at the top of the plate and tightened into position. 100ml of 
XIO Tris buffer was added into a 1 litre measuring cylinder and made up to 1 litre 
with 18MD water and mixed. The top buffer tank was filled with the XI Tris buffer 
upto the maximum mark. The remaining XI Tris buffer was carefully added to the 
lower tank. The lids on the top and bottom buffer tanks were placed on and the main 
sequencer door closed. The pre-run protocol was perfonned following the displayed 
commands.
2.10.16.6 Performing a Sequence Pre-run. After the gel plate was placed into the 
sequencer, the Licor sequencer software was opened and a sequence run file based on 
the present date, the initials of the user and the type of samples being sequenced was 
created. After the file was created the “begin pre-run” icon was selected and the 
sequencer began to focus the gel with respect to the position of the lasers before the 
samples were added.
2.10.16.7 Loading Sequenced Samples. After the pre-run protocol was complete, 
the “load samples” icon was selected on the computer screen. This ensured the high
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voltage and laser light had automatically deactivated. The Licor sequencer door was 
then opened. The top buffer tank lid was removed and a white sheet of paper was 
placed behind the top of the plate between the plate and the heated sequence panel. 
This allowed the user to see samples being loaded into each well. The well was 
washed with the buffer solution within the top tank using a P5000 Gilson pipette. 
After well preparation, approximately 20pi of formamide loading dye was added 
along the length of the well to visualise the top of the gel. An appropriately sized 
comb was placed into the trough using the teeth to pierce the gel and create numerous 
well compartments. The loading dye was flushed out of the well compartment with a 
Gilson pipette and 1 pi of each sample was added to each compartment on the comb 
until all samples were added. After the samples had been added, 1 pi of formamide 
loading dye was added to either end of the comb. The top buffer tank lid was replaced 
and the white sheet from behind the plate was removed. The sequencer door was 
closed and the “start mn” icon on the computer screen was selected.
2.10.16.8 Dismantling and Cleaning the Gel Plates. After sequencing was 
complete both the high voltage and the laser were automatically deactivated. The 
door was opened and the top and bottom buffer tank lids were removed and washed 
with warm water, dried and stored. Using the siphon tube the buffer solution from the 
top buffer tank was removed and discarded. The top buffer tank was removed and 
washed thoroughly with warm water, dried and stored. The gel plate was lifted out of 
the sequencer and placed horizontally on the gel-pouring block. The buffer from the 
bottom tank was removed and the tank was washed with warm water, dried and 
stored. The side screws holding the two plates together were loosened and removed 
leaving the two plates. With a separator, the two plates were carefully prised apart
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exposing the used gel matrix. Using dry paper towels, the exposed gel was covered. 
After removing the paper towels removed the attached matrix was discarded in special 
waste containers. Once the matrix had been removed, the plates were washed with 
warm water and dried. The plates were stored in a special plate rack to ensure safe 
storage.
2.10.17 MegaBACE 1000 DNA Sequencing System
2.10.17.1 Preparation of Sequence Capillaries. Within the sequencing software the 
instrument control window was opened and the “prepare capillaries” icon was 
selected. The instructions on the instrument displays were followed. An empty water 
tank was loaded into the plate drawer and six water tubes were loaded into the tube 
drawer on the instrument. After re-filling the water tubes and several flush procedures 
the capillaries were adequately washed for either storage or matrix pre-fill.
2.10.17.2 Performing a MegaBACE 1000 Seqnence Run. Within the sequencing 
software the instrument control window was opened and the “matrix pre-fill” icon was 
selected. The instructions were followed and six matrix tubes that have been prepared 
were loaded into the tube drawer. A prepared buffer plate containing TBE buffer was 
placed into the plate drawer. Equilibrium with the matrix was achieved and the 
instructions were followed samples injected and mn protocols were followed. A plate 
containing clean sequence DNA was placed into the plate drawer and predetermined 
injection of DNA into the capillaries was performed. Once DNA injection was 
complete the plate was removed and stored at -20°C and the buffer tank was re-loaded 
for sequencing.
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2.10.18 Sequence Interpretation for MLST Gene Fragments
Sequences were automatically read from the Licor L4200 sequencer with the 
integrated Licor base-calling software and from the MegaBACE 1000 sequencer with 
the integi'ated Cimarron vL53 Slim Phredify base-calling software. The post sequence 
analysis software was based on a procedure described by Diggle and Clarke (2002a) 
(Diggle and Clarke 2002a). This was an adapted and modified aligmnent program 
which was held on a local department network and accessed tlirough Windows 
operating software. The original DiscoverIR software was commercially available 
(Licor Biosciences Cambridge, UK). DiscoverlRlOb software was installed using the 
manufacturer’s instructions. Within the software there were eight main folders, two 
of which were of importance, namely (1) database and (2) sample. Within the 
database folder there were tdb. fries which were used to hold the infonnation for the 
database. New tdb. files were created as required; this would consist of 7 files each 
containing an MLST housekeeping gene with all the allele variations and number 
assignments cunently available. The list of alleles was created by procuring 
amiotation for the sequence (a descriptive tag for that sequence type) e.g. 
DATA;abc*01;. This annotation gave the type of infonnation (data), the gene name 
(abcZ) and the sequence type (01). This annotation was followed with the actual 
sequence directly after the semi-colon. This was repeated for each allele starting on a 
new line for each one. For each new gene, a new tbd. file was created and the same 
process repeated. Once this was completed, a database of different files would exist 
containing alleles for MLST identification.
After MLST analysis program set-up, raw sequence data for each sequence was 
viewed as an elecropherogram and this sequence was converted into FASTA (text)
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fomiat. This could be done using the sequencer programs. Each text file containing 
the sequence was downloaded into the previously described local database, containing 
the meningococcal MLST alleles. Using the MLST analysis software, the sample 
sequence was compared with all the other similar allele variants to produce a match 
and an allele number. This step could also be accomplished through the MLST 
website (www.mlst.net) or NCBI Blast seiwer (www.ncbi.nih.gov/blast). Once all 7 
genes for a given meningococcal isolate had been assigned allele numbers, this 
resulting 7-digit number was placed into the MLST web site 
(http://neisseria.org/mn/typing/mlst/). The sequence type (ST) could then be 
determined from a particular combination of alleles. When a new allele number or ST 
was detected, the trace files and isolate data were sent via a spreadsheet on the MLST 
web page to the MLST database curator for verification before its allocation and 
addition to the N. meningitidis MLST database (http://neisseria.org/mn/typing/mlst/). 
A new allele number would be given to the appropriate locus and a new ST type 
would be assigned to that combination of alleles.
2.10.19 Sequence Interpretation ofporA Gene Fragments
After sequence confiimation and editing, the porA gene sequence was converted fiom 
its nucleotide sequence into an amino acid sequence using the Translate program 
(http://expasy.cbr.m-c.cu/tools/dna.html). The variable regions were identified and 
VRl and VR2 downloaded onto the porA  website 
(http://neisseria.org/mn/typing/pora/) where a variant number was assigned. New 
variants were sent to the Centre for the Epidemiology of hifectious Disease at the 
University of Oxford. The porA  database was updated with all new variants only after 
detailed checks of all data collected and appropriate tests were repeated. The variant
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number for VR3 was compared to data contained on the SMPRL website 
(http://www.show.scot.nlis.uk/smprl/)
2.11 Analysis of MLST Data
Analysis of initial nucleotide sequence data was conducted by a number of different 
computer analysis programs. This allowed detailed scrutiny of each sample that 
produces over eight thousand single nucleotide bases. There are a number of different 
programs available that compare the sequence generated with the meningococcal 
MLST database of all known allele sequences.
2.11.1 Basic Local Alignment Search Tool (BLAST).
This is a web-based tool that is used to compare sample nucleotide or protein 
sequence with that contained within the BLAST database of submitted nucleotide 
sequences worldwide. The nucleotide sequence data obtained from the sequencer is 
electronically pasted into the appropriate window within the BLAST website’s 
selected nucleotide-nucleotide alignment icon (www.ncbi.nih.gov/blast). Depending 
on the demand this will take between seconds and minutes to conclude and display the 
results. This is used to check unknown sequence to either identify or confirm both the 
quality and/or origin of the sample nucleotide sequence.
2.11.2 Sequence Type Analysis and Recombinational Tests (START).
This is a web-based package of various tests which allow analysis of MLST data from 
N. meningitidis (Jolley 2001). This package can be separated into four main 
categories including summaiy of data, lineage assignment, recombinational tests and
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tests for selection.
2.11.2.1 Data Summary -  Allele Frequencies. Once the N. meningitidis allelic 
profiles had been entered, allele frequency analysis was performed. To run the 
analysis, the following icons were clicked “Analysis ... Data Summary ... Allele 
Frequencies'”. A table was displayed showing the frequencies of each allele at each 
locus. At the bottom of the table, the total number of different alleles present at each 
locus in the dataset was displayed.
2.11.2.2 Data Summary -  Profile Frequencies. Once the allelic profiles were 
entered, profile frequency analysis was performed. To run the analysis, the following 
icons were clicked “Analysis ... Data Summaiy ... Profile Frequencies”. A table was 
displayed showing the frequencies of each profile in the dataset in fi-equency order.
2.11.2.3 Data Summary -  Polymorphism Frequencies. To determine 
polymorphism frequencies, both the allelic profiles and the allele sequences were 
loaded onto the software. To nm the analysis, the following icons were clicked 
“Analysis ... Data Summaiy ... Polymoiphism Frequencies”. First a sequence map, 
showing the positions and identities of all polymorphic sites at each locus are 
displayed.. Underneath this was a table that displayed the number of alleles in the 
dataset that have a particular nucleotide at each polymorphic site. If only one allele 
had a certain nucleotide, that allele was highlighted in bold. On the right-hand side of 
the table, data for strains in the dataset was handled in the same way.
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2.11.2.4 Lineage Assignment -  Based Upon Related Sequence Types (BURST).
This was used to examine the relationships within clonal complexes while the 
relationships between different clonal complexes were ignored. BURST required 
allelic profile data only, and these also contained their ST numbers. To run the 
analysis, the following icons were clicked “Analysis ... Lineage Assignment ... 
BURST”. Initially a dialog window, offering a number of options, was displayed. The 
first of these was the definition of a group. The number of loci that members of a 
gi'oup must share with at least one other member of the group was entered, which for 
this study was five. This means that for MLST data based on 7 loci, a cut-off point of 
5 identical loci allows the inclusion of strains belonging to a single clonal complex, 
while excluding those that do not.
The next series of options concerned the display of a summary view. If an ancestral 
type was identified for a group, a summary view was displayed. This was displayed by 
a series of concentric circles suiTounding the ancestral type. The middle circle 
contained STs that vary at a single locus (single-locus variants - SLVs) and the outer 
contained STs that vary at two loci (double-locus variants - DLVs). Outside of this 
circle were satellite STs that vary by more than two loci from the central type. STs 
were alos linked by lines showing whether they were SLVs or DLVs of other STs. 
The dialog window provided the option to select the colours and line styles of links, or 
whether or not to show SLV or DLV links. The progiam displayed a series of tables 
showing the members of each group and the number of SLVs, DLVs and satellites 
each of ST. If an ST had been identified as an ancestral type, its ST number would 
have an asterisk next to it and there would be a summary view, as described previous.
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2.11.2.5 Lineage Assignment -  UPGMA. The algoritlim used a distance matrix 
constructed from allelic profile data only. Allele sequences were not used, so each 
allele number difference was treated identically. This is because in systems involving 
recombination, a single genetic event, i.e. recombination, may result in a large number 
of altered sites. This analysis required only the allelic profiles. To run the analysis, 
the following icons were clicked “Analysis ... Lineage Assignment ... LGPGMA”. 
Output displays were in the fomr of a tree. Allelic profiles were displayed along with 
the isolate numbers. The tree could be saved as a Windows Metafile (WMF) by right- 
clicking over it with the mouse and selecting “Save Picture As”. This could then be 
imported into other packages for editing if required.
2.11.2.6 Tests for Recombination - Index of Association. The Index of Association 
(Ia) was calculated as follows; 1a = V o /V e  - 1  if Vo was the observed variance of K and 
V e  was the expected variance of K, where K is the number of loci at which two 
individuals differ. If there was linkage equilibrium because of frequent recombination 
events, the expected value of Ia was zero. Clonal populations were identified by an Ia 
value that differed significantly fi'om zero. This analysis required only the allelic 
profiles. To run the analysis, the following icons were clicked “Analysis ... Tests for 
Recombination ... Index of Association”.
2.11.2.7 Tests for Selection - dS/dN Ratio. Nucleotide substitutions in genes coding 
for proteins can be either synonymous (no change of amino acid), alternatively called 
silent substitutions, or non-synonynious (change of amino acid). Usually, most non- 
synonymous changes would be expected to be eliminated by purifying selection, but 
under certain conditions Darwinian selection may lead to their retention. Investigating
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the number of synonymous and non-synonymous substitutions may therefore provide 
information about the degree of selection operating on a system. This analysis 
required both allelic profiles and the allele sequences to be loaded. This analysis also 
required that the open reading frames were identified for each locus although the 
program would prompt for this information. If necessaiy, it would take you to the 
“Reading Frames” dialog where these could be auto-detected. To run the analysis, the 
following icons were clicked “Analysis ... Tests for Selection ... dS/dN ratio”. A 
classical output result would include the mean number of synonymous and non- 
synonymous sites together with the number of coding sites analysed, number of 
pairwise comparisions made, the mean synonymous substitutions per synonymous 
sites, the standard deviation and confidence intervals, mean non-synonymous 
substitutions per non-synonymous sites with standard deviations and confidence 
intervals and finally the d-n/ds value and the ds/d^ value.
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Chapter 3
M ulti-Locus Sequence Typing (MLST)
3.0 Introduction
Using previously mentioned techniques this chapter concentrates on the characterisation 
of N. meningitidis causing disease in the Scottish population primarily using DNA 
sequencing technology. These meningococci ’were characterised and the molecular 
epidemiology over a number of recent years analysed in detail.
There are numerous groups within the meningococcal population that are commonly 
associated with disease, these include A, B, C, Y and W135. In the past ten years the 
most recent involved the domination of group C meningococci causing disease during 
the 1990s within the UK. Tlu'oughout the 1990s there was a significant increase of 
group C MD. This was seen more commonly in older teenagers and had a case fatality 
rate much higher than in other age groups. The continuing significant presence of 
group C MD coincided with the development and production of a group C 
meningococcal conjugate vaccine and subsequent implementation in a UK national 
vaccine campaign. This campaign required rapid implementation and thus mobilisation 
of health care professionals at both local and national level to achieve a successful 
administration of a MenC vaccine was undertaken in November 1999. This time scale 
was favoured owing to the need to prevent increasing numbers of outbreaks primarily 
effecting school pupils during the forthcoming winter season. The conjugate vaccine 
was therefore initially offered to high-risk groups (under 18 years old) and then
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subsequently a follow-up iiTimunisation campaign was implemented to all ages less than 
24 years of age. This schedule was completed by the end of 2000 and in total, has 
immunised more than 15 million children and young people during a one-year period.
These recent changes resulting in group C dominance in the meningococcal population 
in Scotland add credence to the need for detailed suiweillance of the meningococcal 
population. This study not only details the effect the MenC vaccine had on the 
meningococcal disease causing population but also highlight other serogoups and their 
sequence types which may fill the predicted void. The likelihood of a reduction in the 
serogroup C disease-causing population is very likely, and the serogi'oup B strain is also 
expected to fill the void. However this study will identify along with these predicted 
patterns the unknown sequence types prevailing after the introduction of the MenC 
vaccines. In addition the analysis of sequence data will highlight any interaction 
between different serogoups, possible evidence of a precursor event before capsule 
switch occurs due to selective pressures.
Ever since the isolation of meningococci over 115 years ago, studies have steadily 
highlighted the various inter-relationships between the meningococcus and the host 
(Peltola 1983). Meningococci have developed to employ various complex mechanisms 
involving molecular mimiciy and subsequent immune evasion with resulting 
circumventation of immune responses to elicit disease (van Deuren and Meis 2001). 
Therefore, during this 4-year period between 1999 and 2002 it will be vital that 
enlianced suiweillance is cainied out to ascertain the effect of the MenC conjugate 
vaccine on the disease-causing meningococcal population.
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Shortcomings in some phenotypic techniques for characterising and typing 
meningococci have become more evident, an example being the increasing presence of 
non-groupable, non-typeable and non-subtypeable strains. There are a number of 
reasons, including the introduction of antibiotics, selective pressures such as climate, 
sociological factors and immunological factors, which have altered different 
biochemical structures and processes hindering phenotypic methods and ultimately the 
lack of suitable reagents to identify these changes. Consequently, the development of 
new teclmiques and the development of molecular typing methods for entranced 
characterisation and surveillance of microorganisms have had a constructive effect. 
MLST is an example whereby a collection of isolates from invasive disease and healthy 
carriers that had been previously characterised by multi-locus enzyme electrophoresis 
(MLEE) can be further characterised allowing the possibility of greater discrimination 
between previously identical strains (Maiden et al. 1998; Emight and Spratt 1999). 
This MLST tool has been successfully demonstrated during outbreaks of MD (Feavers 
et al. 1999). As a consequence of the production of nucleotide sequence data, results 
are recorded digitally and therefore, importantly, portable between laboratories. This 
can be useful for the public health management of clusters or outbreaks in institutions 
such as schools, and also for general disease surveillance on a national basis, thereby 
providing infoiTuation to determine national vaccine policy.
hr order for the successful implementation of an MLST scheme within a clinical 
service, a semi-automated system was required. This enabled dependable results to be 
generated with the additional ability to perform sequencing on a large number of 
organisms with minimum complexity. Subsequent analysis was performed on an 
automated 96 capillaiy DNA sequencer, sequencing four 96-well plates during an
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eight hour period. The four plates were equivalent to MLST of 24 bacterial isolates, 
each isolate consisting of positive and negative sense strand sequencing of seven 
housekeeping genes and one antigenic gene. To achieve the sequence preparation, a 
robotic liquid-handling system was progiammed to perfonn the relevant tasks, 
including PCR amplification, PCR clean-up, sequence set-up and sequence clean-up. 
The semi-automated MLST system and subsequent sequence analysis was introduced 
in January 1999, coincidentally as a routine method for the characterization of N. 
meningitidis isolates prior to the introduction of meningococcal serogioup C 
conjugate (MenC) vaccines in November 1999 and has since been used prospectively 
to characterise all meningococci causing disease in Scotland.
This study will aim to collect and analyse data fr om all invasive meningococcal isolates 
received from all 15 NHS boards (figure 3.1) over a 4-year period between January 
1999 and December 2002. The data will hopefully highlight MLST as an extremely 
important tool to identify and characterise the clonal population structure of 
meningococci causing disease over a sustained period. This study, will also have the 
potential to show the effectiveness not only in monitoring the impact of the MenC 
conjugate vaccines, but also providing a detailed genotypic representation of strains 
now commonly associated with disease to enable the constmction of future vaccine 
policy.
MLST can be regarded as the detailed analysis of sequence data fiom a predetermined 
set of genes from bacterial, parasitic or fungal species, identified by their range of 
mutation and recombination enabling sufficient differentiation. In addition, genes such 
as antigenically variable genes, due to their relative high rate of mutation or
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Figure 3.1 National Health Service (NHS) boards throughout Scotland
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recombination may also be included to increase the discrimination power of MLST. 
The frirther expansion of traditional MLST incorporating antigenically variable genes 
provides a more powerful tool for short-term epidemiological studies and suspect 
outbreaks. The gene used with regards to N. meningitidis is the porA class 2 outer 
membrane porin protein. These porA sequence typing results and subsequent analysis 
will be discussed in chapter 4 —porA sequence analysis.
MLST can be a useful epidemiological tool and provide greater knowledge of the 
genetic variation that can occur within a species such as the N. meningitidis 
population. The sequence data obtained from MLST and subsequent analysis can 
determine population structures by analysing the extent of linkage disequilibrium 
between alleles and to identify the recombination events by the noncongmence of 
gene trees (Boyd et al, 1996) and by the presence of significant mosaic structures. For 
highly clonal species, the phylogenetic relationship between isolates can be infened 
from the dendrogram derived from the pairwise differences between sequence types 
(STs), and independently from a consensus tree constructed from the gene sequence. 
In the case of weakly clonal species such as the meningococcus, MLST is valuable for 
the identification of cun'ently circulating hyper-virulent lineages as these are 
recognised as clusters of isolates with identical or very similar sequence types 
(Maiden et al. 1998). Although nucleotide differences between alleles can go 
unscrutinised with just a simple allocation of an allele number and a ST, these 
nucleotide differences can deteimine the evolution of given alleles using nucleotide 
sequence analysis programs.
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Most bacterial species have sufficient variation within housekeeping genes to provide 
many alleles per locus, allowing an almost infinite number of distinct allelic profiles 
to be distinguished using the chosen housekeeping loci. The analysis of data can be 
separated into four main categories:
• The summaiy of data.
• Lineage assignment.
• Recombination tests.
• Tests for selection.
Data summary can provide information regarding allele fi.*equencies, profile 
frequencies, polymorphism h'equencies, codon usage and GC content. Allele 
frequencies can be determined once allelic profiles have been ascertained. These 
results display the basic frequency of each allele at each locus. Profile frequencies are 
performed on complete allelic profiles. The profiles of a selected dataset will be 
displayed showing the frequency of each profile in the dataset in a basic frequency 
order. Polymorphism frequencies will highlight tlu'ough a sequence map all the 
polymorphic sites at each locus. A summary table can be produced which displays the 
number of alleles in the dataset that have a particular nucleotide at each polymoiphic 
site. Using the codon usage analysis requires both allelic profiles and allele sequences 
from the dataset. In addition, the open reading frames must be identified for each 
locus. This analysis will count the codons used across all loci and the dataset and the 
summary data is in the fonn of a table showing the number of occurrences of each 
codon. Finally, the GC content again requires both allelic profiles and allele 
sequences. The output data will highlight the %GC value for each strain at each locus
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with the mean values for each strain and for each locus.
For lineage assignment, there are a number of packages available including BURST, 
which is a web-implemented clustering algoritlim, designed for use on MLST data 
sets from bacterial pathogens. The approach specifically examines the relationships 
between very closely related genotypes within clonal complexes. The relationships 
between different clonal complexes (i.e. between more distantly related isolates) are 
ignored. This approach, therefore, bypasses the difficulties resulting from frequent 
recombination oveiivhelming the deep-rooted phylogenetic signal (Fell et al. 2001; 
Feil and Spratt 2001). There is also the Unweighted Pair Group Method with 
Aiithmetic Mean method (UPGMA) (Sneath 1973) which is a straightforward method 
of tree construction. Its original purpose was to construct taxonomic phenograms, 
which are trees that reflect the phenotypic similarities between operational taxonomic 
units (OTUs).
Recombination may cause variation where phylogenetic analysis assumes that the 
evolutionary process is independent and identical at every region along a sequence 
aligmnent. These recombinational events can result in different regions of the same 
associated sequence having different phylogenetic histories, resulting in 
heterogeneous rates along sequences. Such recombination tests include Sawyer's 
Runs Tests, which looks for evidence of recombinational exchanges within a set of 
aligned sequences by determining if regions of sequence pairs have more consecutive 
identical polymorphic sites in coimnon than would be expected by chance (Sawyer 
1989; Drouin 1999). The maximum chi-squared test is used to identify potential 
recombination events between two sequences or between two sequences and a
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putative derived sequence. The test compares the distribution of polymorphic sites 
along such sequences with those expected to occur by chance (Smith 1992). Index of 
Association (IA) measures the extent of linkage equilibrium within a population by 
quantifying the amount of recombination among a set of sequences and detecting 
association between alleles at different loci (Smith et al. 1993).
Selection is a process whereby the implementation of conditions allows the 
discrimination of specific isolates displaying a required phenotype/genotype, hi terms 
of MLST, a test for selection can be perfonned on the specific housekeeping genes 
used in the scheme. Nucleotide substitutions within these genes that encode for 
proteins can either be synonymous or non-synonymous. Investigating the number of 
synonymous and non-synonymous substitutions that may occur within these genes can 
provide information relating to the degree of selection operating on such a system. 
Tests for selection include dS/dN ratios, these nucleotide substitutions in genes coding 
for proteins can be either synonymous (do not change amino acid), or alternatively 
silent substitutions, or non-synonymous (changes amino acid). Usually, most non- 
synonymous changes would be expected to be eliminated by purifying selection, but 
under certain conditions Darwinian selection may lead to their retention. Investigating 
the number of synonymous and non-synonymous substitutions may therefore provide 
infonnation about the degiee of selection operating on a system.
These are only brief summaries of the various forms of data analysis that are available 
once the initial sequence data has been generated. Depending on the hypothesis 
further more detailed analysis tools could be used.
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3.1 Results
In the two year period before the introduction of the vaccine campaign (1998 and 
1999) the proportion of cases confirmed as group C infection reached a high, 
comparable with group B incidence. The rise in the numbers of gioup C also took 
place alongside a steep yearly increase in meningococcal disease cases overall which 
began in the mid 1990s after a long period of relative stability. The effect of menC 
vaccine on the genetic diversity of group C meningococci and meningococcal disease 
overall will be analysed using molecular characterisation methods during the period 
from January 1999 until December 2002. These results will be sectioned into four
different years and within each year described in specific sections, namely, serogioup
diversity, sequence types, lineages and inter-lineage variability.
3.2 Serogroup Diversity
Over the past 30 years the UK has obseiwed a cyclic pattern of dominance in the 
meningococcal disease population between serogroup B and serogroup C 
meningococci. Throughout the 1990s there was a significant increase in serogroup C 
disease. This continuing increase in serogroup C disease prompted the development 
and introduction of a MenC vaccine. A progiamme was initiated into the UK 
population in November 1999. Subsequent effects of the MenC vaccine have shown a 
decrease in serogroup C disease with the ratio of B:C increasing since the introduction 
of the MenC such that serogroup B menigococci now predominate.
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3.2.1 Serogroup Diversity in 1999.
There were 349 cases of meningococcal disease in Scotland in 1999, representing to 
an incidence rate of approximately 6.4 cases per 100,000. The incidence of disease 
increased in all age groups except those aged 5-9 years and 10-15 years. The biggest 
increase occurred in those aged over 25 years. Serogioup C disease declined for the 
first time in recent years. Within the meningococcal population serogroup B and C 
isolates, comprising B:4:P1.4 and C:2a complex strains continued to predominate.
hi total, 65 of the 130 isolates were serogroup B (50%), 58 were serogroup C (45%), 3 
were serogioup X (2%) and both serogi'oups Y and W135 were represented by 2 
isolates (1.5%) (Figure 3.2). Serogroup B isolates were further differentiated into 31 
different STs contained within 5 recognised complex assignments. These included the 
ST-44 complex (34%), ST-269 complex (18%), ST-18 complex (8%), ST-35 complex 
(5%), ST-32 complex (3%) and the remaining 31% had no complex association. 
Serogroup C isolates were differentiated into 5 different STs contained within 2 
recognised complex assignments. These included the ST-11 (93%), ST-269 complex 
(2%) and the remaining 5% had no complex association. Serogroup X isolates were 
differentiated into 2 different STs, neither ST being associated with a recognised 
complex. Serogl'oup Y isolates were differentiated into 2 different STs contained 
within 1 recognised complex. This included, ST-23, and a single isolate with no 
complex association. Serogroup W135 isolates were differentiated into a single ST 
type and a single sequence complex. These were ST-22 and ST-22 complex, 
respectively (Table 3.1).
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Figure 3.2 Phylogenetic relationship of meningococci isolated in 1999 (year 1) 
and the association with ST complexes and serogroups. The UPGMA tree was 
constructed using the START program and ST complexes were assigned using 
BURST. A total of 130 isolates were characterised with each isolate represented by an 
individual number starting 99-. Each isolate has the sequence type and the allelic 
profile pertaining to this in brackets next to the isolate number. Each coloured region 
has the total number of strains represented as a total equal to N.
Serogroup B is shown in red ■
Serogroup C in blue ■
Serogroup Y in green ■
Serogroup W135 in yellow
Serogroup X in brown m
a»4300 ST-33 <8.10.5.4.6.3.0)
00^1010 ST-33 <8.10A4.e.3.8)
904178 ST-32 (4.10.5.4,6.3.0)
90-3300 ST-2202 (12.9.146.36.6.35.8) 
904364 8T-275 (4.10.2.5.38.11 f )  
004294 ST-275 (4.10.2.5.38.11.0) 
904190 ST-275 (4.10.2.5.38.11J) 
90-1627 ST-1273 (4.10.64A38.11«  
90-2313 ST-352 (4.K U .9A 11 » 
00-1635 ST-3S3 <4.10%5A11A  
00-1636 ST-3S2 (4.102AS.11.9) 
00-3461 ST-2778 (4.10.2*38.11.15) 
003101 ST-3775 (4.10.2A0.0.9) 
004134 Sr-300 (4,10.15.9.0.11.9) 
004089 ST-200 (4.10.15.0.6.11.W 
903018 8T-269(4.10.15.93.11.9) 
003172 ST-200 (4.10.19.03.11.9) 
003100ST-260 (4.10.19*8.11.9) 
003411 ST-280 (4 .10 .15*8 .11*  
902700 ST-1006 (4.10.15.9.8.11.6) 
001657 ST-1416 (4.10.15*0.11.16) 
904315 ST-472 (4,10.11*6.10.12) 
901453 8T467 (4.10.11.17.6.10,12) 
901307 8T-2772 (4.6.11,17.6.10.17) 
004008 8T-79Q (2*2 .0 .19 .20*  
902406 ST-750 ( 2 * 2 * 1 5 * ) *  
003471 8T-29S6 (4 6 *  130.7.11S*).5) 
903240 ST-29 (2 .7 * 9 1 6 .1 8 *  
903064 ST-22 (1 1 * 1 6 * 1 1 * 4 * 1 )  
001623 ST-22 (11.5.18,8.11*4*1) 
004380 8T-23(10* .18*11*17)  
902488 ST-229) (9.13.16.17**4.16) 
904203 ST-18 (7*10.19. i a i * )  
903783 ST-18 (7*10.19.10.1*) 
002312 ST-18 (7*10.19.10.1*) 
90219887-18(7*10.19.10.1*) 
001277 ST-2771 (7.810*4.10*0.18) 
904037 97-213(7*1.13.36,53.15) 
004015 Sr-213 (7*1.13.36*3.15) 
90387887-213(7*1.13.36,53.15) 
003132 87-213 (7*1.13*8.53.15) 
901182 ST-213 (7*1.13*6.53.15) 
003083 ST-60 (1 7 * 1 9 1 7 * * 6 * )  
902043 ST-2013 (17*19 ,13**6* )  
003120 87-2204 (133.5.6.17**6*}  
004330 ST-11 (2.3,4.3*4.8)
004313 ST-11 (2*4.38.4.6)
004203 ST-11 (2*4.3.88.6)
004122 ST-11 ( 2 * 4 .3 * 4 8 )
904003 ST-11 (2.3.4.3.84.6)
903016 ST-11 (2*4.3.8.46)
003917 ST-11 ( 2 .3 4 * * 4 6 )
903616 ST-11 (2 * 4 * * 4 .6 )
903781 ST-11 (2.3.4*88.6)
903660 ST-11 (2.3.4**4.6)
903606 ST-11 (2.3.4.3.*4.6)
903602 8T-11 ( 2 * 4 * 8 .4 8 )
903444 ST-11 (2.3.4.3*4.6)
002003 ST-11 (2.3 .4**4.0)
902000 ST-11 (2.38.3.88.6)
002927 ST-11 (2.3.4*8.46)
902771 ST-11 (2,38*8*4.6)
002770 ST-11 (2.3.4.3.S.4.6) 
00279987-11 (2 * 4 ,3*4 .6 )
002004 ST-11 (2*4.3.88.6)
902567 ST-11 (2,3.4**4.6)
002505 ST-11 (2,3,4*.8.4.6)
002960 ST-11 (2.3.4.3*4.6)
002525 ST-11 (2,3 .4**4.6)  
O02915ST-11 (2.3.4.3.8.4,6)
902424 87 -11 (2 .3 .4**4 .^
902367 ST-11 (2.3.4.3*4.6)
907126 ST-11 (2* .4**4 .m  
002002 ST-11 (28.4.3.S4.6)
902012 ST-11 ( 2 * 8 * 8 8 .6 )
901000 ST-11 ( 2 * 4 * * 4 .6 )
901903 ST-11 (2.3,4*88.6)
901067 ST-11 (2.3.4*54.6)
901963 ST-11 (2*4.3.88.6)
901927 ST-11 (2 * 4 ,3*4 .6 )
901911 ST-11 (2.3.4**4.6)
901832 ST-11 (2 .3.4.3*46)
001693 ST 11 (2 .38*8.4.6)
901619 ST-11 (2.3.4*.8.4.6)
901563 ST-11 (2.3.4*.0.4.6)
901581 ST-11 (2*.4,3.8.4.6)
901570 ST-11 (2 * 4 .3 * 4 .6 )
001532 ST-11 (2*8.3.8.4,6)
001518 ST-11 (2 .3.4**4.6)
901369 ST-11 < 2 * 4 * * 4 ,6 )
901349 87-11 ( 2 * 4 * 8 8 .6 )
001354 ST-11 (2.3.4**4.8)
901356 ST-11 (2 .3.4**4.6)
901271 ST-11 (2.3.4.3.88.6)
001113 ST-11 (2 * 8 .3*4 .6 )
001064 ST-11 (2.3.4.3*4.6)
001077 ST-11 ( 2 * 4 * * 4 8 )
901002 ST-11 ( 2 * 4 * 8 .4 6 )
904325 87-655 (2*4,3.8.4.6)
902626 ST806 (2.3.4.3.6.4,6)
903232 ST-2205 (2.3.133.10*147*) 
003469 ST-271 (8*18.81.44*.3) 
903824 87*71 (8*15.61.44*.3) 
904094 ST-170 (3.6*608.6,9) 
004019 ST81 (3.68*9.6.9)
003919 ST-41 (3.6.9*88.9)
003606 ST-41 (3.6.9.58.6.0)
003276 ST-41 (3,8.08.088)
902987 87-41 (3 .6 8 * 8 * 9 )  
9 029468781  (3.8.0.5.9.88)
902492 ST-41 (3.6.0.58.68)
002491 ST-41 (3.68.588.9)
902434 ST-41 (3.6.0.58.6.9)
901460ST-41 (3.68*9.6.9)
901441 87-41 (3.68.588.9)
001421 ST-41 (3.68.588.9)
001369 ST-41 (3 8 8 .588 .9 )
001078 ST-41 (3.88.5.0.6.9)
001079 ST-1255 (3 8 .9*9 .88 )  
003727 ST-46 ( 3 6 .0 * * 6 9 )
003704 ST-44 (9 .68888 .9 )
001564 ST-146 (8 * 0 .9 8 8 .9 )  
901733 ST-1194 < 38 .34*11*0 )  
902506 87-1738 (3.3.9*48.4.9) 
903171 87-1007 (9*088 .9 .6*) 
901389 ST-1097 (9.20.9.0.9,6*) 
902402 ST-1819 (13.*182.98*6.9) 
002156 87-264 (20.68388 .11*)  
002120 ST-284 (208 .6388 .11*)
901149 ST-264 (20.6.838.9.11 * )
N =I9
N=1
N=4
N=3
N=1
N=2
N=1
N=1
N=13
N=56
N=29
umc g i  OMano*
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Table 3.1 Summary of meningococcal allelic proRle frequencies from 
meningococci isolated in 1999. This represents a summary of all the different 
sequence types (ST) characterised in 1999. The table shows the ST followed by the 
allelic profile pertaining to that ST. Each allelic number represents each gene in order 
as stated in the table. The frequency number is the total number of meningococci 
represented by that ST followed by a percentage in relation to the total number of 
meningococci isolated.
ST Allelic Profile ( abcZ, adk, aroE, fumQ gdh, pdhQ pgm) Frequency
% of
dataset
11 2, 3, 4,3, 8, 4, 6 53 40.77
41 3, 6, 9, 5, 9,6, 9 14 10.77
269 4, 10,15, 9, 8 ,11,9 6 4.62
213 7, 5,1, 13, 36, 53,15 5 3.85
18 7, 8, 10, 19, 10, 1,2 4 3.08
284 20, 6, 63,9, 9, 11,2 3 2.31
352 4, 10, 2, 5, 8, 11,9 3 2.31
275 4,10, 2, 5 ,38,11,9 3 2.31
1097 9, 20, 9, 9, 9, 6, 2 2 1.54
22 11,5,18, 8,11,24,21 2 1.54
33 8, 10, 5, 4, 6 ,3 ,8 2 1.54
750 2, 5, 2, 9, 15, 20, 5 2 1.54
655 2 ,3 ,4 , 3, 6 ,4 ,6 2 1.54
271 8,3, 15,61,44, 2,3 2 1.54
23 10, 5,18, 9 ,11 ,9 ,17 1 0.77
1255 3, 6, 9, 5, 9, 6, 8 1 0.77
2771 7, 8,10, 24,10, 20,18 1 0.77
2772 4, 6, 11, 17, 6, 10, 17 1 0.77
457 4,10, 11, 17, 6,10, 12 1 0.77
146 8, 6, 9, 9,9, 6, 9 1 0.77
1273 4, 10, 64, 5,38, 11,9 1 0.77
1416 4, 10, 15, 9, 8, 11, 16 1 0.77
1194 3, 6, 34, 5, 11,6,9 1 0,77
2013 17,5, 19,13, 3 ,26 ,2 1 0.77
2292 12, 5, 146, 35, 6, 25, 8 1 0.77
1819 13, 6,152, 9, 9 ,38 ,9 1 0.77
2293 9,13 ,18 ,17 ,5 ,24 ,16 1 0.77
1738 3, 3, 9,24, 9,4, 9 1 0.77
1095 4,10,15,9 , 8 ,11,6 1 0.77
2294 133, 5,6, 17,3,26,2 1 0.77
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2775 4, 10, 2, 5, 9, 6, 9 1 0.77
2295 2,3,133,10, 5,147,2 1 0.77
29 2, 7, 6, 9 ,16 ,18 ,8 1 0.77
2776 4, 10, 2, 5,38, 11, 15 1 0.77
2296 46, 5, 130, 7, 118, 20,5 1 0.77
44 9, 6, 9, 9, 9, 6, 9 1 0.77
46 3, 6, 9, 5, 3, 6, 9 1 0.77
60 17, 5, 19, 17, 3, 26,2 1 0.77
170 3, 6, 9, 60, 9, 6, 9 1 0.77
32 4, 10, 5, 4, 6, 3, 8 1 0.77
472 4, 10, 11,9, 6, 10, 12 1 0.77
The 41 different profile(s) in this dataset (displayed in descending order of 
frequency)
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3.2.2 Serogroup Diversity in 2000.
There were 343 cases of meningococcal disease in Scotland in 2000 representing to an 
incidence rate of approximately 6.7 cases per 100,000 population. The incidence of 
disease decreased in years 9 or under but increased in ages 25 years and over. 
Serogroup C disease continued to decline. Within the meningococcal population 
serogroup B and C isolates, comprising B:4:P1.4, B:1:P1.14, B:NT:P1.9 and C:2a 
complex strains, continued to predominate.
In total, 74 of the 130 isolates were serogroup B (57%), an increase of 7% on the 
previous year, 46 were serogi*oup C (35%), a decrease of 10%, 6 were serogioup 
W135 (5%), an increase of 3.5%, and 4 isolates were serogroup Y (3%), an increase 
of 1.5% on the previous year (Figure 3.3). Serogroup B isolates were further 
differentiated into 40 different STs, an increase of 22.5% on the previous year, 
contained within 9 recognised complex assignments, an increase of 44%. These 
included the ST-44 complex (28%), ST-269 complex (19%), ST-32 complex (7%), 
ST-18 complex (5%), ST-11 complex (5%) and ST-35, 53, 92 and 254 complexes the 
latter gi'oup each accounted for 1% of the serogroup B population. The remaining 
30% had no complex association. Serogioup C isolates were differentiated into 2 
different STs contained within 2 recognised complex assignments. These included the 
ST-11 complex (96%), an increase of 3% within the serogroup C population, and ST- 
8 complex (4%), which had not been represented in previous years. Serogioup W135 
isolates were differentiated into 4 different STs contained within 2 recognised 
complex associations. These included the ST-22 (67%) and the ST-11 complex was 
represented once and the remaining isolate with no complex association. Serogi'oup Y 
isolates were differentiated into 3 different STs, all with no recognised complex
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assignment (Table 3.2).
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Figure 3.3 Phylogenetic relationship of meningococci isolated in 2000 (year 2) 
and the association with ST complexes and serogroups. The UPGMA tree was 
constructed using the START program and ST complexes were assigned using 
BURST. A total of 130 isolates were characterised with each isolate represented by an 
individual number starting 00-. Each isolate has the sequence type and the allelic 
profile pertaining to this in brackets next to the isolate number. Each coloured region 
has the total number of strains represented as a total equal to N.
Serogroup B is shown in red ■
Serogroup C in blue ■
Serogroup Y in green ■
Serogroup W135 in yellow
Serogroup X in brown ■
005287 ST-2020 (7.120.10.19.10,1.f«) 
O(M620 ST-2305 (7*10.19.10.15*) 
004627 ST-2306 (7*10.19,10.16*) 
002483 ST-18 (7*10.19.10.1*) 
004068 ST-3660 (7*1.13.36.6,15) 
004519 ST-213 (7,5.1.13,36.53.15) 
004411 81-213(7*1.13.36.53.15) 
004303 ST-213 (7.6.1,13.38.53.15) 
001878 ST-213 (7.5.1.13*8*3.15) 
001800 ST-213 (7.5.1.13.36.53.15) 
001585 ST-213 (7*1.13.36*3.15) 
001624 ST-213 (7*1.13.36.53.15) 
001340 ST-213 (7*1.13.36,53.15) 
002120 8T-23D1 (4.10.1.13.36,53.15) 
004110 ST-2782 (7*72.13,6.6.15) 
004094 ST-22 (11.5.18.8.11*4*1) 
004061 ST-22 (11,5.16.8,11*4*1) 
001187 ST-22 (11*.18.8.11 *4*1  ) 
001416 ST-164 (11*1.8,11.4*1) 
003979 ST-2781 (11**1,19.9*4.2) 
001532 8T-27T9 (17*12*5.60.22.17) 
001491 ST-2290 (8.5.12,36.60.22.17) 
001522 ST-60 (17*19 .17**6* )  
001478 ST-60 (17*19 .17**6* )  
006234 ST-44 (9 * .9** ,6* )
001674 ST-44 (9 .6**9 .6* )
001244 ST-1009 (9 .10*9*6 .9)  
001810 8T-160 (9 .e* * * .6 * )
003362 ST-2120 (12*6.9*.9.6*) 
003264 ST-2861 (27.6*.3*6.17) 
001003 ST-2777 (1.6,63.9,9.1*) 
006015 8T-41 (3.6*,5,9,6.9)
004617 ST-41 (3*,9*9.6.9)
004215 ST-41 (3*9,5*.8.9)
004093 ST-41 (3.6,9.5.9.6.9)
003174 ST-41 (3,6*A9.6.9)
002795 ST-41 (3*9*9 .6 .9 )
002767 ST-41 (3.6*.5*.6,9)
001376 ST-41 (3 ,6**9 .6* )
001375 ST-41 (3,6.9.5.9.6*)
001125 ST-41 (3,e*5.9,6.9)
001046 ST-41 (3.6.9.5.9.6.9)
001564 ST-2300 05*9.5.9.6.9)  
004269 ST-154 (3.6,9*11.6.9) 
001279 ST-154 (3,6,9.5.11.6,9)
003276 ST-46 (3,6.9*3.6*)
002415 ST-2303 (3,6,9,5.154*2*) 
004417 ST-340 0-5.19.5.3,6.8) 
003650 ST-S3 (16*.6*5,17*5*2) 
002540 ST-2304 (4*.6.9.14.11*2) 
002220 ST-2302 (12**9.18*4.10) 
001234 ST-2297 (9**9.16.54.10) 
005078 ST-269 (4,10.15,9.8,11 * )  
004546 ST-269 (4.10,15,9.6,11 * )  
004367 ST-269 (4,iai5*.8.11,9) 
002798 ST-269 (4.10.15.9.8.11*) 
001962 ST-289 (4,10.15,9.8,11,9) 
001392 ST-269 (4,10,15.9.8.11*) 
001297 ST-286 (4,10.15*8,11.9) 
001276 ST-269 (4.10.15,9*11,9) 
004226 ST-1273 (4,10,64.5.36.11.9) 
003583 ST-275 (4.10*.5.38.11*) 
001583 ST-275 (4 ,10**36.11*)  
00126081-275(4.10**36.11.9)
001123 ST-275 (4 .10**38,11*)
001047 ST-362 (4 .10***11,9)  
004661 ST-2784 (8,10*4.118,3.8) 
002436 ST-33 (8.10.5.4.6,3.8) 
001036 ST-64 (8.10.5,4,9*.8) 
004586 ST-32 (4.10,5.4.6.3,8) 
001439 ST-2208 (4.7*4.6*,8)
001705 ST-259 (4.10.5,40,6.3.8) 
002860 ST-467 (4.10,11,17.6.10.12) 
005217 ST-6 (2*.7*.B,5*)
001302 ST-8 (2 * 7 * .8 * * )
005009 ST-11 (Z 3 .4**4 .6)
005077 ST-11 (2*.4.3*4.6)
004967 ST-11 (2.3,4.3,8.4.6)
004902 ST-11 (2 * 4 * 8 .4 * )
004917 ST-11(2.3,4.3*.4.6)
004586 ST-11 {2.3.4.3.8,4,6)
004607 ST-11 (2A4.3A4.6)
004367 ST-11 (2.3.4.3.8.4.B)
004315 ST-11 (2.3.4.3.8.4.6>
004290 ST-11 (2,3.4*8.4.6)
004097 ST-11 (2.3.4,3.8,4.6)
003542 ST-11 (2*4,3.8.4.6)
003537 ST-11 (2.3.4.3.8.4.6)
003635 ST-11 (2.3.4*6.4.6)
003523 ST-11 (2*4 .3*4 .6 )
002978 ST-11 (2.3.4**4.6) 
O02912ST-11 (2,3,4**.4.6)
002702 ST-11 (2*,4.3,8.4.6)
002693 ST-11 (2*4.3*.4.6)
002694 ST-11 (2.3.4.3S.4.6)
002580 ST-11 (2.3.4*.8.4*)
002425 ST-11 (2.3,4.3.8.4.6)
002365 ST-11 (2,3.4,3A4.6)
002187 ST-11 (2,3.4**4,S)
001960 ST-11 (2*4.3.8,4.6)
001910 ST-11 (2.3.4.3A4.6)
001808 ST-11 (2.3,4.3.8.4.6)
001967 ST-11 (2*,4.3,8.4,6)
001814 ST-11 (2,3,4 .3*4*)
001836 ST-11 (2*,4.3*4.6)
001706 ST-11 (2.3,4.3,8.4.6)
001677 ST-11 (2 * 4 * * 4 ,6 )
001652 ST-11 (2,3.4*e.4.6)
001531 ST-11 (2*4.3*.4.6)
001482 ST-11 (2.3.4.3A4.6)
001481 ST-11 (2*.4*A 4.6)
001473 ST-11 (2,3.4.3.8,46)
001380 ST-11 (2 * 4 .3 * 4 * )
001385 ST-11 (2,3.4**4.6)
001346 ST-11 (2,3.4.3*4.6)
001301 ST-11 (2,3.4.38.4.6)
001264 ST-11 (2.3,4.3.8,4.6)
001283 ST-11 (2.3.4.3.8.4.6)
001257 ST-11 (2.3,4.3.8.4.6)
001245 ST-11 (2.3.4.3.S.4.6)
001122 8T-11 (2*.4.3*4.6)
001080 ST-11 (2.3.4.3,8,4.6)
001008 ST-11 (2*.4.3*.4.8)
005303 ST-11 (2,3.4.3.8,4.8)
003325 ST-2662 (15.3,133,3.8.19.10) 
004159 ST-1196 (2,7.6*4.16.18.0) 
001383 ST-167 (2.7.6.17.16,18,8) 
004107 ST-168 (2.16.6,17*18.8)
003277 ST-168 (2.16.6.17*16*) 
004156 ST-772 (2.16.12.17.3.60.7)
N=15
N=4
N=34
N=1
N=23
N=20
N=l
N=26
N=1
N=4
N=1
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Table 3.2 Summary of meningococcal allelic profile frequencies from 
meningococci isolated in 2000. This represents a summary of all the different 
sequence types (ST) characterised in 2000. The table shows the ST followed by the 
allelic profile pertaining to that ST. Each allelic number represents each gene in order 
as stated in the table. The frequency number is the total number of meningococci 
represented by that ST followed by a percentage in relation to the total number of 
meningococci isolated.
ST Allelic Profile { abcZf adk, aroE, fumC, gdh, pdhC, pgni) Frequency
% of
dataset
11 2, 3,4, 3, 8, 4, 6 49 37.69
41 3, 6, 9, 5, 9, 6,9 11 8.46
269 4,10,15, 9, 8 ,11,9 8 6.15
213 7, 5, 1, 13, 36, 53, 15 8 6.15
275 4, 10, 2, 5 ,38,11,9 4 3.08
22 11,5, 18, 8, 11,24,21 3 2.31
154 3,6, 9, 5 ,11 ,6 ,9 2 1.54
8 2, 3, 7,2, 8, 5,2 2 1.54
60 17, 5,19,17, 3, 26,2 2 1.54
44 9, 6, 9, 9, 9, 6, 9 2 1.54
168 2,16, 6,17, 9 ,18,8 2 1.54
2305 7, 8, 10, 19, 10, 16,2 2 1,54
352 4,10, 2, 5, 8 ,11,9 1 0.77
84 8, 10, 5, 4, 9, 3, 8 1 0.77
2777 1,6, 63, 9, 9 ,1 ,2 1 0.77
2297 9, 2, 9, 9,18, 54, 10 1 0.77
1009 9,10, 9, 9, 9, 6,9 1 0.77
167 2, 7, 6, 17, 16, 18,8 1 0.77
2298 4, 7, 5, 4, 6, 3, 8 1 0.77
184 11 ,5 ,1 ,8 ,11 ,4 ,21 1 0.77
2299 8, 5,12,35, 60,22,17 1 0.77
2779 17, 5,12,35, 60, 22,17 1 0.77
2300 35, 6, 9, 5, 9, 6,9 1 0,77
259 4, 10, 5, 40, 6 ,3 ,8 1 0,77
180 9, 6, 9, 9,9, 6,2 1 0,77
2301 4, 10, 1, 13,36, 53, 15 1 0.77
2302 12, 2, 9, 9, 18, 54, 10 1 0.77
2303 3, 6, 9, 5, 154, 22, 9 1 0.77
33 8,10, 5,4, 6, 3,8 1 0,77
2304 4, 2, 6, 9,14,11,22 1 0.77
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18 7, 8, 10 ,19,10,1,2 1 0.77
457 4,10,11,17, 6, 10,12 1 0.77
46 3,6, 9, 5, 3, 6, 9 1 0.77
2851 27, 6, 9, 3, 9 ,6 ,17 1 0.77
2852 15,3,133,3, 8,19,10 1 0.77
2120 12, 26, 9, 9, 9, 6, 9 1 0.77
53 16, 2, 6, 25,17, 25, 22 1 0.77
2781 11,5,21,19, 9, 24,2 1 0.77
2782 7, 5, 72, 13, 6, 6, 15 1 0,77
772 2,16,12,17, 3, 60,7 1 0.77
1198 2, 7,6, 24,16,18,8 1 0.77
1273 4, 10, 64, 5,38, 11,9 1 0,77
32 4, 10, 5, 4, 6, 3, 8 1 0.77
340 3, 6, 19, 5, 3, 6, 8 1 0.77
2784 8 ,1 0 ,5 ,4 ,118 ,3 ,8 1 0.77
2660 7 ,5 ,1 ,13 ,36 , 6,15 1 0.77
2028 7, 120,10, 19, 10,1, 16 1 0.77
The 47 different profile(s) in dataset (displayed in descending order of 
frequency).
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3.2.3 Serogroup Diversity in 2001.
There were 267 cases of meningococcal disease in Scotland in 2001, representing an 
incidence rate of approximately 5.2 cases per 100,000 population. There was an 
overall decrease in all groups aged 19 years or under, however the most significant 
decrease was in the 1-4 year age group. Serogroup C disease continued to decline, 
although, within the meningococcal population the C:2a complex strain together with 
serogroup B isolates, B:4:P1.4, B:1:P1.14, and B:NT:P1.9.complex strains continued 
to predominate.
hr total, 51 of the 80 isolates were serogroup B (64%), an increase of 7% within the 
serogroup B population, 21 were serogroup C (26%), a decrease of a further 9%, 5 
were serogroup W135 (6%), 2 isolates were serogroup X (2%), and 1 isolates was 
serogroup Y (1%) (Figure 3.4). Serogi'oup B isolates were further differentiated into 
37 different STs, a decrease of 10%, contained within 6 recognised complex 
assignments, which was more representative of isolates in 1999. These included the 
ST-269 complex (27%), ST-44 complex (10%), ST-32 complex (8%), ST-18 complex 
(4%) and ST-11 and 364 complexes the latter gi'oup each accounted for 2% of the 
serogroup B population, the remaining 47% had no complex assoeiation, an increase 
of 17%. Serogroup C isolates were differentiated into 3 different STs contained 
within 2 recognised complex assignments. These included the ST-11 complex (90%), 
a decrease of 6% within the serogroup C population, and ST-8 complex (5%) the 
remaining isolate was not associated with any recognised sequence complex. 
Serogroup W135 isolates were differentiated into 3 different STs, contained within a 
single complex association, ST-22 complex. A single serogroup Y isolate had no 
recognised complex assignment (Table 3.3).
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Figure 3.4 Phylogenetic relationship of meningococci isolated in 2001 (year 3) 
and the association with ST complexes and serogroups. The UPGMA tree was 
constructed using the START program and ST complexes were assigned using 
BURST. A total of 80 isolates were characterised with each isolate represented by an 
individual number starting 01-. Each isolate has the sequence type and the allelic 
profile pertaining to this in brackets next to the isolate number. Each coloured region 
has the total number of strains represented as a total equal to N,
Serogroup B is shown in red ■
Serogroup C in blue ■
Serogroup Y in green ■
Serogroup W135 in yellow
Serogroup X in brown 3
01.5751 ST-259 (4,10,5.40,6,3,8)
01-1165 ST-259 (4,10,5,40,6,3,8)
01-1801 ST-32 (4,10,5,4,6,3,8)
01-1467 ST-33 (8,10,5,4,6,3,8)
01-1638 ST-2322 (4,35,161,9,6,21,6$
01-5709 ST-275 (4,10,2,5,38,11,9)
01-3823 ST-275 (4,10,2,5,38,11,9)
01-1624 ST-275 (4,10,2,5,38,11,9)
01-2210 ST-2307 (4,5,2,5,38,11,9)
01-3149 ST-352 (4,10,2,5,8,11,9)
01-4959 ST-2315 (4,10,34,8,38,11,9) N=21
01-5277 ST-1774 (4,10,15,9,14,11,1)
01^1856 ST-269 (4,10,15,9,8,11,9)
01-3962 ST-269 (4,10,15,9,8,11,9)
01-3536 ST-269 (4,10,15,9,8,11,9)
01 -1095 ST-1416 (4,10,15,9,8,11,16)
01-4477 ST-479 (4,10,15,17,8,11,17)
01 -1470 ST-1049(4,10,15,17,8,11,9)
01-1446 ST-1049(4,10,15,17,8,11,9)
01-1045 ST-2324 (4,3,15,3,8,11,9)
01-4716 ST-15 (13,3,16,1,3,11,9)
01-3228 ST-1224 (11,5,18,8,78,24,2"
01-1711 ST-184 (11,5,18,8,11,4,21) N=5
01-1773 ST-184 (11,5,18,8,11,4,21)
01 -1678 ST-184(11,5,18,8,11,4,21)
01-1597 ST-22 (11,5,18,8,11,24,21)
01-1647 ST-36 (12,7,4,8,5,21,16)
01-5752 ST-41 (3,6,9,5,9,6,9)
01 -1430 ST-2323 (3,6,9,5,9,36,9) js|= \ q
01-4857 ST-2314 (3,6,9,5,9,6,2)
01-5416 ST-154 (3,6,9,5,11,6,9)
01-4559 ST-2306 (3,76,9,5,9,22,117)
01-1784 ST-2306 (3,76,9,5,9,22,117)
01-2362 ST-2309 (3,76,9,5,11,22,11)
01-1816 ST-2313 (9,6,9,3,9,6,16)
01-1308 ST-284 (20,6,63,9,9,11,2)
01-5406 ST-11 (2,3,4,3,8,4,6)
01-5379 ST-11 (2,3,4,3,8,4,6)
01-4667 ST-11 (2,3,4,3,8,4,6)
01-4564 ST-11 (2,3,4,3,8,4,6)
01-1099 ST-11 (2,3,4,3,8,4,6)
01-4043 ST-11 (2,3,4,3,8,4,6)
01-3575 ST-11 (2,3,4,3,8,4,6) N=19
01-3326 ST-11 (2,3,4,3,8,4,6)
01-2980 ST-11 (2,3,4,3,8,4,6)
01-2979 ST-11 (2,3,4,3,8,4,6)
01-2782 ST-11 (2,3,4,3,8,4,6)
01-2767 ST-11 (2,3,4,3,8,4,6)
01-2667 ST-11 (2,3,4,3,8,4,6)
01-2035 ST-11 (2,3,4,3,8,4,6)
01-1575 ST-11 (2,3,4,3,8,4,6)
01-1152 ST-11 (2,3,4,3,8,4,6)
01-1046 ST-11 (2,3,4,3,8,4,6)
01-5770 ST-11 (2,3,4,3,8,4,6)
01-2691 ST-1189(2,4,4,3,8,4,6)
01-1138 ST-2031 (2,6,4,3,9,4,6)
01-3181 ST-8 (2,3,7,2,8,5,2)
01-1012 ST-168 (2,16,6,17,9,18,8)
01-5561 ST-2316 (46,5,2,7,9,20,5)
01-4439 ST-750 (2,5,2,9,15,20,5)
01-3704 ST-212 (8,26,9,24,26,20,18)
01-5471 ST-213 (7,5,1,13,36,53,15)
01-3166 ST-213 (7,5,1,13,36,53,15)
01-3167 ST-213 (7,5,1,13,36,53,15)
01-2948 ST-213 (7,5,1,13,36,53,15)
01-4499 ST-1218 (7,5,1,13,36,1,15)
01-2757 ST-1218 (7,5,1,13,36,1,15)
01-2361 ST-2308 (15,1,133,13,8,6,1!
01-2687 ST-2311 (6,5,9,23,8,19,15)
01-2398 ST-286 (43,5,9,60,3,19,15) N=19
01-5191 ST461 (12,5,12,35,60,22,1)
01-4186 ST-461 (12,5,12,35,60,22,1)
01-2729 ST-1217 (8,5,12,13,6,22,17)
01-1506 ST-1217 (8,5,12,13,6,22,17)
01-3755 ST-1345 (6,5,12,12,12,13,1'
01 -3756 ST-1345 (6,5,12,12,12,13,1'
01-3968 ST-60 (17,5,19,17,3,26,2)
01-3478 ST-1157 (8,25,7,17,21,26,49)
01-3328 ST-18 (7,8,10,19,10,1,2)
01-2647 ST-2310 (34,8,10,19,10,1,2)
N=1
N=1
N=I
N=2
N=1
0.7 0.6 0.5
Linkage Distance
0.3 0.2 0.1 0 
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Table 3.3 Summary of meningococcal allelic profile frequencies from 
meningococci isolated in 2001. This represents a summary of all the different 
sequence types (ST) characterised in 2001. The table shows the ST followed by the 
allelic profile pertaining to that ST. Each allelic number represents each gene in order 
as stated in the table. The frequency number is the total number of meningococci 
represented by that ST followed by a percentage in relation to the total number of 
meningococci isolated.
ST Allelic Profile {abcZ, adk, aroE, fumC, gdh, pdhC, pgm) Frequency
%
of dataset
11 2, 3,4, 3, 8, 4,6 18 22.50
213 7, 5, 1, 13, 36, 53, 15 4 5.00
275 4, 10, 2, 5,38, 11,9 3 3.75
184 11,5, 18, 8, 11,4,21 3 3.75
269 4, 10, 15, 9, 8 ,11,9 3 3.75
259 4,10, 5 ,4 0 ,6 ,3 ,8 2 2.50
1049 4, 10,15,17, 8,11,9 2 2.50
1217 8, 5 ,12,13,6, 22,17 2 2.50
2306 3,76, 9, 5, 9, 22, 117 2 2.50
1218 7,5, 1, 13,36, 1, 15 2 2.50
1345 6, 5, 12, 12, 12,13,14 2 2.50.......
461 12, 5, 12,35, 60, 22, 17 2 2.50
168 2,16, 6,17, 9 ,18,8 1 1.25
2324 4,3,15, 3, 8 ,11,9 1 1.25
1416 4, 10,15, 9, 8,11,16 1 1.25
2031 2, 6, 4, 3, 9, 4, 6 1 1.25
284 20, 6 ,63,9, 9 ,11,2 1 1.25
2323 3, 6, 9, 5, 9, 36, 9 1 1,25
33 8, 10, 5, 4, 6, 3, 8 1 1.25
22 11,5,18, 8, 11,24,21 1 1.25
2322 4, 35, 161,9, 6,21,69 1 1.25
36 12, 7, 4, 8, 5,21,16 1 1.25
32 4, 10, 5, 4, 6 ,3 ,8 1 1.25
2307 4, 5, 2, 5,38, 11,9 1 1.25
2309 3,76, 9, 5,11,22,117 1 1.25
2308 15,1,133,13,8, 6,15 1 1.25
286 43,5, 9, 60, 3,19,15 1 1.25
2310 34, 8,10,19, 10,1,2 1 1.25
1189 2, 4 ,4 ,3 ,8 , 4 ,6 1 1.25
2311 6, 5 ,9 ,23 ,8 ,19 ,15 1 1.25
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352 4, 10, 2, 5, 8 ,11,9 1 1.25
8 2, 3, 7, 2, 8, 5, 2 1 1.25
1224 11,5,18, 8, 78,24,21 1 1.25
18 7, 8, 10, 19,10,1,2 1 1.25
1157 8, 25, 7, 17,21,26, 49 1 1.25
212 8,26, 9, 24, 26,20, 18 1 1.25
60 17, 5 ,19 ,17 ,3 ,26 ,2 1 1.25
750 2, 5,2, 9, 15,20, 5 1 1.25
479 4, 10, 15, 17, 8, 11, 17 1 1.25
15 13 ,3 ,16 ,1 ,3 ,11 ,9 1 1.25
2313 9, 6, 9 ,3 ,9 , 6,16 1 1.25
2314 3, 6, 9, 5, 9, 6, 2 1 1.25
2315 4, 10, 34, 8,38, 11,9 1 1.25
1774 4,10,15, 9, 14,11,17 1 1.25
154 3, 6,9, 5 ,1 1 ,6 ,9 1 1.25
2316 46, 5, 2, 7, 9, 20, 5 1 1,25
41 3, 6, 9, 5, 9, 6, 9 1 1.25
The 47 different profile(s) in dataset (displayed in descending order of 
frequency).
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3.2.4 Serogroup Diversity in 2002.
There were 178 cases of meningococcal disease in Scotland in 2001, representing an 
incidence rate of approximately 3.5 cases per 100,000 population. There was an 
overall decrease in notified cases for all age gi'oups. Again the most significant 
decrease was in the 1-4 age gi’oup. Serogioup C disease continued to decline. Within 
the meningococcal population serogi'oup B isolates, comprsing B:4:P1.4, B:1:P1.14, 
B: 15 :P 1.7;P 1.16, B:NT:P 1.14 and B:NT:P 1.15 complex strains were predominatant.
In total, 69 of the 88 isolates were serogi'oup B (78%), an further increase of 14% 
within the serogi'oup B population, 10 were serogi'oup C (11%), a further decrease of 
15%, 4 were serogroup W135 (5%), 3 isolates were serogi'oup Y (4%), and serogi'oups 
X and Z were represented once (1%) (Figui'e 3.5). Serogroup B were isolates further 
differentiated into 40 different STs, an increase of 8%, contained within 5 recognised 
complex assigmnents. These included the ST-269 complex (26%), ST-44 complex 
(19%), ST-32 complex (16%), ST-18 complex (4%) and ST-254 complexes, the latter 
group each accounted for 3% of the serogi'oup B population. The remaining 32% had 
no complex association, a decrease of 15%. Serogroup C isolates were differentiated 
into 2 different STs contained within 2 recognised complex assigmnents. These 
included the ST-11 complex (91%), and ST-269 complex (9%). Serogroup W135 
isolates were differentiated into 2 different STs, contained within a single complex 
association the ST-22 complex. Serogroup Y isolates were differentiated into 3 
different STs, with no recognised complex association. Serogroups X and Z had no 
recognised complex association (Tahle 3.4).
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Figure 3.5 Phylogenetic relationship of meningococci isolated in 2002 (year 4) 
and the association with ST complexes and serogroups. The UPGMA tree was 
constructed using the START program and ST complexes were assigned using 
BURST. A total of 89 isolates were characterised with each isolate represented by an 
individual number starting 02-. Each isolate has the sequence type and the allelic 
profile pertaining to this in brackets next to the isolate number. Each coloured region 
has the total number of strains represented as a total equal to N.
Serogroup B is shown in red ■
Serogroup C in blue ■
Serogroup Y in green ■
Serogroup W135 in yellow
Serogroup X in brown ■
Serogroup Z in purple ■
02-5334 ST-2276 (4,10.5.4.118,3,8)
02-4423 ST-32 (4,10,5,4,6,3,8)
02-3564 ST-33 (8,10,5,4,6,3,8)
02-4093 ST-259 (4,10,5,40,6,3,8)
02-3007 ST-259 (4,10,5,40,6,3,8)
02-2685 ST-259 (4,10,5,40,6,3,8)
02-2684 ST-259 (4,10,5,40,6,3,8)
02-2527 ST-259 (4,10,5,40,6,3,8)
02-2526 ST-259 (4,10,5,40,6,3,8)
02-4654 ST-34 (8,10,5,4,5,3,8)
02-4560 ST-34 (8,10,5,4,5,3,8)
02-1551 ST-1098 (8,83,5,4,5,3,8)
02-6199 ST-2205 (4,10,64,9,38,11,9)
02-4890 ST-2205 (4,10,64,9,38,11,9)
02-5159 ST-275 (4,10,2,5,38,11,9)
02-4613 ST-275 (4,10,2,5,38,11,9)
02-3772 ST-275 (4,10,2,5,38,11,9)
02-3252 ST-275 (4,10,2,5,38,11,9)
02-3361 ST-2157 (4,10,3,5,38,11,9)
02-4629 ST-2166 (4,10,15,9,8,11,8)
02-4196 ST-1095 (4,10,15,9,8,11,6)
02-3740 ST-269 (4,10,15,9,8,11,9)
02-3547 ST-269 (4,10,15,9,8,11,9)
02-2718 ST-269 (4,10,15,9,8,11,9)
02-1947 ST-269 (4,10,15,9,8,11,9)
02-2835 ST-283 (4,10,15,9,8,11,17)
02-1430 ST-467 (4,10,15,9,8,11,13) N=48
02-4049 ST-2319 (4,10,15,96,8,11,9)
02-2068 ST-13 (4,10,15,7,8,11,1)
02-5011 ST-2239 (4,29,135,9,8,11,53)
02-5095 ST-1167 (4,10,161,9,118,21,3)
02-5314 ST-1233 (3,6,9,21,9,6,9)
02-5153 ST-41 (3,6,9,5,9,6,9)
02-4522 ST-41 (3,6,9,5,9,6,9)
02-4432 ST-41 (3,6,9,5,9,6,9)
02-3284 ST-41 (3,6,9,5,9,6,9)
02-2822 ST-41 (3,6,9,5,9,6,9)
02-5204 ST-155 (3,6,9,9,11,6,9)
02-1259 ST-2203 (10,6,9,5,11,6,9)
02-3520 ST-207 (28,6,9,9,9,6,9)
02-3201 ST-180 (9,6,9,9,9,6,2)
02-3064 ST-180 (9,6,9,9,9 6,2)
02-2081 ST-180 (9,6,9,9,9,6,2)
02-4273 ST-136 (27,6,9,3,9,6,16)
02-3458 ST-2159 (3,16,9,5,9,6,8)
02-1741 ST-340 (3,6,19,5,3,6,9)
02-4858 ST-2204 (42,6,46,24,2,6,17)
02-5293 ST-2275 (17,16,79,11,3,60,7)
02-1774 ST-2151 (2,16,9,11,3,60,7)
02-5188 ST-11 (2,3,4,3,8,4,6)
02-4868 ST-11 (2,3,4,3,8,4,6)
02-4812 ST-11 (2,3,4,3,8,4,6)
02-4554 ST-11 (2,3,4,3,8,4,6)
02-3929 ST-11 (2,3,4,3,8,4,6)
02-3643 ST-11 (2,3,4,3,8,4,6)
02-2740 ST-11 (2,3,4,3,8,4,6)
02-2671 ST-11 (2,3,4,3,8,4,6)
02-1386 ST-11 (2,3,4,3,8,4,6)
02-1191 ST-11 (2,3,4,3,8,4,6)
02-3366 ST-168 (2,16,6,17,9,18,8)
02-2507 ST-766 (2,7,6,17,9,1,8)
02-5230 ST-60 (17,5,19,17,3,26,2)
02-4782 ST-60 (17,5,19,17,3,26,2)
02-1229 ST-60 (17,5,19,17,3,26,2)
02-3018 ST-1650 (17,5,19,5,3,26,2)
02-1300 ST-103 (8,4,6,17,5,18,2)
02-1299 ST-866 (8,5,19,136,58,18,2)
02-1345 ST-2317 (46,5,2,7,6,20,2)
02-4394 ST-2337 (7,8,225,19,10,1,2)
02-2443 ST-18 (7,8,10,19,10,1,2)
02-5319 ST-18 (7,8,10,19,10,1,2)
02-5149 ST-213 (7,5,1,13,36,53,15)
02-5032 ST-213 (7,5,1,13,36,53,15)
02-4744 ST-213 (7,5,1,13,36,53,15)
02-3758 ST-213 (7,5,1,13,36,53,15)
02-2410 ST-213 (7,5,1,13,36,53,15)
02-2387 ST-213 (7,5,1,13,36,53,15) N= 16
02-1532 ST-213 (7,5,1,13,36,53,15)
02-3096 ST-2161 (16,3,133,13,8,19,15)
02-5028 ST-2240 (13,5,12,40,59,8,18)
02-4441 ST-2147 (13,5,4,40,59,8,18)
02-2178 ST-1345 (6,5,12,12,12,13,14)
02-1540 ST-1345 (6,5,12,12,12,13,14)
02-1405 ST-2318 (12,5,12,35,60,22,9)
02-4809 ST-1466 (6,5,173,13,5,24,17) N=1
02-4292 ST-22 (11,5,18,8,11,24,21)
02-3587 ST-22 (11,5,18,8,11,24,21) ^ = 4
02-1323 ST-22 (11,5,18,8,11,24,21)
02-1649 ST-1224 (11,5,18,8,78,24,21)
N=10
N=2
N=3
N=1
N=2
N=1
—r
0.3
T"
0.2
— T
09
~ r
0.8
—T
0.7 0.6 0.5
Linkage Distance
I
0.4
124
Table 3.4 Summary of meningococcal allelic profile frequencies from 
meningococci isolated in 2002. This represents a summary of all the different 
sequence types (ST) characterised in 2002. The table shows the ST followed by the 
allelic profile pertaining to that ST. Each allelic number represents each gene in order 
as stated in the table. The frequency number is the total number of meningococci 
represented by that ST followed by a percentage in relation to the total number of 
meningococci isolated.
ST Allelic Profile {abcZj adky aroE, fumQ gdh, pdhQ pgm) Frequency
%
of dataset
11 2 ,3,4, 3, 8,4, 6 10 10.99
213 7,5, 1, 13, 36, 53, 15 7 7.69
259 4,10, 5,40, 6 ,3 ,8 7 7.69
41 3, 6, 9, 5, 9, 6,9 5 5.49
269 4, 10,15, 9, 8 ,11,9 4 4.40
275 4, 10, 2, 5,38, 11,9 4 4,40
60 17, 5, 19, 17, 3, 26,2 3 3.30
22 11,5, 18, 8, 11,24,21 3 3.30
180 9, 6, 9, 9, 9, 6, 2 3 3.30
18 7, 8, 10, 19, 10, 1,2 2 2.20
1345 6, 5, 12, 12, 12, 13, 14 2 2.20
1224 11,5, 18, 8, 78, 24,21 2 2.20
34 8, 10, 5, 4, 5, 3, 8 2 2.20
2205 4,10, 64, 9 ,38 ,11 ,9 2 2.20
2203 10, 6, 9, 5 ,1 1 ,6 ,9 1 1.10
866 8, 5, 19, 135, 58, 18,2 1 1.10
103 8,4, 6,17, 5 ,18 ,2 1 1.10
2317 46, 5, 2, 7, 6, 20, 2 1 1.10
2318 12, 5, 12, 35, 60, 22, 9 1 1.10
467 4, 10,15, 9, 8,11,13 1 1.10
1098 8, 83, 5, 4, 5, 3, 8 1 1.10
340 3 ,6 ,1 9 ,5 ,3 ,6 ,9 1 1.10
2151 2, 16, 9, 11,3,60,7 1 1.10
13 4, 10, 15, 7, 8, 11, 1 1 1.10
766 2, 7, 6, 17, 9 ,1 ,8 1 1.10
283 4,10,15, 9, 8,11,17 1 1.10
1650 17, 5, 19, 5 ,3 ,26 ,2 1 1.10
2161 16,3,133, 13,8,19,15 1 1.10
168 2, 16, 6 ,17 ,9 ,18 ,8 1 1.10
2157 4 ,1 0 ,3 ,5 ,3 8 ,1 1 ,9 1 1.10
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2159 3, 16, 9, 5, 9, 6, 8 1 1.10
207 28, 6, 9, 9, 9, 6, 9 1 1.10
33 8, 10, 5, 4, 6, 3, 8 1 1.10
2319 4, 10, 15, 98, 8, 11,9 1 1.10
1095 4, 10, 15, 9, 8, 11,6 1 1,10
136 27, 6, 9, 3, 9, 6, 16 1 1.10
2337 7, 8, 225,19, 10,1,2 1 1.10
32 4,10, 5, 4, 6, 3,8 1 1.10
2147 13,5, 4,40, 59, 8, 18 1 1.10
2166 4, 10, 15, 9, 8, 11,8 1 1.10
1466 6,5, 173, 13,5, 24, 17 1 1.10
2204 42, 6, 46,24, 2,6, 17 1 1.10
2239 4, 29, 135, 9, 8, 11,53 1 1.10
2240 13, 5, 12,40, 59, 8, 18 1 1.10
1167 4,10,161,9 ,118,21,3 1 1.10
155 3,6, 9, 9 ,1 1 ,6 ,9 1 1.10
2275 17,16, 79,11,3, 60,7 1 1.10
1233 3,6, 9 ,21,9, 6 ,9 1 1.10
2276 4, 10, 5,4, 118,3,8 1 1.10
The 49 different profile(s) in dataset (displayed in descending order of 
frequency).
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3.3 Sequence Types, Lineages and Inter-Lineage Variability
The introduction of MLST in Scotland has provided a routine method for the 
characterisation of N. meningitidis isolates since Januaiy 1999. Coincidentally, this is 
just prior to the introduction of meningococcal MenC vaccines in November 1999.
All N. meningitidis isolates from invasive disease have been analysed. This has 
allowed the production of valuable data highlighting the effect the MenC vaccine has 
on serogroup C disease and its potential decline after the introduction of the 
immunisation campaign. At the same time, the overall number of cases was monitored 
including the effect on serogi'oup B between 1999 and 2002. This will then he linked 
with sequence typing data such as the typical complex patterns seen with serogroups B 
and C pre, during and post implementation of the initial MenC vaccination program. 
The incidence of ST-ll/ET-37 strains in serogi'oup C disease will he assessed along 
with ST-ll/ET-37 strains of other serogroups. The number of different STs isolated 
will also be monitored from the introduction of the MenC vaccine and this will be 
linked with their corresponding serogroups and subtypes.
A decrease in serogroup C disease will be expected, but it remains to be seen if this is 
accompanied by a relative increase in serogroup B disease. Any suspected capsule 
switch will be clarified and applied to the whole data set for subsequent conclusion. 
This will hopefully show that MLST is extremely important for the surveillance of 
meningococcal disease over a period of years and, and that this data, will have been 
effective not only in monitoring the impact of the MenC vaccines, but also providing a 
detailed genotypic representation of strains now commonly associated with disease.
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3.3.1 Sequence Types, Lineages and Inter-Lineage Variability in 1999.
With reference to section 3.0 these isolates were categorised into 41 different STs 
(Figure 3.6). Using BURST analysis they were further differentiated into six distinct 
lineages, with 15 singleton types (11.5%). These lineages occurred between one 
(0.8%) and 55 (42%) times during 1999. The ST-11 complex accounted for the 
majority with 55 (42%) of all the isolates and these were divided into two STs; 53 
were ST-11 (96%) and two were ST-655 (4%) a gdh locus variant of ST-11. The ST- 
44 complex accounted for 22 isolates (17%) and these were divided into eight 
different STs; 14 were ST-41 (64%), two were ST-1097 (9%) and ST-44, 46, 146, 
170, 1194 and 1255 were each represented by a single isolate (4.5%). Within this 
lineage there were eight single locus variants combined with 20 double locus variants 
and 28 satellites. The ST-269 complex accounted for 17 isolates (13%), which were 
divided into eight different STs; ST-269 (35%) ST-275, and ST-352 (18%), and ST- 
1095 1273 1416 2775, and 2776 were represented by a single isolate (6%). Within 
this lineage there were eight single locus variants combined with nine double locus 
variants and 25 satellites. The ST-35 complex accounted for tluee isolates (2%), these 
were divided into tluee different STs, 457, 472 and 2772, and contained two single 
locus variants combined with two double locus variants and two satellites. The ST-32 
complex accounted for tluee isolates; these were divided into two different STs, ST- 
33 (67%) and ST-32 (33%). There were two single locus variants. The remaining 
tluee isolates, ST-60, 2013 and 2294 were assigned to the final group but with no 
complex association. The singletons accounted for 27 isolates differentiated between 
15 different STs; ST-213 (19%) ST-18 (15%) ST-284 (11%) ST-271, 750, and 22 
(7%) and ST-23 29 1738 1819 2292 2293 2295, and 2771 were all represented once 
(4%) (Appendix 6.4) (Tahle 3.5). These represented STs that were not closely
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associated with other STs within the population, although some are assigned to 
complex lineages.
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Figure 3.6 Meningococcal analysis based upon related sequence types 
(BURST) from meningococci isolated in 1999 (year 1). The complete dataset of 
sequence types (ST) are grouped based upon the similarity of five or more allele 
numbers within an allelic profile. These are tabulated and presented as the ST 
combined with its frequency within the population and the genetic relatedness 
between other STs within the group. Each group is analysed based upon any single 
locus, double locus or satellite nucleotide changes between associated STs. If there 
are numerous STs associated to a single group a central ST is identified and is 
signified within the table with an asterisk (*). Furthermore this diagram highlighting 
the relatedness between different STs is displayed below the table. This diagram 
highlights the central ST within the centre of the circle and each ST located in the first 
outer circle will have a single locus variant (SLV) association with the central ST. 
Similarly, each ST within the second ring will have a double locus variant (DLV) 
association with the central ST. In addition, lines linking different STs will highlight 
either SLV or DLV associations with each other. Any STs that do not group are listed 
at the end and are termed “singletons”. Because they have no other closely associated 
ST they are displayed with their ST and the frequency within the population.
Group: 1 (55 isolates)
ST Frequency Single locus variants Double locus variants Satellites
11 53 1 0 0
655 2 1 0 0
Group: 2 (22 isolates)
ST Frequency Single locus variants Double locus variants Satellites
1255 1 1 2 4
41* 14 3 3 1
1097 2 0 1 6
146 1 1 2 4
1194 1 0 2 5
44 1 1 3 3
46 1 1 3 3
170 1 1 4 2
Summary view:
11Ô4 44
46
1097
146
1255
170
SLV ST DLV ST SAT ST SLV Link DLV Link
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Group: 3 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2772 1 0 1 1
457 1 1 1 0
472 1 1 0 1
Group: 4 (17 isolates)
ST Frequency Single locus variants Double locus variants Satellites
352 3 1 4 2
1273 1 1 2 4
1416 1 2 0 5
269 6 2 1 4
1095 1 2 0 5
2775 1 0 2 5
2776 1 1 2 4
275* 3 3 1 3
Summary view:
i 4i6
1095 2692775
1273
275
352
SLV ST DLV ST SAT ST SLV Link DLV Link
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Group: 5 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
33 2 1 0 0
32 1 1 0 0
Group: 6 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2013 1 1 0 1
2294 1 0 1 1
60 1 1 1 0
Singleton sequence types (27 isolates)
ST Frequency
23 1
284 3
213 5
2771 1
22 2
18 4
2292 1
1819 1
2293 1
750 2
1738 1
2295 1
29 1
271 2
2296 1
These isolates are grouped into 6 lineage(s), with 15 singleton sequence type(s). 
Founder sequence types are marked with an asterisk (*).
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Table 3.5 Distribution of meningococcal housekeeping genes represented by 
allele number from meningococci isolated in 1999 (year 1), A complete list of 
allele types directly correlated with the total number identified within each specific 
housekeeping gene from meningococci isolated during 1999.
Allele abcZ adk aroE fumC gdh pdhC pgm
1 5 4
2 59 10 2 13
3 19 59 55 4 3 2
4 21 55 3 56
5 15 3 26 2 3
6 25 2 9 23 56
7 10 1 1
8 5 5 2 64 6
9 4 22 21 26 1 35
10 1 22 5 1 5 3
11 2 3 4 19
12 1 2
13 1 1 6
15 10 2 6
16 1 2
17 2 5 2
18 4 1 1
19 2 4
20 3 2 4
21 2
24 2 3
25 1
26 3
34 1
35 1
36 5
38 5 1
44 2
46 1
53 5
60 1
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3.3.2 Sequence Types, Lineages and Inter-Lineage Variability in 2000.
With reference to section 3.0, these isolates were categorised into 47 different STs, an 
increase of 13% on the previous year (Figure 3.7). Using BURST analysis they were 
further differentiated into nine distinct lineages, an increase of 33% on the previous 
year, with a 27% decrease in singleton representation. These lineages occurred 
between one (0.8%) and 49 (38%) times during 2000. This was statistically similar to 
the previous year with a variation in range of less than 5%. Sequence type complex 
11 continued to account for the majority with 49 (38%) isolates these were not 
associated with any other STs and represented all the STs within the ST-11 complex. 
This large proportion of isolates accounted for 80% of all singletons during 2000. The 
ST-44 complex accounted for 22 isolates (17%), which were divided into 10 different 
STs, an increase within the complex of 20%. There was a decrease of 14% in ST-41 
isolates and the presence of only two further STs that were present in 1999, both ST- 
44 (9%) and ST-46 (4.5%). The remaining STs had not been isolated in the previous 
year. These were ST-154 (9%) and ST-180 340 1009 2120 2300, and 2303 (4.5%). 
Within this lineage there were 12 single locus variants, an increase of 33%, combined 
with 22 double locus variants, an increase of 10%, and 56 satellites, an increase of 
100%. The ST-269 complex accounted for 14 isolates (11%), a decrease of 18%. 
These were divided into four groups, a decrease of 50% on the previous year, ST-269 
(57%), an increase of 25%, ST-275 (29%), an increase of 25%, ST-352 and 1273 were 
represented once (7%). hiter-lineage variation accounted for four single locus 
variants, a decrease of 50%, four double locus variants, a decrease of 55%, and four 
satellites, a decrease of 84%. A further 11 (8%) isolates were grouped without any 
association to a ST complex. These were divided with eight ST-213 isolates (73%), 
an increase of 37.5% and thi'ee isolates, ST-2301 2660, and 2782 all represented once
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(9%). These isolates were not represented in the previous year. This highlights an 
expansion of isolates closely associated with ST-213 by 27%. Inter-lineage variation 
accounted for two single locus variants combined with four double locus variants and 
six satellites. The ST-32 complex accounted for 6 isolates, an increase of 100%, these 
were represented by six individual STs, ST-32 33 84 259 2298, and 2784 (16.7%). 
Inter-lineage variation accounted for 12 single locus variants with 10 double locus 
variants and eight satellites. The ST-18 complex accounted for four isolates (3%), 
with two ST-2305 (50%) and one ST-18 and 2028 (25%). This complex highlights an 
expansion of a singleton ST-18 from the previous year however a 75% decrease in 
ST-18 isolates was observed. Inter-lineage variation accounted for two single and 
double locus variants combined with two satellites. The ST-22 complex had four 
isolates represented by tliree ST-22 strians (75%) and a single ST-184, with two 
double locus variants. This again was an expansion of a singleton ST-22 from the 
previous year with a 33% increase hom the previous year. The tluee remaining ST 
gi’oups had no complex association. The first group contained four isolates (3%) 
represented by two ST-168 (50%) isolates and a single ST-167 and 1198 (25%). 
Inter-lineage variation accounted for two single and double locus variants combined 
with two satellites. The second group contained two isolates (2%), ST-2779 and 
2299, with inter-lineage variation accounting for two single locus variants. The final 
group contained two isolates (2%), ST-2297 and 2302, with inter-lineage variation 
accounting for two single locus variants. All three groups containing these STs had 
not been represented in the previous year. The singletons accounted for 61 isolates, an 
increase of 111% on the previous year. These were differentiated between 11 
different STs, ST-11 accounting for the majority of isolates (80%), ST-8 and ST-60 
(3%) with ST-53 457 772 2304 2777 2781 2851, and 2852 all represented once
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(2%) (Appendix 6.5) (Table3.6) with the exclusion of ST-11 isolates the singletons 
would account for 9% of the total number of isolates, a decrease of 11% on the 
previous year.
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Figure 3.7 Meningococcal analysis based upon related sequence types 
(BURST) from meningococci isolated in 2000 (year 2). The complete dataset of 
sequence types (ST) are grouped based upon the similarity of five or more allele 
numbers within an allelic profile. These are tabulated and presented as the ST 
combined with its frequency within the population and the genetic relatedness 
between other STs within the group. Each group is analysed based upon any single 
locus, double locus or satellite nucleotide changes between associated STs. If there 
are numerous STs associated to a single group a central ST is identified and is 
signified within the table with an asterisk (*). Furthermore, this diagram highlighting 
the relatedness between different STs is displayed below the table. This diagram 
highlights the central ST within the centre of the circle and each ST located in the first 
outer circle will have a single locus variant (SLV) association with the central ST. 
Similarly, each ST within the second ring will have a double locus variant (DLV) 
association with the central ST. In addition, lines linking different STs will highlight 
either SLV or DLV associations with each other. Any STs that do not group are listed 
at the end and are termed “singletons”. Because they have no other closely associated 
ST they are displayed with their ST and the frequency within the population.
Group: 1 (14 isolates)
ST Frequency Single locus variants Double locus variants Satellites
352 1 1 2 0
275* 4 2 0 1
269 8 0 1 2
1273 1 1 1 1
Summary view:
269
1273 352
275
SLV ST DLV ST SAT ST SLV Link DLV Link
Group: 2 (6 isolates)
ST Frequency Single locus variants Double locus variants Satellites
84 1 2 1 2
2298 1 1 2 2
259 1 1 2 2
33 1 3 2 0
32 1 3 2 0
2784 1 2 1 2
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Group: 3 (22 isolates)
ST Frequency Single locus variants Double locus variants Satellites
41* 11 3 2 4
1009 1 1 2 6
154 2 2 2 5
2300 1 1 3 5
44 2 2 3 4
180 1 1 1 7
2303 1 0 3 6
46 1 2 3 4
2120 1 0 2 7
340 1 0 1 8
Summary view:
Group: 4 (4 isolates)
3^
120
154
2^
1009
SLV ST DLV ST SAT ST SLV Link DLV Link
ST Frequency Single locus variants Double locus variants Satellites
22 3 0 1 0
184 1 0 1 0
Group: 5 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2297 1 1 0 0
2302 1 1 0 0
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Group: 6 (11 isolates)
ST Frequency Single locus variants Double locus variants Satellites
213 8 1 1 1
2301 1 0 1 2
2782 1 0 1 2
2660 1 1 1 1
Group: 7 (4 isolates)
ST Frequency Single locus variants Double locus variants Satellites
167 1 1 1 0
168 2 0 1 1
1198 1 1 0 1
Group: 8 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2299 1 1 0 0
2779 1 1 0 0
Group: 9 (4 isolates)
ST Frequency Single locus variants Double locus variants Satellites
18 1 1 1 0
2305 2 1 0 1
2028 1 0 1 1
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Singleton sequence types (61 isolates)
ST Frequency
11 49
2777 1
8 2
60 2
2304 1
457 1
2851 1
2852 1
53 1
2781 1
772 1
The isolates are grouped into 9 lineage(s), with 11 singleton sequence type(s). 
Founder sequence types are marked with an asterisk (*).
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Table 3.6 Distribution of meningococcal housekeeping genes represented by 
allele number from meningococci isolated in 2000 (year 2). A complete list of 
allele types directly correlated with the total number identified within each specific 
housekeeping gene from meningococci isolated during 2000.
Allele abcZ adk aroE fumC gdh pdhC pgm
1 1 11 3
2 56 4 5 2 10
3 16 52 51 5 6
4 20 49 5 50
5 19 6 23 2
6 22 6 6 24 49
7 14 3 2 1
8 4 3 4 61 11
9 5 24 17 23 34
10 22 4 4 1 3
11 5 1 6 15
12 2 3 1
13 11
14 1
15 1 8 11
16 1 3 2 2 1
17 3 7 1 3
18 3 2 4
19 3 5 1
21 1 4
22 3 2
24 1 4
25 1 1
26 1 2
27 1
35 1 2
36 10
38 5
40 1
53 9
54 2
142
60 2 1
63 1
64 1
72 1
118 1
120 1
133 1
154 1
Total 14 10 18 13 15 17 12
143
3.3.3 Sequence Types, Lineages and Inter-Lineage Variability in 2001.
With reference to section 3.0, these isolates were categorised into 47 different STs, 
remaining consistent with the previous year (Figure 3.8). Using BURST analysis they 
were further differentiated into eight different lineages, a decrease of 11% from the 
previous year. These lineages occurred between one (1%) and 18 (23%) times during
2001. This range variation was significant smaller, with a 15% decrease in the upper 
percentage limit. This highlights a significant decrease in the representation of 
multiple isolates and the subsequent increase in single represented isolates. Sequence 
type complex 11 continued to account for the majority with 20 isolates (25%) 
containing 18 ST-11 isolates (90%) a 63% decrease on the previous year with both 
ST-1189 and 2031 represented once (5%). The highlighted an expansion in the ST-11 
complex, neither closely associated ST-11 isolate had been represented in previous 
years. Inter-lineage variation accounted for two single locus variations combined with 
four double locus variations. The ST-269 complex accounted for 15 isolates (19%), 
an increase of 5% on the previous year. These were divided into 10 different STs, an 
increase of 150% on the previous year. ST-269 and 275 accounted for tlnee isolates 
(20%), a decrease of 133% and a 25% increase on the previous year respectively. ST- 
352 was represented once (7%) and remained unchanged from the previous year. ST- 
1049 appeared twice (13%) and was not represented in previous years. The remaining 
STs, ST-479 1416 1774 2307 2315, and 2324 were all represented once (7%). Only 
ST-1416 was represented previously in 1999. hiter-lineage variation accounted for 10 
single locus variations, a 120% increase combined with 24 double locus variations, a 
500% increase and 56 satellites, an increase of 1300% increase. This highlighted 
statistically significant increases in sequence variation within this complex, which is a 
result of the expansion of closely associated STs within the complex. A further six
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isolates (7.5%) were grouped without any association to an ST complex. This 
represented four ST-213 isolates (67%), a decrease of 50% on the previous year, and 
two ST-1218 isolates (33%). This highlighted a decrease in ST-213 and their closely 
associated isolates with inter-lineage variation accounted for only two single locus 
variations. The ST-22 complex had five isolates (6%), a 20% increase on the previous 
year with three ST-184 isolates (60%) a 67% increase, ST-22 and 1224 were 
represented once, hrter-lineage variation accounted for four single locus variants 
combined with two double locus variants. The ST-32 complex accounted for four 
isolates (5%) a 33% decrease. This complex was represented by two ST-259 isolates 
(50%) with ST-32 and 33 represented once. This complex shows significant 
contraction with a 50% decrease in the number of different STs represented within the 
complex. The remaining STs have all been represented previously and have 
consolidated their presence within the complex. As a consequence, the inter-lineage 
variation accounted for four single locus variants combined with two double locus 
variants. The ST-18/44 complex accounted for three isolates (4%), a 25% decrease on 
ST-18 complex isolates, with ST-18, 41, and 2310 all represented once. Again this 
complex has maintained its presence with closely associated isolates and although ST- 
18 and 41 are associated with different eomplexes, BURST analysis has grouped these 
together in the same group within this year, hiter-lineage variation accounted for two 
single locus variations, combined with one double locus variation and five satellites. 
The second ST-44 complex accounted for three isolates (4%), with a single 
representation of ST-154, 2314, and 2323, a significant decrease of 733% on the 
previous year. One remaining group had no complex association and accounted for 
tlii’ee isolates (4%) represented by two ST-2306 strains and a single ST-2309. Inter­
lineage variation accounted for two single locus variations. The singletons accounted
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for 21 isolates (26%), with the exclusion of ST-11 isolates this represented a 43% 
increase in the previous year. These were differentiated into 18 different STs, ST-461, 
1217 and 1345 were represented twice (10%), with ST-8, 15, 36, 60, 168, 212, 284, 
286, 750, 1157, 2308, 2311, 2313, 2316, and 2322 represented once (Appendix 6.6) 
(Table 3.7).
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Figure 3.8 Meningococcal analysis based upon related sequence types 
(BURST) from meningococci isolated in 2001 (year 3). The complete dataset of 
sequence types (ST) are grouped based upon the similarity of five or more allele 
numbers within an allelic profile. These are tabulated and presented as the ST 
combined with its frequency within the population and the genetic relatedness 
between other STs within the group. Each group is analysed based upon any single 
locus, double locus or satellite nucleotide changes between associated STs. If there 
are numerous STs associated to a single group a central ST is identified and is 
signified within the table with an asterisk (*). Furthermore, this diagram highlighting 
the relatedness between different STs is displayed below the table. This diagram 
highlights the central ST within the centre of the circle and each ST located in the first 
outer circle will have a single locus variant (SLV) association with the central ST. 
Similarly, each ST within the second ring will have a double locus variant (DLV) 
association with the central ST. In addition, lines linking different STs will highlight 
either SLV or DLV associations with each other. Any STs that do not group are listed 
at the end and are termed “singletons”. Because they have no other closely associated 
ST they are displayed with their ST and the frequency within the population.
Group: 1 (8 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2324 1 0 2 2
1049* 2 2 1 1
269 3 1 3 0
479 1 1 2 1
1774 1 0 2 2
Summary view:
1%74
479
1049 269 2324
Group: 2 (19 isolates)
SLV ST DLV ST SAT ST SLV Link DLV Link
ST Frequency Single locus variants Double locus variants Satellites
2031 1 0 2 0
11 17 1 1 0
1189 1 1 1 0
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Group: 3 (4 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2323 1 0 1 2
2314 1 1 1 1
154 1 1 1 1
41* 1 2 1 0
Summary view:
154 2314
2323
SLV ST DLV ST SAT ST SLV Link DLV Link
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Group: 4 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
33 1 1 1 0
32* 1 2 0 0
259 1 1 1 0
Summary view:
259
SLV ST DLV ST SAT ST SLV Link DLV Link
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Group: 5 (5 isolates)
ST Frequency Single locus variants Double locus variants Satellites
22* 1 2 0 0
184 3 1 1 0
1224 1 1 1 0
Summary view:
1224
184
SLV ST DLV ST SAT ST SLV Link DLV Link
Group: 6 (5 isolates)
ST Frequency Single locus variants Double locus variants Satellites
275 3 1 1 0
2307 1 1 0 1
2315 1 0 1 1
Group: 7 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2306 2 1 0 0
2309 1 1 0 0
150
Group: 8 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2310 1 1 0 0
18 1 1 0 0
Group: 9 (6 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2321 1 0 2 0
213 4 1 1 0
1218 1 1 1 0
Singleton sequence types (19 isolates)
ST Frequency
168 1
284 1
1217
2322 1
36 1
2308 1
286 1
8 1
1157 1
212 1
1345
60 1
461
15 1
2313 1
2316 1
The isolates are grouped into 9 lineage(s), with 16 singleton sequence type(s). 
Founder sequence types are marked with an asterisk (*).
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Table 3.7 Distribution of meningococcal housekeeping genes represented by 
allele number from meningococci isolated in 2001 (year 3). A complete list of 
allele types directly correlated with the total number identified within each specific 
housekeeping gene from meningococci isolated during 2001.
Allele abcZ adk aroE fumC gdh pdhC pgm
1 1 6 1 4
2 23 7 1 6
3 7 21 22 3 4
4 19 1 21 2 23
5 23 4 12 1 1 2
6 3 7 1 7 5 20
7 7 1 2 1
8 5 2 7 31 5
9 1 11 8 10 16
10 17 2 2
11 5 6 17
12 3 6 2 2
13 1 9 2
14 1 2
15 1 9 1 9
16 1 1 3
17 1 6 6
18 5 1 1
19 1 2 2
20 1 3
21 1 2 5
22 7
23 1
24 1 2
25 1
26 1 1 2
34 1 1
35 1 2
36 6 1
38 5
40 2
152
43 1
46 1
49 1
53 ■ ^ 4
60 1 2
63 1
69 1
76 3
78 1
117 3
133 1
161 1
Total 16 13 17 17 16 16 14
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3.3.4 Sequence Types, Lineages and Inter-Lineage Variability in 2002.
With reference to section 3.0, these isolates were categorised into 49 different STs, a 
4% increase on the previous year (Figure 3.9). Using BUSRT analysis they were 
further differentiated into nine different lineages, an increase of 11 %on the previous 
year. These lineages occurred between one (1%) and 10 (11%) times during 2002. 
The range variation was again significantly smaller, with a 12% decrease in the upper 
limit. This was a further continuation towards a gieater proliferation of different STs 
and thus a greater representation of single isolates. The ST-269 complex accounted 
for 17 isolates (19%), an increase of 12% on the previous year. These were divided 
into 10 different STs which remained consistent. ST-269 and 275 accounted for four 
isolates (24%), ST-2205 accounted for two isolates (12%), with ST-13, 283, 467, 
1095, 2157, 2166, 2205 and 2319 represented once (6%). ST-269 and 275 both 
increased by 25% on the previous year and of the remaining STs none had been 
represented in previous years, hiter-lineage variation accounted for 24 single locus 
variations, a 140% increase, combined with 26 double locus variations, an 8% 
increase, with 40 satellites, a decrease of 29% on the previous year. The ST-44 
complex accounted for 14 isolates (15%), an increase of 367% and more 
representative of the ST-44 complex in 2000. ST-41 accounted for five isolates
(36%), with tln-ee ST-180 isolates (21%) and ST- 155, 207, 340, 1233, 2159 and 2203 
were represented once (7%). hiter-lineage variation accounted for two single locus 
variations combined with 20 double locus variations and 34 satellites. This was more 
consistent with inter-lineage variation of this complex representation during 2000. 
ST-32 complex accounted for 13 isolates (14%) a 225% increase. This complex was 
represented by six different STs. ST- 259 accounted for seven isolates (54%), an 
increase of 250% with two ST-34 isolates (15%) and ST- 32, 33, 1098 and 2276
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represented once (8%). This complex shows significant expansion with a 100% 
increase in the number of different STs represented within the complex. As a 
consequence the inter-lineage variation accounted for 10 single locus variations 
combined with 12 double locus variations and eight satellites. The ST-22 complex 
had five isolates (6%), with three ST-22 isolates (60%), and ST-1224 represented 
twice. This represented a consolidation of ST-22 and 1224 and the disappearance of 
ST- 184 from the previous year. Inter-lineage variation accounted for two single locus 
variations. The ST-18 complex accounted for three isolates (3%) with two ST-18 
isolates and a single ST-2337. On this occasion ST-41 was not gimiped within this 
complex and was considered more closely associated with alternative STs within
2002. hiter-lineage variation accounted for two single locus variations. The 
remaining four gimips had no complex association. The first group contained four 
isolates (4%) with three ST-60 isolates and a single ST-1650, with an inter-lineage 
variation of two single loci. The non-complex associated group represents an 
expansion of ST-60 from a singleton sequence type in the previous year. The second 
gi’oup contained two isolates, ST-168 and 766 and again this was an expansion of a 
previously associated singleton sequence type in the previous year, with inter-lineage 
variation of two double loci. The third group contained two isolates, ST 2147 and 
2240 with two single locus variations. The forth group contained two isolates, ST- 
2151 and 2275 with two double locus variations. Both previous groups had not been 
represented in the previous year. The singletons accounted for 29 isolates (32%), an 
increase of 28% on the previous year. These were differentiated into 13 different STs, 
ST-11 (35%), ST-213 (24%), ST-1345 (7%) and ST-103, 136, 866, 1167, 1466, 2161, 
2204, 2239, 2317 and 2318 were represented once (Appendix 6.7) (Table 3.8). ST-11 
decreased by a further 44% on the previous year. ST-213 increased by 43% on the
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previous year although ST-213 was not closely associated with other STs during 2002. 
Existing singletons from 2002 had remained non-associated with other STs compared 
with the previous year.
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Figure 3.9 Meningococcal analysis based upon related sequence types 
(BURST) from meningococci isolated in 2002 (year 4). The complete dataset of 
sequence types (ST) are grouped based upon the similarity of five or more allele 
numbers within an allelic profile. These are tabulated and presented as the ST 
combined with its frequency within the population and the genetic relatedness 
between other STs within the group. Each group is analysed based upon any single 
locus, double locus or satellite nucleotide changes between associated STs. If there 
are numerous STs associated to a single group a central ST is identified and is 
signified within the table with an asterisk (*). Furthermore, this diagram highlighting 
the relatedness between different STs is displayed below the table. This diagram 
highlights the central ST within the centre of the circle and each ST located in the first 
outer circle will have a single locus variant (SLV) association with the central ST. 
Similarly, each ST within the second ring will have a double locus variant (DLV) 
association with the central ST. In addition, lines linking different STs will highlight 
either SLV or DLV associations with each other. Any STs that do not group are listed 
at the end and are termed “singletons”. Because they have no other closely associated 
ST they are displayed with their ST and the frequency within the population.
Group: 1 (14 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2203 1 0 2 5
340 1 0 1 6
180 3 0 1 6
41 5 1 5 1
2159 1 0 1 6
207 1 0 4 3
155 1 0 4 3
1233 1 1 2 4
Group: 2 (12 isolates)
ST Frequency Single locus variants Double locus variants Satellites
1098 1 1 1 3
259 6 1 2 2
33 1 2 3 0
32* 1 3 1 1
34 2 2 2 1
2276 1 1 3 1
Summary view:
2276 259
33
34
1098
SL V ST  
DLVST 
SAT ST 
SLV Link 
DLV Link
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Group: 3 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
1224 1 1 0 0
22 2 1 0 0
Group: 4 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2151 1 0 1 0
2275 1 0 1 0
Group: 5 (16 isolates)
ST Frequency Single locus variants Double locus variants Satellites
269* 4 4 2 2
13 1 0 5 3
283 1 3 2 3
275 4 1 1 6
2157 1 1 1 6
2319 1 1 4 3
1095 1 3 2 3
2166 1 3 2 3
2205 2 0 3 5
Summary view;
’2205
1095
2692157
SLV ST DLV ST SAT ST-  SLV Unk-  DLV Link
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Group: 6 (3 isolates)
ST Frequency Single locus variants Double locus variants Satellites
18 2 1 0 0
2337 1 1 0 0
Group: 7 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
766 1 1 0 0
168 1 1 0 0
Group: 8 (2 isolates)
ST Frequency Single locus variants Double locus variants Satellites
2147 1 1 0 0
2240 1 1 0 0
Singleton sequence types (30 isolates)
ST Frequency
11 9
60 3
866 1
103 1
2317 1
2318 1
1345 2
213 6
2161 1
136 1
1466 1
2204 1
2239 1
1167 1
The isolates are grouped into 8 lineage(s), with 14 singleton sequence type(s). 
Founder sequence types are marked with an asterisk (*).
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Table 3.8 Distribution of meningococcal housekeeping genes represented by 
allele number from meningococci isolated in 2002 (year 4), A complete list of 
allele types directly correlated with the total number identified within each specific 
housekeeping gene from meningococci isolated during 2002.
Allele abcZ adk aroE fumC gdh pdhC pgm
1 1 4 1
2 13 5 1 13
3 9 11 1 11 7 13 1
4 28 1 11 6 10
5 24 13 14 5
6 3 15 3 10 16 11
7 10 1 2 2
8 6 3 5 22 2 17
9 3 15 17 14 23
10 1 30 2 3
11 5 2 5 18
12 1 4 2 2
13 2 9 2 1
14 2
15 10 8
16 1 4 1
17 5 6 3
18 5 3 2
19 6 3 1
20 1
21 1 1 5
22 1
24 1 6
26 4
27 1
28 1
29 1
35 1
36 7
38 7
40 9
160
Total
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3.4 Diversity of Housekeeping Genes and Sequence Types.
During this four-year study the distribution of housekeeping genes within a ST and the 
diversity of STs displayed specific patterns or lack of depending on the serogroup of 
the meningococci. Serogi'oup C isolates were extremely clonal and this was 
confirmed with an almost exclusive association with ST-11 and the ST-11 complex. 
The other major serogroup causing disease in Scotland displayed the opposite, with a 
wide range of different STs although these do conform to major ST complexes and 
these complexes have been consistently, and in some cases increasingly prominent, 
over the past four years.
The number of alleles present at each locus for each of the four years (1999, 2000, 
2001 and 2002), ranged between 8 for adk in 1999 and 20 for aroE in 2002. The 
number of polymoiphic sites present at each locus for each year ranged between 14 in 
1999 (3% of sites for adl^ and 128 in 2002 (26% of sites for aroE). Table 3.10 shows 
the comparison of this data for all four years. The number of alleles as a function of 
the number of isolates examined was calculated and there was a clear conelation 
between the increase in the alleles identified with an increase in the number of isolates 
examined (data not shown). This also correlated with previous studies where similar 
results were obtained (Holmes et al. 1999; Jolley et al. 2000).
It was found that the meningococcal population was highly diverse and an increasing 
trend of complex diversity was noted in individual years. The incidence of serogioup 
C meningococci changed significantly during the study, decreasing fiom 58 (45%) in 
year one to 10 (11%) in year four (p = <0.0001). The isolation of serogroup B
162
meningococci also changed resulting in a slight increase from 65 (50%) in yeai- one to 
69 (78%) in year four, although this was not significant (p = 0.06). Similarly, there 
was no significant change in the isolation of other serogroups (p = 0.6). In year one, 
serogl'oup C meningococci were assigned to only five different STs, 95% of which 
were contained within two complexes (ST-11 complex (93%) and ST-269 complex 
(2%)). Serogroup B meningococci were assigned to 31 different STs, 68% of which 
were contained within five complexes (ST-44 complex (34%), ST-269 complex 
(18%), ST-18 complex (8%), ST-35 complex (5%) and ST-32 complex (3%)). 
However, the serogroups associated with different STs changed between year one and 
four, such that, in year four, serogi'oup C meningococci were assigned to only two 
different STs, all of which were contained within two complexes (ST-11 complex 
(91%), and ST-269 complex (9%)). Serogroup B meningococci were assigned to 40 
different STs, 68% of which were contained within five complexes (ST-269 complex 
(26%), ST-44 complex (19%), ST-32 complex (16%), ST-18 complex (4%) and ST- 
254 (3%)) (table 3.9). hnportantly, over the study period, the serogi’oup C ET-37/ST- 
11 genetic lineage declined significantly (p = <0.0001) and there was no 
corresponding increase in serogroup B of the ET-37/ST-11 genetic lineage (p = 1). 
Moreover, there was no development of capsule switch as determined by serogioup 
and ST association. Analysis of allele fi'equency showed that the number of alleles 
present at each locus for each of the four years ranged between eight for adk 
(adenylate kinase) in year one and 20 for aroE (shikimate dehydrogenase) in year four. 
The number of polymoiphic sites present at each locus for each year ranged between 
14 in year one (3% of sites for adk) and 128 in year four (26% of sites for aroE). The 
number of alleles as a function of the number of isolates indicated a clear correlation 
between the increases in the alleles identified with an increase in the number of
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isolates examined. This is further evidence of meningococcal genetic diversity.
Disregarding serogroup, in year one, meningococci were assigned to 41 different STs 
and six distinct lineages, with 15 singleton types (11.5%) (i.e. no complex 
association). These lineages occun'ed between one (0.8%) and 55 (42%) times during 
year one. Isolates of the ST- II complex accounted for 55 (42%) isolates and were 
assigned to two STs (ST-11 (n=53) and ST-655 (n=2)), the latter of which is a gdh 
(glucose-6-phosphate dehydrogenase) locus variant of ST-11. The ST-44 complex 
accounted for 22 isolates (17%) and these were divided into eight different STs, 14 
were ST-41 (64%), two were ST-1097 (9%) and ST-44, 46, 146, 170, 1194 and 1255 
were each represented by a single isolate (4,5%). hi year two, meningococci were 
assigned to 47 different STs, an increase of 13% on the previous year. They were 
further differentiated into nine distinct lineages, an increase of 33% on the previous 
year, with a 27% decrease in singleton representation. These lineages occuned 
between one (0.8%) and 49 (38%) times during year two. This was statistically similar 
to the previous year (p = 0.714). Meningococci of the ST-11 complex continued to 
account for the majority (38%) of isolates. In year three, meningococci were assigned 
to 47 different STs and were differentiated into eight different lineages, a decrease of 
11% from the previous year, demonstrating an increase in ST diversity. These lineages 
occun'ed between one (1%) and 18 (23%) times during year tliree. This range variation 
was significant smaller (p =0.0443), This highlights a significant decrease in the 
representation of multiple isolates and the subsequent increase in single represented 
isolates. Meningococci of the ST-11 complex continued to account for the majority 
(25%) of isolates. In year four, meningococci were assigned 49 different STs, a 4% 
increase on the previous year and were differentiated into nine different lineages, an
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increase of 11% on year tliree. These lineages occurred between one (1%) and ten 
(11%) times and were therefore again smaller, but not significantly so (p = 0.2621), 
resulting in a greater proliferation of different STs and thus a gieater representation of 
single isolates. The ST-269 complex accounted for 17 isolates (19%), an increase of 
12% on year tliree. These were divided into 10 different STs that remained consistent. 
ST-269 and 275 accounted for four isolates (24%), ST-2205 accounted for two 
isolates (12%), with ST-13, 283, 467, 1095, 2157, 2166, 2205 and 2319 represented 
once (6%). ST-269 and 275 both increased by 25% on year tliree and of the remaining 
STs none had been represented in previous years. Inter-lineage variation accounted for 
24 single locus variations, a 140% increase, combined with 26 double locus 
variations, an 8% increase, with 40 satellites, a decrease of 29% on year tliree. The 
singletons accounted for 29 isolates (32%), an increase of 28% on the previous year. 
These were differentiated into 13 different STs, ST-11 (35%), ST-213 (24%), ST- 
1345 (7%) and ST-103, 136, 866, 1167, 1466, 2161, 2204, 2239, 2317 and 2318 were 
represented once each (3.5%). ST-11 decreased by a further 44% on year tlnee. 
Mutation and/or recombination events were calculated by determining the number of 
substitutions per nonsynonymous (<7N) and synonymous (JS) site within a particular 
nucleotide sequence, and by calculating the index of association (lA) (table 3.10). 
Firstly, (7N /dS ratios were calculated for the 432 isolates in this study which showed 
that nonsynonymous nucleotide sequence changes were selected out of the population. 
This data was then compared to invasive meningococci contained within the global 
dataset (http://neisseria.mlst.net). The data was comparable, with only a few 
differences between the ratio values, except for aroE, suggesting that the proteins that 
they encode are well conseiwed. The /dS ratio value was >1 for aroE indicating 
that the proteins they encode are not so well conserved and nonsynonymous changes
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were coiTected faster than their occuiTence by mutation (appendix 6.8). The index of 
association (lA) for the meningococcal population in years one to four was high 
(between 2.564 and 4.469) indicating a clonal population (table 3.10).
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Table 3.9 Complex assignment, association, intra-complex variation and 
serogroup distribution from 1999 to 2002 (years 1 to 4). Sequence Type (ST) 
complexes displayed with their associated STs combined with both percentage 
nucleotide difference between represented STs within a complex (intra complex 
variation) and the serogroup distribution within each year.
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3.5 Synonymous and Non synonymous Nucleotide Substitutions
This represents the number of substitutions per synonymous (ds) and non-synonymous 
(dM) site within a particular sequence. This is calculated fiom the sequence of interest 
using the method of Nei and Gojobori and is implemented within the Sequence type 
analysis and recombinational tests (START) program located on the internet 
(http://outbreak.ceid.ox.ac.uk/software.htm). The START software will therefore 
determine the d^ /ds ratio, which can be used as a marker of selection pressure. The 
individual ds and dn values were calculated and the ratio obtained. This data is 
compared with isolates pertaining to the same criteria as our population, namely the 
isolates were exclusively from invasive sites and patients with confirmed 
meningococcal disease. The data was comparable, with only a few differences 
between the ratio values, except for aroE. The J/v /ds ration value was significantly 
higher then previously calculated for similar isolates (table 3.10).
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Table 3.10 The synonymous (ds), nonsynonymous (d„) and index of association 
rates from 1999 to 2002 (years 1 to 4). The dS/dN ratio was obtained using the 
method developed by Nei et al, which estimates synonymous substitutions by means 
of an unweighted pathway method. The index of association ( I a )  measures the extent 
of linkage equilibrium within a population. If there is frequent recombination events 
within the meningococci within that year the value will be close to zero. If clonal 
populations are identified the Ia will differ significantly fiom zero. These values are 
in relation to both a specific housekeeping gene and the year isolated.
Year
Housekeeping Gene 1999 2000 2001 2002
abcZ (putative ABC transporter) 0.0544 0.0570 0.0496 0.0647
adk (adenylate kinase) 0.0208 0.0137 0.0121 0.0166
aroE (shikimate dehydrogenase) 1.7749 1.6128 1.5805 1.6553
fumC (fumarate hydratase) 0.0115 0.0158 0.0178 0.0288
gdh (glucose-6-phosphate dehydrogenase) 0.0520 0.0494 0.0420 0.0557
pdhC (pyruvate dehydrogenase subunit) 0.0679 0.0688 0.0618 0.0646
pgm (phosphoglucomutase) 0.1275 0.1081 0.1162 0.1089
Ia ( Index of association) 4.469 4.372 2.979 2.564
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3.6 Discussion
A number of studies have been performed with collections of meningococci that have 
either caused disease or have been taken fiom healthy individuals who cairy 
meningococci as a commensal residing at the back of the tlii'oat. This is represented by 
an ever-increasing number of ST types closely associated with meningococcal disease 
or carriage within the MLST database (Jolley et al. 2000; Clarke et al. 2001b; Nicolas et 
al. 2001; Van Looveren et al. 2001; Jacobsson et al. 2003). These collections have 
concentrated on sample populations and subsequent inference has been made on a 
limited number of strains in proportion to the perceived total population of both 
diseased patients and/or natural earners (Clarke et al. 2001b; Maiden and Stuart 2002). 
This study had taken all available invasive isolates over a four-year period and 
characterised through sequencing, the genes responsible for the MLST and subtype 
profile of the organism, these include the seven housekeeping genes responsible for 
meningococcal MLST. The diversity of the different serogroups, types and subtypes 
within the meningococcal population fi'om Scotland compared to data fiom the MLST 
website and annual reports released by various national reference facilities are not 
dissimilar to many other European countries therefore such unique data is extremely 
informative not only to Scotland. The diversity of housekeeping genes and STs over 
the four-year period remained stable, however, the continuous nature of the sampling 
technique and the number of isolates did give rise to a significant proportion of new 
combinations of alleles thus pertaining to new ST profiles. Interestingly, no novel gene 
sequences were obtained within the same population, except one novel aroE gene was 
identified. This would confirm the obseiwations, which place aroE above all others 
with the highest percentage of polymorphic sites, with a range of between 25% and
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26% of the total gene sequence.
This information combined with detailed patient data including immunisation status, 
age, location and sex (data not shown) can provide a detailed picture of the 
meningococci causing disease at a national level. As the immunisation of high-risk 
groups continues, the definitive effect of the vaccine has been analysed and primarily 
shows a significant decrease in serogroup C meningococcal disease since the MenC 
vaccine was introduced, however obseiwing the national trend during the past 20 years 
does indicate a continual flux between serogroup B and C isolates predominating and 
this will require further obseiwations.
Polysaccharide conjugate vaccines are providing essential and highly effective 
immunization against some of the major human pathogens (Rappuoli 2001a; 
Rosenstein et al. 2001a; Maiden and Stuart 2002; Ada and Isaacs 2003). To coincide 
with the introduction of the UK MenC immunisation programme, prospective 
enlianced surveillance of those meningococci associated with throat carriage and 
invasive disease was investigated (Anon 1998c; Clarke et al. 2001b; Maiden and 
Stuart 2002). The implementation of MenC vaccines has led to a reduced level of 
serogroup C meningococcal tlnoat carriage and also a reduced level of invasive 
disease (Ramsay et al. 2001; Maiden and Stuart 2002; Ramsay et al. 2003). However, 
since the population dynamics of meningococcal disease is veiy fluid, with serogroup 
B and serogroup C historically undergoing a complementaiy cyclic pattern (Ramsay et 
al. 1997; Clarke et al. 2002), it is essential to understand the intra- and inter-lineage 
population dynamics of this disease. We used multi-locus sequence typing (MLST) to 
characterise a collection of 429 meningococci, isolated from cases of invasive
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meningococcal disease between 1999 and 2002 (years one to four).
Four hundred and twenty nine isolates of N. meningitidis from invasive 
meningococcal disease in Scotland were analysed between Januaiy 1999 and 
December 2002 by MLST (Maiden et al. 1998; Clarke et al. 2001b). Genotypic 
characterisation through DNA sequencing followed by nucleotide sequence analysis 
and subsequent sequence type (STs) and complexes allocation was perfonned as 
previously described (Chan 2001; Clarke et al. 2001b; Clarke et al. 2002; Diggle and 
Clarke 2002a). Furthermore, intra- and inter-lineage comparisons were made using 
the START facility of programs, including previously described sequence type 
specialty programs such as BURST (http://neisseria.org/mn/typing/mlst/). The 
calculation of synonymous (JS) and nonsynonymous (dN) rates within specific sites 
within a particular sequence was calculated from the allele sequence using the method 
of Nei and Gojobori which is included in the START suite 
(http://outbreak.ceid.ox.ac.uk/software.htm). A suimnary of the single multi-locus 
measure of linkage disequilibrium was achieved by the index of association (LA) 
(Smith et al. 1993) using the START progiams. hi addition further statistical analysis 
highlighting the likelihood of these sample populations and subsequent hypothesis 
being significant was calculated using the standard t-test fomiula to achieve a two- 
tailed p value.
The clonality within the meningococcal population reduced year by year with a 
significant reduction observed between years two, thi'ee and four. This naturally 
coincides with the reduction in serogroup C ST-11 complex strains that are associated 
as a highly clonal complex. The large number of isolates represented on the
172
meningococcal MLST website is a reflection of the numerous studies performed with 
collections of meningococci that both cause disease and are present as carriage strains, 
and this is subsequently represented by a significant number of STs closely associated 
with either meningococcal disease or carnage within the MLST database (Maiden et 
al. 1998; Feil et al. 1999; Jolley et al. 2000; Clarke et al. 2001b; Tzanakaki et al. 
2001).
However, these collections have centred upon both carriage and disease and therefore, 
subsequent conclusions based on disease-causing isolates are limited. In addition, 
these studies have been perfonned during time periods where the selective pressures 
are normal (i.e. outwith vaccine programmes). Consequently, this study has taken all 
available invasive isolates over a 4-year MenC vaccine implementation period and 
determined the change in the genetic diversity of the meningococcal population.
The genetic diversity of meningococci has significantly increased after the 
introduction of MenC vaccines, initially significant changes in genetic diversity within 
the meningococcal population were not observed between years one and two, however 
a significant increase in diversity was observed between years two, three and four and 
this increase was directly reflected in a significant decrease in serogroup C ET-37/ST- 
11 meningococci, hiterestingly, this was not accompanied by an increase in serogroup 
B meningococci of the same genetic lineage, as this may highlight a possible capsular 
switch between both serogioup C and B meningococci.
The diversity of the cuivent meningococcal population has changed from 41 different 
profiles representing the meningococcal population in year one to 49 different profiles
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in year four, an increase of over 16%. However, a significant increase of over 12% 
was observed between years one and two even though ST-11 maintained a significant 
presence in the population (37.7%), This increase in diversity was due, however, to 
the presence of new combinations of pre-existing alleles resulting from a process of 
recombination, resulting in new ST profiles, rather than novel allele sequences 
resulting from mutation. The increase in recombination between years one to four 
must therefore, be due to natural selection compounded by the lacking ability with 
which non ST-11 meningococci compensate for the artificial rapid decline in ST-11 
complex meningococci with any subsequent increase in alternative non ST-11 
meningococci.
Interestingly, this niche has been gradually filled by meningococci of numerous STs 
and from a number of clonal complexes including ST-41-44, ST213 and ST-269. 
Currently, therefore, there is no single ST complex or subsequent hyper-endemic 
clone present in the UK that has directly replaced the ST-11 clone with the same 
percentage of the population. However, some clones, such as the ST-41-44 and the 
ST-269 complex, must be monitored closely as they now represent a significant 
percentage of the meningococcal disease-causing population. These results will have 
an important impact on conjugate vaccine strategy for the control of meningococcal 
disease, as well as other bacterial pathogens, because the medium to long teim effects 
of vaccines directed against a single serogioup clearly have an effect on the 
meningococcal population biology. Although introduction of MenC vaccines has not 
led directly to serogi'oup switch (to serogi'oup B), a definite increase in clones of 
serogroup B has been obsei-ved although much of this may be due to the typical 
cyclical pattern between serogi'oup B and serogroup C incidence previously described.
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As a consequence continued analysis of the meningococcal population must be 
performed in order to gain further insights into the long-term effects of the MenC 
vaccine upon the whole meningococcal population, importantly this should include 
both invasive and non-invasive caniage isolates, as this combination will highlight the 
true emergence of important genetic lineages in the future.
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Chapter 4
Genosubtvping and Analysis of PorinA (porA) Variable Regions 
4.0 Introduction
The genus Neisseria comprises a number of species associated with mucosal carriage 
and disease in animals and humans (Morse 1992; Barnett and Sneath 1994), including 
N. meningitidis, a major cause of meningitis and septicemia worldwide (Cartwight 
1995) and Neisseria gonorrhoeae, the etiological agent of gonorrhoea (Sherrard 
1995). Studies of these two pathogenic species (Guibourdenche et al. 1986), are 
helpful in understanding both the pathogenesis of meningococcal and gonococcal 
infections and the evolutionary events that led to their emergence. Sueh studies are 
particularly valuable when they target cell components potentially involved in 
immunity or other host-pathogen interactions, such as OMPs (van der Ley et al. 1991; 
Ward et al. 1992; Suker et al. 1993).
Serogroup B meningococci significantly contribute to the cause of meningitis and 
septicaemia worldwide, mainly because there is no effective vaccine (Rosenstein et al. 
2001a). As a consequence there is an urgent need for effective vaccines against the 
serogroup B meningococcus. However, there are difficulties with N. meningitidis 
serogroup B that are not encountered with plain polysaccharide or conjugated vaccines 
designed against serogi'oups A, C, Y and W135 (Rappuoli 2001a)
The meningococcus serogroup B capsular polysaccharide topology is identical to a 
human carbohydrate ((2 8) W-acetyl neuraminic acid or polysialic acid). As a
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consequence a vaccine based on this construct configuration would be poorly 
immunogenic and would ultimately induce only a transient antibody response (Finne 
et al. 1987; Hayiinen et al. 1995). A vaccine based on the serogroup B 
meningococcus therefore requires the development of a vaccine based on an 
alternative target. This could be based on different genes that have been identified as 
possible candidates from complete genome sequence analysis teimed reverse 
vaccinology (Rappuoli 2001a). An effective candidate could be virulence-based 
vaccine.
Using vast amounts of sequence-based data, numerous genes could be identified as 
potential candidates. The most studied of which are those based on OMPs (AfAldeen 
and Cartwright 1996; Rosenstein et al. 2001a). Although OMP-based vaccines are not 
the ideal solution for combating serogroup B meningococcal infection, they may 
provide a short-teim solution. Previous research has shown great promise for the 
control of serogroup B meningococcal infection based on these vaccines (Rappuoli 
2001a).
There are many OMPs possessed by the meningococcus and like other bacteria these 
are ordered into different classes, namely 1-5. Numerous OMPs from classes 1-5 
have been studied as potential vaccine candidates (Tsai et al. 1981). Phenotypic 
markers class 2/3porB and class 1 porA protines are used for typing and subtyping 
meningococci respectively. These have been used for many years and as a 
consequence have been studied extensively as possible vaccine candidates. These are 
porin protines that have surface exposed regions subjuected to external forces and 
selective pressures. As a result these exposed porins contain variahle and
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hypervariable regions. From topological studies a two-dimensional structural model 
has been predicted for the meningococcal PorA protein that predicts eight surface 
exposed loops (I-VIII) (van der Ley et al. 1991). From this structural model the most 
exposed and therefore the most variability are thought to occur in variable regions 1 
and 2 (VRl and VR2) which correspond to loops I and IV, respectively (Maiden et al. 
1991; van der Ley et al. 1991; McGuinness et al. 1993).
Phenotypic studies involving serosubtype-specific monoclonal antibodies react with 
peptide epitopes located in these loops and therefore serosubtyping is used to identify 
these PorA VR epitopes. A widely recognised nomenclature is used which has been 
recently updated to take into account new data now available through nucleotide 
sequence typing. A novel subtyping nomenclature has also been proposed (Sacchi et 
al. 1998a; Maiden et al. 1999) but this has not been adopted.
The major OMPs that are expressed at high levels have been recognised for over 15 
years (Frasch 1985). There are two OMPs that have been fimctionally characterised as 
porins. These are two different classes of protein from a collection of five different 
classes (1-5), isolated based on differences in molecular weight. Initial experiments 
revealed that the meningococcal class 1 porin protein (porA) and class 2 and 3 porin 
proteins (porB) perfoim as selective channels, which permit the passage of cations and 
anions across the cell membrane. Recently the advent of sequencing has confinned 
the porin nature of these proteins with homology with well-characterised Escherichia 
coli porins.
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Interest in the antigenic variability of the Neisseria porins, from both typing and 
vaccination perspectives, has resulted in the generation of many sequences of their 
genes. Detailed interpretation of this database of sequences has been hindered by the 
lack of a molecular structure for the gene products, although a two-dimensional model 
has been proposed on the basis of sequence similarity (Maiden et al. 1991; Morse 
1992). This model comprises a P-barrel porin structme, similar to that of the 
Escherichia coli porins (Cowan 1992), with regions that are relatively conserved 
among Neisseria sequences fonning the P banel. Other regions, which are less well 
conserved among and within species, fomi surface-exposed loops which protrude 
from the bacterial surface into the surrounding environment (Maiden et al. 1991; 
Morse 1992). While this model was useful, it was not three-dimensional, being 
proposed before the molecular structures of the E. coli porins were established; the 
assignment of residues to membrane-embedded or surface-exposed enviromnents was 
somewhat uncertain.
These Neisseria porins, maintain a distinct class within the porin superfamily 
(Jeanteur 1991) and are major components of the outer membranes of all members of 
the genus Neisseria (Ward et al. 1992; Suker et al. 1993; Feavers and Maiden 1998). 
Most Neisseria species express only one, referred to as For. The meningococcus 
exceptionally expressing two; PorA and PorB (Hitchcock 1989). The gonococcus is 
the only other Neisseria species known to have a porA gene, which is not expressed 
due to frameshift and promoter mutations (Feavers and Maiden 1998). The 
meningococcal and gonococcal porins are targets for serological typing schemes 
(Frasch et al. 1985; Gill 1991), candidates for inclusion in vaccines (Frasch et al. 
1985), and have been implicated in pathogenesis (Rudel 1996).
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Virtually all meningococci possess the class 1 OMP (PorA) (Suker et al. 1994; van der 
Ende et al. 2003). The secondary structure of the class 1 OMP has been formulated 
and subsequent construction of topology models were possible these displayed highly 
conserved trans-membrane regions with eight strain-variable exposed loops, which 
play a crucial role in the host immune response. These surface exposed loops are the 
most prominent regions within the protein and thus most exposed to immune 
responses. There are tlu*ee regions considered important in sero-subtype 
characterisation; variable regions at loops 1, 4 and 5 correspond with variable regions 
I, II and HI (VRl, VR2 and VR3) (Figure 1.12) (Moiling et al. 2000; Tondella et al. 
2000; Moiling et al. 2002; Clarke et al. 2003).
Detection and characterisation of the outer membrane protein (OMP) gene porA can 
be achieved by several methods (Frasch 1985; Diggle and Clarke 2003a). Typing may 
be perfonned on the basis of SDS-PAGE, specific monoclonal antibodies and whole 
cell ELISA typing methods (Hoehn 1990; Lehmami et al. 1999; Tondella et al. 2000; 
Wang et al. 2000). More recently, molecular characterisation of the meningococcal 
porins have included nucleotide gene sequencing of previously described variable 
regions or the whole gene (Urwin et al. 1998a; Clarke et al. 2003). These porins have 
not only been used for sero-typing and sero-subtyping but also for epidemiological 
analysis of meningococcal carnage and disease (Poolman et al. 1986), although the 
variability of these proteins means they are not entirely accurate as epidemiological 
markers (Urwin et al. 1998b).
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As previously noted, vaccines based on OMPs are being developed against the 
serogoup B meningococcus. These may contain a number of different common 
circulating porB and porA types and subtypes, respectively. Although the probability 
of a highly successful vaccine is dependent on circulating variants within the 
population. This is confounded by the limited amount of data available from all the 
different circulating types and subtypes throughout Europe and the world.
This highlights the importance in the comprehensive analysis of OMP genes such as 
porA. As described previously this gene encodes a protein with eight surface exposed 
loops of which thi'ee main variable regions, VRl, VR2 as well as VR3, of the porh  
gene from N. meningitidis have been analysed. This analysis highlighted that with in 
429 strains studied, there were a total of 86 different strains. No new VRl or VR2 
alleles were found but five new VR3 alleles are described (Appendix 6.9 -  6.13). This 
indicates the importance of analysing these variable regions of porA and also 
highlights, in general teims, the need for genosubtyping meningococci. Such analyses 
could have major implications for the design of new meningococcal OMP vaccines.
In this ehapter, there have been a number of different techniques used, including 
phylogenetic analysis, individual variable region phonograms and sequence 
aligmnents enabling a more precise identification of the differences between 
individual isolates. Phylogenetic analyses of the porins fi'om different meningococcal 
isolates were enlianced when the model was used to assist sequence alignment and to 
identify structurally conseiwed parts of the proteins, identifying features likely to be 
important in the emergence of novel sequences within a particular serogroup.
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4.1 Results
Numerous vaccines containing single and multi-valent components have been 
developed and evaluated over the past decade (Wedege and Michaelsen 1987; 
Rosenqvist et al. 1995; Peeters et al. 1996; Rouppe van der Voort et al. 1997). These 
have been based on several factors, including most importantly geographical area and 
prevalent circulating variants (Van Der Ley and Poolman 1992; Peeters et al. 1996; 
Perkins et al. 1998; Cartwright et al. 1999; Tappero et al. 1999; de Kleijn et al. 
2000b). However the numbers of different variants are ever increasing due to the veiy 
nature of the highly antigenic regions, therefore OMP vaccines will not protect against 
all variants including all the different types and subtypes of N. meningitidis. For 
example, the histitute for Public Health and the Enviromnent (RTVM) based in the 
Netherlands has developed a recombinant hexavalent PorA outer membrane vesicle 
(OMV) vaccine comprised of PI.7, 16; P I.19, 15; PI.5, 2; PI.5c, 10; P I .12, 13 and 
P1.7h, 4 (Rouppe van der Voort et al. 2000). These subtypes correlate to genosubtype 
families 2, 5, 7, 10,12, 13, 15, 16 and 19. This vaccine has undergone trials and is 
being developed for the commercial market. This OMV vaccine was represented in 
over 80% of UK meningococcal case isolates in 1996 (Cartwright et al. 1999) and in 
phase I and phase H clinical trials has shown promising results (Peeters et al. 1996; 
Cartwright et al. 1999). As a result successful OMP vaccines must use high quality 
data pertaining to the prevalent types and subtypes in any given geogiaphical area 
such as a country or collection of countries.
It has been widely documented that VRl (loop I) and VR2 (loop IV) are highly 
variable regions (Figure 1.12). However genosubtyping involving PorA VR3 (loop V)
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have also been described to a much lesser extent (Aiiiin et al. 1998; Moiling et al. 
2000; Riesbeck et al. 2000; Clarke et al. 2001b; Moiling et al. 2001). As a 
consequence this suggest that more data is required to determine the significance of 
VR3 and any other variable regions which are subjected to an immune response and 
are subsequently important in both disease surveillance and vaccine development.
Monoclonal antibody testing is still perfonned in most laboratories as a method for 
serotyping and serosubtyping meningococci, however with new types and subtypes 
occurring these are going undetected unless alternative techniques such as nucleotide 
sequencing are perfonned. Here, this chapter describes the efforts of perfoiming 
sequence-based genosubtyping of VRl, VR2 as well as VR3 on all invasive 
meningococci isolated tlnoughout Scotland over a period of four-yeai's and the 
subsequent effects of the MenC vaccine on this dynamic population.
The meningococcal subtype is deteimined by amino acid sequence variation in the cell 
surface exposed loops I, IV and V of the porin protein PorA (van der Ley et al 1991). 
These antigenically variable loops are encoded by variable regions 1, 2 and 3 (VRl, 
VR2 and VR3) of the porA gene respectively. This was first recognised with regards 
VRl and VR2 by using murine monoclonal antibodies (Mabs) (Abdillahi and 
Poolman 1988).
This chapter uses meningococcal subtype nomenclature based primarily on the amino 
acid sequence deduced from the nucleotide sequence. This is to minimise any 
possible non-typable results and therefore can include novel sequences since porA is 
underimmune selection in humans. The results displayed will contain the
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conventional genetic designation PorA foIloAved by a number representative of the 
original amino acid sequence of each sample (Appendix 6.1, 6.2 and 6.3).
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4.1.1 Genosubtyping of meningococcal isolates from 1999
4.1.1.1 Serogroup C isolates. The majority of serogroup C isolates from 1999 fell 
into a single group within variable region one (VRl) and two distinct gioups within 
VR2 and VR3. The first variable region was represented by seven different variable 
types within six distinct families namely, 5, 7, 17, 18, 19 and 21 with over 87% 
characterised as variable regions 5 and 5-1. The second variable region was 
represented by nine different variable types within six distinct families namely, 2 ,3 ,4 , 
10, 15 and 16 with over 68% allocated to variable regions 10-1, 10-4 and 10-8. The 
third variable region was represented by five different variable types within tlnee 
distinct families namely, 36, 37, and 38 with over 87% allocated to variable region 36- 
2. This followed a similar pattern to the MLST data whereby large clonal complexes 
were formed from large collections of serogroup C data, although a gi'eater 
proliferation and subsequent differentiation was observed with the addition of porA 
sequence data. The variable region distribution chart for 1999 (Figure 4.1 -  4.7) 
highlights a pattern whereby in general within the serogroup C population a few VRl 
types expand into a larger number of VR2 types before converging into a single VR3 
type (Figure 4.1 - 4.7). This association between these different vaiiable regions is 
highly conserved not only within specific variable regions but also within this 
serogroup. Therefore it is rare to find serogioup C isolates with alternative variable 
region profiles as highlighted with the statistical distribution described previously.
The first variable region was represented in the majority from the type 5-family or the 
P I.5 family (n=50). Within this family to date there are eleven different variants 
associated with the original representative amino acid sequence. The subsequent
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variants range between one and tiiree amino acids either by substitution, insertion or 
mutation from the original twelve amino acid sequence (Appendix 6.1). The two 
represented in Scotland were 5 (n=12) and 5-1 (n=38). The latter varies with the 
addition of an extra amino acid within the middle of the region. This con elates with 
the top of the VR2 loop displayed in within Chapter 1 (Figui'e 1.12).
The second variable region was represented in the majority from the type 10-family or 
the PI. 10 family (n=39) and to a lesser extent the type 2-family or the PI.2 family 
(n=ll). This variable region contains more variant types in comparison to the other 
two. Within the type 10-family there are to date forty different variants of the 
representative variant. This family has variants between one and seven amino acids 
either by substitution, insertion or mutation from the original fifteen amino acid 
sequence (Appendix 6.2). The thiee represented in Scotland were 10-1 (ir=4), 10-4 
(n=17) and 10-8 (n=18). The first type had a mutation in the latter region, whereas 
type 10-4 had the addition of a recognised “QNK” (Glutamine, Asparagine, Lysine) 
amino acid motif repeated along with the same mutation present in type 10-1. The 
third type had the addition of another recognised “QNQ” (Glutamine, Asparagine, 
Glutamine) amino acid motif repeated again along with the same mutation present in 
type 10-1. The variant type 10-1 in relation to variant 10 had a substitution of an 
arginine for a proline. This resulted in the exchange of a basic charged amino acid 
into a neutrally charged amino acid and as a consequence the overall molecular weight 
and hydrophobicicty were not significantly affected. The variant type 10-4 in relation 
to 10-1 had the substitution of glutamine for a lysine. This resulted in the exchange of 
a basic charged amino acid into a neutrally charged amino acid and as a consequence 
the overall molecular weight and hydrophobicity were not significantly affected.
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Within the type 2-family there are to date thirty-one different variants of the 
representative variant. This family has variants between one and six amino acids 
either by substitution, insertion or mutation from the original fifteen amino acid 
sequence (appendix 6.1). The two represented in Scotland were 2 (n=10) and 2-2 
(n=l). The first variant was the original whereby all others are eompared. The second 
type varies by the mutation of a single amino acid within the centre of the amino acid 
sequence.
A single variant type represents the third variable region in the vast majority of 
serogroup C meningococci and this was from the type 36-family (n=52). This 
variable region has recently been added to the profile in the last few years to increase 
discrimination of more clonal types (Clarke et al 2003). As a consequence the number 
of different variants is smaller in comparison to the other two. The 36-family to date 
contains four variants and each representative type varies by only a single amino acid 
by mutation (appendix 6.3). The majority of serogroup C strains were represented by 
the type 36-2 (n=50) variant. This variant had a single mutation within the centre of 
the amino acid sequence when aligned with the original representative type.
4.1.1.2 Serogroup B Isolates. The distribution of isolates was much more extensive 
within the serogroup B population. The first variable region was represented by 
thirteen different variable types, this was over double the amount when compared to 
the serogroup C isolates. These were contained within eight distinct families namely, 
5, 7, 12, 17, 18, 19, 21 and 22 with over 74% allocated to variable regions 7-2, 18-1, 
19 and 22. The second variable region was represented by eighteen variable types, 
again this was over double the amount when compared to the serogroup C isolates.
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These were contained within twelve families namely, 2, 3, 4, 9, 10, 13, 14, 15, 16, 23, 
25 and 30 with over 69% allocated to variable regions 3 ,4 ,9 ,1 4  and 15. The third 
variable region was represented by nine different variable types within five distinct 
families namely, 35, 36, 37, 38 and 40 with over 90% allocated to variable regions 35- 
1, 36, 36-2, 37 and 38.
The first variable region was represented by a number of distinct variable types from 
the 7, 18, 19 and 22 family or the P I.7, P I.18, P I.19 and PI.22 family. Within this 
collection the 22 variant (n=18) was represented by the original variant with the 
exception of a single isolate 22-1 which had tlrree amino acid changes compared to 
the original (Appendix 6.1). The PI.22 family has to date 8 different variants with an 
eighteen amino acid chain length. The 7-variant family (n=18) has to date seventeen 
distinct variants with between 20-25 amino acids (Appendix 6.1). The represented 
types in Scotland were 7 (n=4) and 7-2 (n=14). The first type was the original 
representative type. The second type had the deletion of a recognised “VTK” (Valine, 
Threonine, Lysine) amino acid motif removed from the end of the region. This 
resulted in the removal of two neutrally charged amino acids and a single basic 
charged amino acid and as a consequence the overall length was decreased and the 
molecular weight within this region was reduced by 382.46. The 19-variant family 
(n=14) has to date eighteen distinct variants with between 14-19 amino acids 
(Appendix 6.2). The represented types in Scotland were 19 (n=ll) and 19-1 (n=3). 
The first was the original representative type and the second had a single amino acid 
mutation in the centre of the region. The 18-variant family (n=7) has to date twelve 
distinct variants with a fourteen amino acid chain length (Appendix 6.1). The 
represented variant in Scotland was the 18-1, which had a single amino acid change at
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the start of the region.
The type 3, 4, 9, 14 and 15 families or the PI.3, P I.4, PI.9, P I.14 and P I .15 families, 
represented the majority in the second variable region. The 4-variant family (n=15) 
has seven distinct variants with between 8-21 amino acids. The representative types 
were all from the original type 4-variant. The 14-variant family (n=ll) has to date 
thirteen distinct variants, and has variants between one and two amino acid changes 
either by substitution or mutation from the original ten amino acid sequence 
(Appendix 6.2). The two represented in Scotland were 14 (n=10) and 14-6 (n=l). The 
first type was the original representative variant, whereas the second had tlrree 
consecutive amino acids changes at the latter end of the variable region. The 15- 
variant family (n=ll) has to date twenty-two distinct variants, and has variants 
between one and six amino acid changes either by substitution, insertion or mutation 
from the original thirteen amino acid sequence (Appendix 6.2). The two represented 
in Scotland were 15 (n=8) and 15-11 (n=3). The first type was the original 
representative variant, whereas the second had a single amino acid change within the 
centre of the region. Finally, the 9-variant family (n=8) has to date seven distinct 
variants, and has variants between one and two amino acid changes either by 
substitution or mutation from the original ten amino acid sequence (Appendix 6.2). 
The two represented in Scotland were 9 (n=7) and 9-4 (n=l). The first was the 
original representative variant, whereas the second had a single amino acid change 
within the centre of the region.
A considerable collection of different variants types represents the third variable 
region. These include 35-1 (n=ll), 36 (n=20), 36-2 (n=6), 37 (n=16) and 38 (n=8).
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The 36-family represents a significant proportion of these isolates. Unlike serogroup 
C isolates, the 36 variant rather than the 36-2 variant was mainly represented. This is 
the original representative variant in the family. The 36-2 variant is differentiated by a 
single amino acid change at the end of the region. The 37-family has two 
representative variants and these are significantly different to the 36-family with an 
amino acid length of nine (rather than eight). Again the original representative variant 
was predominant. The 35-family has thi'ee representative variants and the 35-1 was 
predominant. This eight amino acid chain has a single amino acid change at the start 
of the region. Finally, the 3 8-family represents a small proportion of serogroup B 
isolates. The family contains two variants and has an amino acid length of ten. All 
the represented isolates were from the 38-variant (Appendix 6.3).
4.1.1.3 Miscellaneous Serogroup Isolates. These represented less than 5% of the 
total population in 1999. These were serogroups W135 (n=2), Y (n=2) and X (n=3). 
At this stage these isolates could represent future dominant strain characteristics. 
Therefore, although they were statistically insignificant, they could be important 
markers to monitor and analyse.
Variable regions 18-1, 3 and 38, represented serogioup W135 isolates. These within 
1999 have also been associated with serogroup B isolates. Variable regions 21, 16 
and 37-1, represented two serogroup X isolates. These have been associated with both 
serogroup B and C isolates. Variable regions 7-1, 4 and 37-1, represented the 
remaining serogroup X isolate. This displays significant differences within the VRl 
and VR2 and are closely associated with a clonal serogroup B collection, namely 7-2, 
4, 37-1. The serogroup X VRl had an additional five amino acids, a “GA” (Glycine,
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Alanine) amino acid insertion and an additional “KVT” (Lysine, Valine, Tlireonine) 
amino acid repeat. This resulted in the addition of four neutrally charged amino acids 
and a single basic charged amino acid and as a consequence the insertions produced a 
slightly larger variable region with the additional molecular weight of 546.62. 
Variable regions 5-1, 10-2, 2-13 and 36-2, represented serogroup Y isolates. The VRl 
and VR3 were consistent with a clonal serogi'oup C collection. The VR2 was 
different within each isolates and were unique to the meningococcal population in 
1999. The 10-2 was more closely associated with the original representative variant 
10 than the commonly found 10-4 and 10-8, although there are conseiwed regions at 
the start and at the end. The 2-13 was more closely associated with VR2 2-2, which 
had only a single amino acid change at the start of the region. Both VR2s were close 
relations to a clonal serogioup C collection in 1999.
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Figure 4.1 Association between porin A variable region 1 (VRl), variable 
region 2 (VR2) and variable region 3 (VR3) from meningococci isolated in 1999 
(year 1). Each identified porin A profile (VRl, VR2, VR3) is linked through a series 
of individually coloured and styled arrows. The total number represented within that 
variable type is indicated within the brackets. Following the single VRl 22-1 (green) 
the dotted line finishes at VR2 14 (purple) with 9 others VRl s. These are further 
distributed through a dotted line to VR3 36 (n=8), 36-2 (n=l) and 38 (n=l).
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Figure 4.2 Distribution of porin A variable region 1 (VRl) from meningococci
isolated in 1999 to 2002 (years 1 to 4).
The year 1999 in light blue ■
The year 2000 in plum ■
The year 2001 in light yellow □
The year 2002 in pale blue ■
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Figure 4 3  Distribution of porin A variable region 2 (VR2) from meningococci
isolated in 1999 to 2002 (years 1 to 4).
The year 1999 in light blue ■
The year 2000 in plum ■
The year 2001 in light yellow □
The year 2002 in pale blue ■
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Figure 4.4 Distribution of porin A variable region 3 (VR3) from meningococci
isolated in 1999 to 2002 (years 1 to 4).
The year 1999 in light blue ■
The year 2000 in plum ■
The year 2001 in light yellow □
The year 2002 in pale blue ■
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Figure 4.5 Association between porin A variable region 1 (VRl) and related 
serogroups from meningococci isolated in 1999 to 2002 (years 1 to 4). Each 
variable type is represented by year with the proportion of each serogroup present 
within that variant type displayed by a colour-coded line.
The year 1999 in dark red
The year 2000 in blue
The year 2001 in light purple
The year 2002 in yellow
Serogroup B is shown in red
Serogroup C in blue
Serogroup Y in yellow
Serogroup W135 in purple dash
Serogroup X in green
Serogroup Z in brown
Serogroup NG in black
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Figure 4.6 Association between porin A variable region 2 (VR2) and related 
serogroups from meningococci isolated in 1999 to 2002 (years 1 to 4). Each 
variable type is represented by year with the proportion of each serogroup present 
within that variant type displayed by a colour-coded line.
The year 1999 in dark red
The year 2000 in blue
The year 2001 in light purple
The year 2002 in yellow
Serogroup B is shown in red
Serogroup C in blue
Serogroup Y in yellow
Serogroup W135 in purple dash
Serogroup X in green
Serogroup Z in brown
Serogroup NG in black
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Figure 4.7 Association between porin A variable region 3 (VR3) and related 
serogroups from meningococci isolated in 1999 to 2002 (years 1 to 4). Each 
variable type is represented by year with the proportion of each serogroup present 
within that variant type displayed by a colour-coded line.
The year 1999 in dark red
The year 2000 in blue
The year 2001 in light purple
The year 2002 in yellow
Serogroup B is shown in red
Serogroup C in blue
Serogroup Y in yellow
Serogroup W135 in purple dash
Serogroup X in green
Serogroup Z in brown
Serogroup NG in black
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4.1.2 Geiiosubtyping of Meningococcal Isolates in 2000.
4.1.2.1 Serogroup C Isolates. The majority of isolates fall into a single group within 
VRl, VR2 and VR3. There had been a consolidation within VR2 and VR3 into single 
groups rather than two groups previously described in section 4.1.1.1. The first 
variable region was represented by four different variable types within only two 
distinct families namely, 5 (n=45) and 21 (n=l) with over 97% allocated to variable 
regions 5 (n=10), 5-1 (n=34) and 5-4 (n=l). This represents a di'amatic decrease in the 
distribution tliroughout different families from six into two. The second variable 
region was represented by four different variable types within thiee distinct families 
namely, 2 (n=l 1), 10 (n=34) and 16 (n=l) with over 98% allocated to variable regions 
2, 10-4 (n=31) and 10-8 (n=3). The third variable region was represented by two 
different variable types within two distinct families namely, 36 (n=45) and 37 (n=l) 
with over 98% allocated to variable region 36-2. This followed a similar pattern to 
the previous year with VRl, VR2 and VR3 patterns consistently appearing with the 
same profile compared with 1999. There had been a dramatic consolidation of 
different variable types and consequently specific variable regions associated with 
large clonal complexes were predominant and more diverse variable types had 
disappeared in 2000. A single exception was the isolation and characterisation of a C, 
2B, non-subtypable (NST) strain with the porA profile 21, 16, 37-1. This was unique 
within the Scottish meningococcal population. The porA profile was more commonly 
associated with serogroup B and X isolates, although the MLST profile (ST8) was 
consistent with serogroup C Scottish isolates from the 1980s.
The first variable region was represented in the majority h'om the type 5-family. The
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three represented were 5 (n=10), 5-1 (n=34) and 5-4 (n=l). This follows a similar 
pattern to serogionp C isolates characterised in 1999. The total number of serogi'oup 
C isolates had decreased, however the major variant types still remained dominant.
The type 10-family (n=34) and the type 2-family (n=l 1) represent the second variable 
region. The type 10 variants represented were 10-4 (n=31) and 10-8 (n=3) and the 
type 2 (n=ll) represents the 2-family. This displays a similar variant distribution 
compared with isolates from 1999.
The type 36-family (n=45) and the type 37-family (n=l) represent the third variable 
region. As with 1999 the majority of serogroup isolates (over 97%) were represented 
by the type 36-2 (n=45). However there was a single representation from the type 37- 
family from the 37-1 variant as discussed previously
4.1.2.2 Serogroup B Isolates. The first variable region was represented by thirteen 
different variable types. This again was significantly larger than the dispersion of 
VRls between serogroup C isolates, although this represented the same number of 
variants compared with serogroup Bs in 1999. These were represented within seven 
distinct families namely, 5, 7, 17, 18, 19, 21 and 22 with over 91% allocated to 
variable region families 5,7, 19 and 22. The second variable region was represented 
by fifteen variable types, a slight reduction in the total number of different VR2s 
compared with 1999. These were contained within nine families namely, 1 ,2 ,4 , 9, 
10, 14, 15, 16 and 30 with over 82% allocated to variable regions 4,9, 14, 15 and 16. 
This highlighted a change in the dominant VR2s with variable type 3 diminishing and 
variable type 16 significantly emerging. The third variable region was dispersed
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between seven different variable types within four distinct families namely, 35, 36, 37 
and 38 with over 91% allocated to variable regions 35-1, 36, 36-2 and 37.
The first variable region was represented by a number of distinct variable types from 
the 5, 7, 17, 18, 19, 21 and 22, Within this collection the 7 variant (n=23) was 
represented by tlu'ee variant types 7 (n=4), 7-1 (n=l) and 7-2 (n=18). Both 7 and 7-2 
had been consistently prominent tlnmighout 1999 and 2000, though a single 7-1 
variant had emerged. This variant had been obseiwed in a single serogroup X isolate 
fi'om 1999 (section 4.1.1.3), however this had not been previously observed in 
serogroup B isolates. The 22-variant family (n=20) is represented by 22 (n=19) and 
22-3 (n=l). The type 22 had been observed previously in 1999 whereas the 22-3 had 
not been identified before. This variant had a single amino acid change compared 
with the original type 22 variant. The 19-variant family (n=16) was represented by 
thi'ee different variant types namely, 19 (n=7), 19-1 (n=7) and 19-3 (n=2). Both 19 
and 19-1 had been obseiwed previously, whereas 19-3 had not, this variant type had a 
single amino acid change compared to the original type 19 variant. The 5-variant 
family (n=9) was represented by both 5 (n=6) and 5-1 (n=3). These were rarely 
associated with meningococcal serogi'oup B isolates in Scotland and more commonly 
found associated with serogroup C isolates, although a small number were observed 
associated with serogi*oup B isolates in 1999. The emergence of type 5 within the 
serogroup B population in 2000 had not been observed previously except in large 
clonal complexes within the serogroup C population.
The type 4, 9, 14, 15 and 16 represented the majority in the second variable region. 
All the 4-variant family (n=16) were represented by the type 4 variant and continued
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to dominate within the type 4 sub-population. The 15-variant family (n=14) were 
represented by the 15-variant (n=6) and the 15-11-variant (n=8). These variants had 
been observed previously, hi 2000 a notable shift between the 15-variant and 15-11- 
variant was noted. The 14-variant family (n=13) had maintained a significant 
presence in the population in 2000 and the single type 14-variant represented these. 
This represented a consolidation in this variant type within the population. The 9- 
variant family (n=10) followed a similar pattern to 1999 with a significant presence 
fi’om the 9-variant (n=9) and a single isolate from the 9-4-variant. Finally, the 16- 
variant family (n=8) had increased and proliferated during 2000 with the presence of 
variant-16 (n=5) and the single representation fi'om variant 16-3, 16-4 and 16-26, both 
16-4 and 16-26 had not been observed before. The 16-4-variant had 3 amino acid 
changes compared to the original representative variant, although when compared 
with 16-3 only had a single amino change. The 16-26 was more closely associated 
with the original representative 16-variant with a deletion of the “KD” (Lysine, 
Aspartic acid) amino acid motif and the insertion of an “N” (Asparagine) amino acid. 
This resulted in the exchange of both an acidally charged amino acid and a basic 
charged amino acid for a single neutally charge amino acid and as a consequence 
slightly reduced both the length and molecular" weight of this region by 147.21.
The third variable region was represented by 35 (n==l), 35-1 (n=15), 36 (n=28), 36-2 
(n=9), 37 (n=16), 37-1 (n=4) and 38 (n=l). The distribution was similar to that 
displayed in 1999. The 36-family again represented a significant proportion of these 
isolates. These were mainly represented by the 36-variant. There had been an 
increase in the proliferation of other variants within families, such as the emergence of
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variant 35, and variant 37-1, from a pre-existing population containing closely related 
variants, notably 35-1 and 37 respectively.
4,1.2.3 Miscellaneous Serogroup Isolates. These represented over 9% of the total 
population in 2000. These were serogroups W135 (n=6), Y (n=4) and two non- 
groupable isolates. Variable region one was represented by 18 (n=l), 18-1 (n=3), 5 
(n=l) and 7 (n=l) within the W135 population. The W135 population had shown an 
increased proliferation of its variable region characteristics. Previously, W135 was 
exclusively associated with variant 18-1, and this was subsequently associated with 
serogroup B isolates. The proliferation in 2000 included variant 18, which was 
closely associated to 18-1. Although these variants had not been observed during 
2000 in other major serogroups, the emergence of the 18-7-variant within the 
serogroup B population was noted. The variant 5 is strongly, associated with 
serogi'oups B and C and the variant 7, which, was apart from a single W135 
exclusively associated with the serogi’Oup B population. VR2 was represented by a 
smaller set of variants that were 2 (n=l), 3 (n=4) and 30-2 (n=l). Variant 2 was 
associated with VRl type 5 and consequently had a VR3 36-2 type. This was a 
common profile within both the serogroup B and C populations. Variant 3 was 
associated with the VRl type 18 family and consequently had a VR3 38 type. This 
was a common profile within the serogi'oup W135 population. Variant 30-2 was 
associated with VRl type 7 and subsequent VR3 38 type. This porA profile had not 
been observed before although the VR2 variant 30-family had been represented within 
the serogroup B and non-gioupable populations. The porA profiles of both non- 
gioupable isolates were, 7-2, 4, 37 and 7, 30, 38. These had been observed before 
within the serogroup B population in both 1999 and 2000.
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Variable regions 5-1 (n=3) and 7-2 (n=l) represented the VRls within the serogroup 
Y population. Both these were associated with serogoups C and B respectively. 
Subsequent variable regions 10-4 (n=3) and 14 (n=l) represented VR2s and variable 
regions 36-2 (n=3) and 36 (n=l) represented VR3s with both close associated with the 
VRls and consequently again represented common porA profiles with serogi'oups C 
and B respectively. Previously serogroup Y porA profiles were closely associated 
with the serogroup C population and this represented a slight shift towards common 
association between both serogroups B and C. Finally, two non-gioupable isolates 
were identified during 2000 that had porA profiles 7-2, 4, 37 and 7, 30, 38 
respectively. These had been observed before within the serogroup B population.
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Figure 4.8 Association between porin A variable region 1 (VRl), variable 
region 2 (VR2) and variable region 3 (VR3) from meningococci isolated in 2000 
(year 2). Each identified porin A profile (VRl, VR2, VR3) is linked through a series 
of individually coloured and styled arrows. The total number represented within that 
variable type is indicated within the brackets. Following the 18-1 VRl variants 
(yellow) the dash/dot line finishes at VR2 3 (purple) (n=4). These are further 
distributed through a dashed line to VR3 38 (n=6).
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4.1.3 Geiiosubtyping of Meningococcal Isolates in 2001.
4.1.3.1 Serogroup C Isolates. The total number of serogi'oup C isolates characterised 
in 2001 fell by over 50% compared with the previous year. The majority of isolates 
fell into a single VRl family, two distinct VR2 families and a single VR3 family. 
This displayed a similar pattern to those described in 1999 rather than 2000 described 
in section 4.1.1.1. The first variable region was represented by four different variable 
types within only two distinct families namely, 5 (n=19) and 19 (n=2) with over 90% 
allocated to variable regions 5 (n=5) and 5-1 (n=14). This maintained the trend 
towards consolidation into a smaller sub-population within a single variant family. 
There had been a change in the representation of the remaining variants types within 
the serogroup C population, the shift from type 21 to type 19 was observed. This type 
was more commonly associated with serogroup B isolates, although the previous type 
was also commonly represented in the serogroup B population. The second variable 
region was represented by six different variable types within tliree distinct families 
namely, 2 (n^9), 10 (n=10) and 15 (n=2) with over 90% allocated to variable regions 
2, 10-1 (n=2), 10-4 (n=l) and 10-8 (n=7). There had been a dramatic decrease in type 
10-4 although other variant types within this family had been unaffected consequently 
with the emergence of previously unobserved variants such as 10-1. The third 
variable region was represented by thi'ee different variable types all contained within a 
single distinct family namely 36 (n=21). These were dispersed into variant type 36 
(n=4), 36-1 (n^2) and 36-2 (n=15). There had been a greater proliferation into 
different variable types obseiwed in 2001 compared with the previous year and this 
represented a similar pattern obsei-ved in 1999. Specific variable regions had 
maintained a presence within this serogi'oup although a change within specific
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families was observed. Again two exceptions were the isolation and characterisation 
of a C, 2A, non-subtypable and a non-groupable that was later confirmed as a group 
C, 1, PI. 15, The first was classified non-subtypable by traditional ELISA methods 
and subsequently sequenced. This was considered an unusual porA profile for a 
serogroup C isolate. The second was successfldly sub-typed and sequenced and both 
correlated to produce another unusual result for a serogroup C isolate.
The first variable region was represented in the majority hom the type 5-family. The 
two represented were 5 (n=5) and 5-1 (n=14). This followed a similar distribution to
1999 and 2001. The total number of serogroup C isolates had decreased by over 50% 
but the major variants types still remained dominant.
The type 10-family (n=10) and the type 2-family (n=9) represented the second 
variable region. The type 10 variants had reduced in number but had expanded to 
include 10-1 (n=2) as well as previously observed variants 10-4 (n=l) and 10-8 (n=7). 
This followed a similar family distribution to 1999 and 2000, although specific 
variants had changed in number and type.
The type 36-family (n=21) represented the third variable region. As with 1999 and
2000 the majority of serogroup isolates (over 71%) were represented by the type 36-2 
(n=15). This highlighted a consolidation towards a single family type, although 
variation within this family to include type 36 (n-4) and type 36-1 (n=2) was 
observed.
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4.1.3.2 Serogroup B Isolates. The first variable region was represented by thirteen 
different variable types. This remains significantly larger than the dispersion of VRls 
between serogroup C isolates, although this remains consistent within the serogroup B 
populations fiom 1999 and 2000. These were contained within eight distinct families 
namely, 5, 7, 12, 18,19, 20, 21 and 22 with over 68% allocated to variable region 
families 7, 19 and 22. This displayed exactly the same pattern as 2000 with the 
exception of the absence of type 5 fiom the significant contributors. However, type 5 
was not eliminated, rather than significantly reduced with variant type 5-1 (n=4) 
contributing less than 8% of the total serogroup B population. The second variable 
region was represented by fifteen variable types, the same number of types observed 
in 2000. These were contained within ten families namely, 2, 3, 4, 9, 10, 13, 14, 15, 
16 and 30 with over 76% allocated to variable regions 9, 13, 14, 15 and 16. This 
highlighted another change in the dominant VR2s with variable type 4 diminishing 
and variable type 13 significantly emerging. The third variable region was represented 
by eight different variable types within four different families namely, 35, 36, 37 and 
38 with over 74% allocated to variable regions 35, 35-1, 36 and 36-2.
The first variable region was represented by a number of distinct families from the 5, 
7, 12, 18, 19, 20, 21 and 22. Within this collection all the 22 variant types (n=14) 
were represented by the original representative type-22. This variant continued to 
maintain a significant presence within the serogi'oup B population with a similar 
variant distribution to 1999 and 2000. The 19-varinat family (n=13) was represented 
by three different variant types namely, 19 (n=7), 19-1 (n=5) and 19-2 (n=l). Both 19 
and 19-1 continued to dominate as previously described, whereas 19-2 had not, this 
variant type has a single amino acid change compared to the original type 19 variant.
208
Interestingly, this mutation was found in the same position as the mutation that 
produced the 19-3 the previous year. The 7-varinat family (n=8) was represented by 
two variant types namely, 7 (n=5) and 7-2 (n=3). Both 7 and 7-2 had been observed in 
significant numbers previously throughout 1999 and 2000. There had been a notable 
consolidation and significant reduction of isolates pertaining to the type 7 family.
The types 9, 13, 14, 15 and 16 represented the majority in the second variable region. 
With the demise of the type 4-variant family in 2001 the type 16-variant family (n=10) 
had continued to increase during this time, although consolidation into a single 
representative type had been obseiwed and no other variants types had been 
characterised during this time period. The 9-variant family (n=8) follows a similar 
pattern to 1999 and 2000 with a significant presence fiom the single variant type 9. 
The 14-variant family (n=8) had maintained a significant presence and the single type 
14-variant had represented these. This represented a continued consolidation with this 
particular type within the population. The 15-variant family (n=7) were represented 
by 15 (n=3), 15-11 (n=3) and 15-13 (n=l). With the exception of 15-13 these variants 
had been obseiwed in previous years. The notable shift obseiwed in 2000 between 
variant 15 and 15-11 had re-adjusted to similar levels. The variant 15-13 had not been 
characterised previously and displayed a close relationship to 15-11 with a repeat 
insertion of the “QNN” (Glutamine, Asparagine, Asparagine) amino acid motif within 
the central region. This resulted in the addition of three neutrally charged amino acids 
and as a consequence increased both the length and the molecular weight by 410.39. 
This insertion in relation to this relatively small type of variable region has 
significantly extended it by another 30%. Finally, the 13-variant family (n=6) had 
been introduced diuing 2001 with the presence of variant 13 (n=l), 13-1 (n=4) and 13-
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6 (n=l). These types were not obseiwed during 2000, however variant 13 and 13-1 
were observed during 1999 and variant 13-6 had been obseiwed for the first time. The 
13-variant family has an 18 amino acid chain length and has 18 different variants 
ranging from between one and four amino acid changes either by substitution insertion 
or mutation when compared to the original representative type (Appendix 6.2). The 
newly emerged 13-6 had an additional “TTTT” (Threonine, Threonine, Tlireonine, 
Threonine) animo acid motif inserted within the existing “TTTT” (Tlu'eonine, 
Threonine, Threonine, Tlireonine) animo acid region when compared to the 13-1 
variant and an additional “TTT” (Tlu'eonine, Thi eonine, Tlueonine) animo acid within 
the same region when compared to the original 13 variant. This resulted in the 
addtion of tluee or four tlueonine neutrally chaged amino acids and as a consequence 
increased both the length and the molecular weight by either 357.36 or 476.48.
The third variable region was represented by 35 (n=4), 35-1 (n=12), 36 (n=19), 36-2 
(n=3), 37 (n=3), 37-1 (n=4), 38 (n=4) and 38-1 (n=2). The distribution had 
similarities to 1999 and 2000, although a significant reduction if type 37 was 
observed. The 3 5-family (n=16) and the 36-family (n=22) represented a significant 
proportion of the isolates. These were mainly 35-1 and 36 variants. There had been a 
continued trend towards greater proliferation within families with the emergence of 
the 38-1-variant, which has not been observed since 1999.
4.1.3.3 Miscellaneous Serogroup Isolates. These represented over 12% of the total 
population in 2001. These were serogroups W135 (n=5), X (n=2), Y (n=l) and two 
non-groupable isolates. Variable region one was represented by 18-1 (n=4) and 19-1 
(ii“ l) within the W135 population. The W135 population in 2001 had a close
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association to the W135 population of 1999 rather than 2000, where a gi'eater number 
of different variants types were identified. The emergence of 19-1 had not been 
observed before and is more closely associated with serogi'oup B isolates, as is 18-1. 
VR2 was represented by variants 3 (n=4) and 15-11 (n=l). These were associated 
with 18-1 and 19-1 respectively, hrterestingly, although these conform to pre-existing 
VRl and VR2 profiles, the VR3 showed gi'eater variation than expected. VR3 was 
represented by 36 (n=l), 38 (n=3) and 40 (n=l), of these porA profile 18-1, 3, 40 had 
not been identified previously within the W135 population although a single 
serogi'oup B isolate fiom 1999 did share the same porA profile.
The serogroup X profiles were 21, 16, 37-1 and 22, 9, 35-1. The first profile had been 
observed before, however the second profile had not been observed in serogroup X 
isolates and was commonly identified within common serogroup B complexes.
A single serogroup Y isolated was identified as 5-1, 10-8, 36-2. This profile had a 
slight variation in the VR2, which had been identified previously as a 10-2 or 10-4 
and as a consequence had not been observed before within the serogi'oup Y 
population. This profile was commonly identified in serogroup C isolates.
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Figure 4.9 Association between porin A variable region 1 (VRl), variable 
region 2 (VR2) and variable region 3 (VR3) from meningococci isolated in 2001 
(year 3). Each identified porin A profile (VRl, VR2, VR3) is linked through a series 
of individually coloured and styled arrows. The total number represented within that 
variable type is indicated within the brackets. Following the 12-1 VRl variants (blue) 
the dashed line finishes as VR2 13-1 (black) (n=3). These are further distributed 
through a dashed line to VR3 35-1 (n=13).
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4.1.4 Genosubtyping of Meningococci Isolates in 2002.
4.1.4.1 Serogronp C Isolates. For the second year in a row the total number of 
serogroup C isolates fell by over 47% compared to the previous year. The majority of 
isolates fell into one single VRl family, two distinct VR2 families and one single 
VR3 family. This pattern had been consistent tlu’oughout this four-year study. The 
first variable region was represented by five different variable types within four 
distinct families namely, 5 (n=8), 19-1 (n=l), 21 (n=l) and 22 (n=l) with over 70% 
allocated to variable regions 5 (n=5) and 5-1 (n^3). This highlighted a slight increase 
in dispersion thi'oughout a number of different family variants, although the majority 
of isolates still remained in the same families and family variants compared to 
previous years. The second variable region was represented by five different variable 
types within four distinct families namely, 2 (n=5), 10 (n=4), 15(n==l) and 16 (n=l) 
with over 70% allocated to variable regions 2, 10-4 (n=l) and 10-8 (n=3). The level 
of type 10-4 had remained low since 2000 and type 10-8 remained dominant within 
the family. The third vai'iable region was represented by four different variable types 
contained within two distinct families namely, 36 (n=10) and 37 (n=l) with over 90% 
allocated to variant types 36 (n=l), 36-1 (n=2) and 36-2 (n=7). The dispersion within 
this family remained consistent with patterns observed in the previous year. Overall a 
similar pattern was observed within the serogroup C population compared with the 
previous year, although there was the continued presence of variable types that had 
been commonly associated with serogroup B isolates.
The first variable region was represented in the majority fi'om the type 5-family. The 
two represented are 5 (n=5) and 5-1 (n=3). This followed a similar distribution to
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1999, 2000 and 2001. The total number of serogroup C isolates had decreased by 
over 47% but the major variant types still remained dominant. The existence of 
variants 19-1 (n=l), 21 (n=l) and 22 (n=l) were obseiwed, these had been 
characterised within the serogi'oup C population previous but usually either the 19 or 
the 21 was obsei*ved, this was the first instance where both had been observed within 
the population within a single year. As previously described these were more 
commonly observed within the serogi'oup B population.
The type 2-family (n=5) and the type 10-family (n=4) represented a large proportion 
of the VR2 variants with the type 15-family and type 16-family represented by a single 
isolate respectively. With the exception of the single representatives this followed a 
similar family distribution to the previous years.
The type 36-family (n=10) and the type 37-family (n= l^) represented the third variable 
region. As with all previous years the majority of serogroup C isolates (over 63%) 
were represented by the type 36-2 (n=7). From previous years this trend was shown to 
consolidate towards a single variant type, however there had been a decrease in the 
percentage identified as type 36-2 and an increase in the presence of other types either 
within the same family such as type 36 (n=l) and 36-1 (n=2) or from other family 
types namely, 37-1 (n=l).
4.1.4.2 Serogroup B Isolates. The first variable region was represented by fifteen 
different variable types and this highlighted an increase of over 10% on the previous 
year. These were contained within eight distinct families namely, 5,7, 12, 17, 18, 19, 
21 and 22. Consequently, an increase in variable types within the same number of
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variant families highlights increased diversity within specific families. However type 
20 was not obseiwed in 2002 and type 17 was obseiwed and this maintained stability in 
the total number of families obseiwed within the serogroup B population. Within 
these eight distinct families over 79% were allocated to variable region families 7,19 
and 22. These dominant variant families remain the same compared with the previous 
year. The variant type 5 that was significantly reduced in previous years had not been 
observed in 2002 although variants 5-1 (n=3) and 5-2 (n=2) maintained a presence. 
The second variable region was represented by fifteen variable types, again the same 
number of types were observed in the previous year. These were contained within ten 
families namely, 1, 2, 4, 9, 10, 13, 14, 15, 16 and 26 with over 82% allocated to 
variable regions 4, 9, 14, 15 and 16. This highlighted another change within this 
group of dominant families with variable type 4 re-emerging and type 13 maintaining 
a presence albeit slightly reduced. The third variable region was represented by six 
different variable types within tlnee different families namely 35,36 and 37 with even 
distribution across each family with 35%, 41% and 24% respectively within variant 
types 35 (n=9), 35-1 (n=15), 36 (n=24), 36-2 (n=4), 37 (n=9) and 37-1 (n=8).
The first variable region was represented by a number of distinct families from the 5, 
7, 12, 17, 18, 19, 21 and 22. The 22-variant family (n=22) was represented by two 
variant types namely, 22 (n=21) and 22-1 (n=l). This represented an expansion of the 
22-variant family with the emergence of 22-1 although the type 22 had remained 
consistently dominant over a number of years within the serogi'oup B population. The 
7-variant family (n=22) was represented by four variant types namely, 7 (n=9), 7-1 
(n=2), 7-2 (n=10) and 7-9 (n=l). Both 7 and 7-2 had been obseiwed in the previous 
year however 7-1 and 7-9 had not although 7-1 had been identified in 2000. There
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was a notable consolidation and significant reduction of isolates pertaining to the type 
7 family that in 2002 had been significantly reversed. The newly emerged 7-9 had a 
“GANGGAS” (Glutamine, Alanine, Asparagine, Glutamine, Glutamine, Alanine, 
Serine) amino acid motif inserted within the central region compared to the commonly 
identified 7-2. This resulted in the addtion of seven neutrally chaged amino acids and 
as a consequence of the size of this inserted motif it increased the size of the variable 
region by over 40% and increased the molecular weigth by 640.60. The 19-variant 
family (n=ll) continued to maintain a presence within the population with 
representative types 19 (n=4), 19-1 (n=6) and 19-2 (n=l) following a similar pattern 
from the previous year.
The types 4, 9, 14, 15 and 16 represent the majority within the VR2 group. The type 
16-variant family (n=16) had continued to increase during this time with proliferation 
into 16 (n=14), 16-3 (n=l) and 16-10 (n=l) whereas in previous years type 16 
predominated as the single representative type. The 16-10 variant had not been 
observed previous and has a “TKD” (Threonine, Lysine, Aspartic acid) amino acid 
motif deleted compared to the type 16-varinat. This resulted in the deletion of a single 
neutrally, basic and acidicly charged amino acid with the combined molecular weight 
of 398.41. The motif was reduced in length by over 20%. The 14-varinat family 
(n=13) had maintained a significant presence with two variant types, namely 14 
(n=12) and 14-6 (n=l). This represented an expansion within the type 14-family and 
mirrored a similar distribution pattern to 1999. The 15-variant family (n=10) were 
represented by 15 (n=5) and 15-11 (n=5). This highlighted a consolidation into two 
representative variant types more indicative of the type-15 population in 1999 and 
2000 rather than 2001. The demise of the type 4-varinat (n=9) was short lived and its
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re-emergence had been observed in 2002. The 9-variant family (n=9) followed a 
similar pattern to previous years with a significant impact from the single variant type 
9.
The third variable region was represented by 35 (n=9), 35-1 (n=15), 36 (n=24), 36-2 
(n=4), 37 (n=9) and 37-1 (n=8). This highlighted a consolidation into tliree main 
families with the inconsistent appearance and non-appearance of the 3 8-family over 
the past few years mainly associated with the serogi'oup W135 population. The 35- 
family (n=24) and 36-family (n=28) maintained a dominant presence within the 
population although the 37-family had significantly increased and displayed levels 
similar to 1999 and 2000.
4.1.4.3 Miscellaneous Serogroup Isolates. These represent over 10% of the total 
population in 2002. These were serogroups W135 (n=4), X (n=l), Y (n=3) and Z 
(n=l). The serogi'oup W135 population was represented by a single VRl and VR2 
and two distinct VR3s. The first variable region was represented by 18-1 (n==4) these 
represented a common VRl associated with serogroup W135 isolates and displayed a 
similar pattern to previous years. Variable region two was represented by variant type 
3 (n=4) and again this was a common VR2 associated with both the VRl and the 
W135 population. Variable region three was represented by two types namely, 38 
(n=3) and 40 (n=l). The first type was common with pre-existing W135 porA profiles 
however the second type was less common although had been identified previously.
The serogroup Y (n=3) population was represented by two VRls, VR2s and two 
VR3s. The first isolate had a 22, 9, 35-1 porA profile that was more commonly
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associated with serogroup B isolates. The remaining two isolates had 5-1, 10-4 and 
two VR3s namely, 36 and 36-1. The variable region one and two were consistent with 
previous serogroup Y profiles however both VR3s were not expected within both this 
porA profile and the serogroup Y population. These VR3s were more commonly 
associated with serogroup B isolates whereas previous years had displayed variant 
type 36-2, which was more commonly associated with serogroup C isolates.
The single serogi'oup X profile was 7-1, 4-1 and 37-1. This profile has a slight 
variation on a previously identified serogroup X isolate from 1999. The second 
variable region has a single amino acid mutation and both these variant types are 
commonly identified within serogroup B isolates.
The single serogroup Z profile was 5-1, 10-8 and 36-1. This profile has a common 
association with serogi'oup C profiles. This serogi'oup is rare and this profile has not 
been identified within this serogroup previously consequently comparisons with 
isolates out with this population within the MLST database do conflnn this profile is 
unique.
218
Figure 4.10 Association between porin A variable region 1 (VRl), variable 
region 2 (VR2) and variable region 3 (VR3) from meningococci isolated in 2002 
(year 4). Each identified porin A profile (VRl, VR2, VR3) is linked through a series 
of individually coloured and styled arrows. The total number represented within that 
variable type is indicated within the brackets. Following the 5 VRl variants (blue) 
the dashed line finishes at VR2 2 (red) (n=5). These are further distributed through a 
dashed line to VR3 36-1 (n=l) and 36-2 (n=4).
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4.2 Discussion.
This study has highlighted that the VR3 region, along with VRl and VR2, was useful 
for the analysis of meningococcal strains. Strains were isolated from a number of 
different NHS boards within Scotland. A total of 86 different strains were identified 
fi'om 431 isolates. Five new VR3 variants were identified (Appendix 6.9 -  6.13) 
indicating the variability of this gene and this showed previous and on-going variation 
of the VR3 region of porA. Such variation, like that in VRl and VR2, will have an 
impact on the development of porA vaccines, which may include VR3 in their 
composition. Although VR3 has not been extensively researched in other laboratories, 
the significance of the immune response to porA YR3 is poorly understood, however a 
number of VR3 components are contained within the RTVM OMV vaccine, though, 
those VR3 components designations have not been published yet. The availability of 
VR3 nucleotide sequence information and typing combined with the VRl and VR2 
profile data has been clearly demonstrated in this chapter and is therefore important. 
This sequence surveillance of bacterial infections is important and leads to a better 
understanding of diseases.
The porin A variable region distribution over the four years shows a significant shift 
from VRs closely associated with serogioup C, namely variant 2, 5 and 36-2 families 
towards a wider distribution of VRs closely associated with serogroup B 
meningococci, namely 3, 4, 7, 14, 15, 16, 18, 19, 22, 35, 36 and 37 families. The 
clonality with which serogroup C meningococci are expressed phenotypically and 
genotypically is reflected in the porA profiles displayed within this serogioup 
population. A significant reduction as described in section 4.1 was observed within
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variant 2, 5, 10 and 36-2 families between years two, three and four. However there 
still remain a significant number of these variant families present in the population.
Interestingly, the number of different variant family types associated with serogroup B 
meningococci did not increase even though the proliferation of different MLST types 
has been documented. However there has been a greater variation between pre­
existing porA profiles whereby new combinations of previously characterized profiles 
have been observed. This would highlight the continued ability with which the 
meningococcus can display a wide range of different OMP configurations.
These molecular methods have further improved our knowledge of the population 
structure of some bacteria and this has been exemplified by the use of MLST and 
genotyping (Enright and Spratt 1999; Yakubu et al. 1999; Clarke et al. 2001b; 
Tzanakaki et al. 2001). The use of sequence-based systems for bacterial typing have 
been highlighted previously (Maiden et al. 1992; Enright and Spratt 1999; Spratt 
1999) and the availability of a national genotyping seiwice for the characterisation of 
pathogens with public health significance, such as N. meningitidis, have been 
documented and clearly highlight their importance (Clarke et al. 2001b; Clarke et al. 
2001c). Such systems can often provide rapid results when cultures are available and 
be useful for public health management (Clarke et al. 2001b) as well as invaluable 
data where culture negative clinical samples are used to obtain the genotype. As a 
consequence the provision of this information also provides long-tenn surveillance 
data which can then be used for informing vaccine policy. The development of 
vaccines relies on the availability of such data so that the design can be representative 
of strains circulating in the community.
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With the successfully implementation of the serogroup C vaccines and the availability 
of serogroup A, Y and W135 vaccines, there is an urgent need for a serogroup B 
meningococcal vaccine as this serogroup is now very common, if not the most 
common, serogroup of infection in many countries (Comiolly and Noah 1999). For 
example, it accounts for over 60% of disease in the UK (Connolly and Noah 1999). 
Although a serogroup B vaccine is now undergoing clinical trials, OMP vaccines may 
provide a short-term solution by providing protection in countries where predominant 
serosubtypes exist.
However, the sequencing of porA VRl, VR2 and VR3 provides a vast amount of 
information than is gained tlnough phenotypic characterisation and this is useful for 
strain characterization and differentiation especially in case cluster scenarios, hi this 
chapter some strains, which appeared identical by phenotypic analysis, were in fact 
different when the VRl VR2 and VR3 profile infoimation was examined.
hi conclusion this chapter combines porA profiles this MLST profiles, and the cost of 
performing additional nucleotide sequencing on several small but highly 
discriminatory regions is minimal compared to the extra discrimination gained. 
However, this chapter illustrates that a universal nomenclature is required for the 
PorA VR regions which are being analysed to avoid duplication or misinteipretation. 
This would also be important for those working within microbiology, but not 
necessarily the meningococcal field, where the understanding and interpretation of 
meningococcal typing may currently be confusing. Further development of the 
meningococcal porA website (http://www.neisseria.org/mn/typing/pora) would 
therefore be required to incoiporate this extra variable region and enable
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standardisation of genotyping of meningococci. These results within this chapter 
include porA  VR3 and this has displayed a gi'eater level of discrimination than using 
just VRl and VR2 alone. This ultimately enables more complete porA  
characterisation and data that can be useful for epidemiological purposes and vaccine 
design.
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Chapter 5
General Discussion
5.0 Introduction
Neisseria meningitidis has been documented as a causative agent of meningitis and 
septicaemia for over 100 years and has been well documented during this time period 
as a disease of rapid onset with high mortality and morbidity if untreated. After more 
than 80 years of major developments in detection, characterization and treatment, it 
still holds true today (Knapp 1988a). However after recent advances in engineering, 
molecular techniques and analysis systems the answers to questions raised over 
decades of research are becoming achievable. This study was in the first instance 
conducted over a numbers of years and set out to develop an automated system that 
performed MLST from an extracted isolate and as a consequnce allow the genotypic 
anaysis on meningococci over a number of years spanning the introduction of the 
MenC Vaccine. This would ultimately highlight the effect the MenC vaccine had on 
the disease-causing meningococcal population. Combined with detailed genotyic 
analysis of carriage strains, this would ultimately give a realistic picture of the 
dynamics of meningococcal within the enviromnent. This involved in the first 
instance detailed trials with automated liquid handling robots and as a consequence 
development and optimisation of novel chemical protocols to achieve MLST. 
Consequently, development of analysis software was required to characterise a 
relatively large number of nucleotide sequences. Finally detailed analysis of the data 
set allowed the generation of conclusions based on preformed hypotheses as described
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V in chapter 2.
5.1 Is Semi-Automated MLST and porA Sequencing Useful?
The identification and spéciation of bacteria has a long history and is important 
because it enables the monitoring of the occurrence, differences and similarities 
between different gi'oups of bacteria. Data provided from such analysis improves our 
understanding of bacterial species, genera, and populations, which supplies important 
information for epidemiological and public health interventions. Microbiological 
techniques have moved on since the early days of bacterial identification and new 
methods enable the availability of a much greater breadth of information. As time has 
progressed the cost of analysing bacteria to a DNA level has decreased such that 
routine analysis of genes from bacteria is possible and subsequently enable us to 
decipher the secrets within a whole genome. It is these latter methods that have 
become important in modern microbiology where the characterisation and 
differentiation of bacteria is increasingly important.
Ultimately semi-automation of this MLST scheme has been highly successftil and 
subsequently essential where high numbers of isolates are analysed involving the 
amplification and sequencing of multiple loci within a reference-laboratoiy 
environment. As a consequence it has reduced cross-contamination, enabled 
continuity of perfoimance, and reduced the cost per sample, all key goals in settings in 
which throughput is relatively high (Clarke 2002a). The semi-automated protocol 
described in this thesis fulfils these requirements.
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¥ The combination of N. meningitidis MLST housekeeping genes and the OMP porA 
within a semi-automated procedure enabled quick, reliable and reproducible 
production of results that aided public health management of meningococcal disease 
in Scotland. There have been many advantages highlighted from using a sequence- 
based system for typing organisms such as N. meningitidis (Maiden et al. 1998; 
Emight and Spratt 1999; Spratt 1999; Clarke et al. 2001b). The use of MLST and 
porA gene sequencing integiated within a semi-automated set-up gives a greater level 
of discrimination than perfoiming MLST alone (Clarke 2002d). This has been 
highlighted repeatedly thi'oughout this study fr om successful differentiation of large 
clonal complexes to small case clusters (Clarke et al. 2001b; Clarke 2002d; Clarke et 
al. 2003).
The importance of enlianced molecular methods and subsequent enhanced 
surveillance has been proven with this four-year study on the effect of the MenC 
vaccine on the disease-causing meningococci in Scotland pre, during and post 
vaccination campaign. At this stage it is important to emphasise the requirement for 
continual use of these systems to monitor the long-term effect as well as the short­
term effect of this vaccine campaign. It has been well documented as to the predicted 
reduction of serogroup C disease, however it is far more difficult to predict possible 
replacement serogroups, and their genetic profiles. The continual use of these systems 
will enable the scientific community to monitor any possible capsule switch between 
common serogi'oups and the detailed genetic profile of future dominant strains such as 
serogroup B isolates. These profiles will also highlight any fundamental genetic 
switch that may occur between common and less common serogroups.
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5.2 Is the Meningococcal Serogroup C Conjugate Vaccine Effective?
During the 1990s, the incidence of MD was higher in the UK than most other 
European countries. This was primarily due to an increase in serogroup C disease, 
particularly those within the ET-37/ST-11 genetic lineage. MenC vaccines were 
introduced in the UK at the end of 1999 with an uptake rate of approximately 70% by 
the end of 2000. However no meningococcal genetic population study has yet 
confimied that serogroup C disease has decreased. This study clearly shows both an 
overall decrease in serogroup C disease over the first fours years since January 1999 
and a significant increase in the diversity within the disease-causing population of 
meningococci after the introduction of the MenC vaccines, although there has been no 
genetic evidence for capsule switch.
This study found that the meningococcal population was highly diverse with an 
increasing trend of complex diversity coinciding with a decrease in serogioup C 
disease. A number of studies have been performed with collections of meningococci 
that cause disease within the MLST database (Maiden et al. 1998; Fell et al. 1999; 
Jolley et al. 2000; Clarke et al. 2001b; Tzanakaki et al. 2001). These collections have 
centred upon carriage and disease and therefore subsequent conclusions have been 
based on a limited number of disease-causing isolates. Moreover, these studies have 
been performed during time periods where the selective pressures are considered 
normal (i.e. out-with large-scale vaccine programmes). This unique study has taken 
into account all invasive isolates over a four-year period during which the MenC 
vaccine programme was executed. This study has shown that the genetic diversity of 
meningococci has significantly increased and in reflection the serogi'oup C ET-37/ST-
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11 meningococcal population has significantly decreased. This increase in diversity 
has been represented in the majority by the serogioup B meningococci, although this 
niche has been filled by a number of different STs fiom a number of different clonal 
complexes. Therefore currently, there is no hyper-endemic clone present in Scotland 
that has directly replaced the void left by the ST-11 clone.
hi summary the main conclusions drawn hom this study include:
• hi 1999, under half (43.5%) of all meningococcal disease was due to 
serogroup C meningococci
• In 2000, 2001 and 2002, this decreased to 35%, 26% and finally 12% of the 
total disease casuing population.
• The proportion of serogroup C’s characterised as ST-11 remained high 
between 1999 and 2002 ranging fiom 93% to 100%.
• Less than 1% of the STs were only associated with a single year.
• In 1999, 2000, 2001 and 2002, 19%, 18.5%, 35% and 31% of STs had no 
complex association.
• The analysis of N. meningitidis MLST data from patients with MD pre, during 
and post MenC vaccine implementation and subsequent success of this 
campaign on the targeted meningococcal serogi'oup C disease causing 
population.
• The analysis of N. meningitidis MLST data ascertaining the subsequent 
sequence profile within the meningococcal population after the anticipated 
reduction in the serogroup C population.
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• No clear conformity was observed between meningococcal serogroup and 
porA variable region profile.
• Genosubtyping of the porA gene increases the power of differentiation within 
clonal meningococcal populations.
• porA profiles associated with serogroup C have decreased significantly.
• porA profiles specifically associated with serogroup B have increased.
• The diversity of other serogrous within the population has notably increased.
• Non-groupable meningococci are specifically associated with porA profiles 
namely, VRl variants 7 and 18, VR2 variants 2, 16 and 30 and VR3 variants 
36 and 38.
• Specific porA variants such as VRl 5, 7, 18, 21, VR2 3, 4 and 16 and VR3 
36-1, 37-1 and 38-1 had mixed serogioup populations which could be 
conducive to capsular switch under selection pressure.
5.3 Further W ork
Multi-Locus Sequence Analysis (MLST) incorporating a combination of either 
housekeeping genes alone or in combination with more variable and discriminating 
genes can be incorporated with similar laboratory methods in most laboratories as a 
routine technique and consequently can provide data which is useful for the public 
health management of clusters or outbreaks in institutions such as schools, and also 
for general disease surveillance on a national basis, thereby providing information to 
determine national vaccine policy. This, however, is not yet commonplace in all 
laboratories responsible for detection and characterisation of N. meningitidis. 
However the development of a centralised facility within the European Union based in
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■V Oxford will allow access to this technique for all European member states and EMGM 
members (EU-Men-Net), whereby specific facilities working in the meningococcal 
field within Europe can utilise the expertise and equipment enabling them to perform 
MLST on their selected sample populations. This undoubtedly will allow members 
access to highly teclmical teclmiques with which they have no ability to obtain within 
their own scientific communities and allow gi'eater definition of meningococcal 
populations tliroughout Europe and with its success hopefiilly expansion thi'oughout 
the world.
A large proportion of cases within the UK are not culture confirmed due to the 
effective administration of antibiotics on suspicion of MD, consequently there is a 
need for nucleotide sequence-based typing of meningococci directly fiom clinical 
samples. Non-culture characterisation has been mainly basic detection and 
confiimation of MD rather than detailed characterisation thi'ough serogrouping, typing 
and sub-typing as well as full sequence typing with MLST. As MLST is a PCR-based 
technique, it has the advantage that it can be applied directly to culture negative 
clinical specimens such as cerebrospinal fluid (CSF) (Enright et al. 2000b) and blood. 
The development of such techniques is paramount in highlighting the true picture of 
meningococcal disease within the population. Recent studies have described nested 
MLST approaches to the laboratory confirmation and characterisation of 
meningococci directly fiom clinical sample (Diggle et al. 2003a). Along with other 
non-culture methods for the laboratory confirmation of MD, non-culture MLST will in 
the future play an important part in the sui-veillance of the disease. It is important to 
note that treatment with antibiotics can successfully limit the onset or decrease the 
level of disease and is recommended treatment upon immediate suspicion of
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meningitis (Cartwright et al. 1992). Although this therapy may lead to culture- 
negative samples, DNA usually remains in a clinical sample taken after onset of MD 
and can therefore be detected and characterised as demonstrated by non-culture 
MLST. Nucleotide sequencing, once an expensive and highly specialised technique, 
has become more widely available, mainly due to reduced consumable and equipment 
costs (Diggle and Clarke 2002b). The availability of MLST data is important as, 
along with serogi'oup (Diggle et al. 2003b) and sero-subtype (Diggle and Clarke 
2003a) infoi-mation, it can be used to monitor capsule switch in meningococci. 
Moreover, with porA nucleotide sequence data that can be gained by culture (Clarke 
2002d) or non-culture methods (Diggle and Clarke 2003a), it can be used for public 
health management during case clusters (Leavers et al 1999). These highly sensitive 
detection and characterisation methods will provide an invaluable source of 
information to aid public health management of MD as more effective treatments 
continue to be used.
With the decrease in serogroup C disease and therefore the apparent success of the 
MenC vaccine campaign within the UK, serogroup B meningococci account for a 
large percentage of disease for which there is no effective vaccine (Rosenstein et al. 
2001a). Although plain polysaccharide or conjugate vaccines are now available 
against serogroups A, C, Y and W135 (Rappuoli 2001a) there is an urgent need for a 
vaccine against the serogioup b meningococcus. With the well documented problems 
the development of a serogroup B vaccine therefore requires a different approach, 
perhaps based on an essential virulence gene gained from data gained through genome 
sequencing projects (Rappuoli 2001a). During such development, there is the option 
to develop vaccines based on other antigens the most studies of which are those based
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on OMPs (Al'Aldeen and Cartwright 1996; Rosenstein et al. 2001a). Although OMP- 
based vaccines are not the optimal solution for combating serogroup B meningococcal 
infection, they may provide a short-term solution and have shown great promise for 
the control of serogroup B meningococcal infection (Rappuoli 2001a).
The publication of complete genomes of a number of different N. meningitidis isolates 
has provided a comprehensive profile of the genetic complement of this important 
organism. However, the genome sequences emphasise inadequacies in our 
understanding of meningococcal pathogenesis. For example, it is not known which of 
the 2,158 A. meningitidis genes are involved in the disease process. Therefore, with 
the increased accessibility of genome sequencing methods for high-throughput, 
analysis of gene functions are needed to exploit the vast amount of information from 
an ever-increasing pool of genome projects. This could lead to the development of 
potential vaccines targeted at problematic serogroups such as serogroup B. This 
technique, namely reverse vaccinology, has already been attempted with the N. 
meningitidis genome.
The evidence provided by several reports highlights microarrays as simple 
characterisation tools, allowing minimal processing of samples and required practical 
experience after system set-up (Bavykin 2001). The limitations with such new 
technology include cost and the practicality within laboratories with limited resources 
and technical support. The challenge with such technology is to find ways in which 
this can be used to study different aspects of the bacterial population. For example, 
the comparison of selected genes expressed by a pathogenic strain compared with that 
expressed by a nonpathogenic stain by hybridization to an array made from the
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genome of the pathogenic strain (Clewley 2000). In this way, this method could be 
used to develop DNA arrays that are suitable for both diagnosis and typing of bacterial 
species such as N. meningitidis (Boitow R, personal communication).
The use of single nucleotide polymorphisms as a practical approach for identifying 
genetic diversity within a bacterial population has been available for a number of 
years (Emonts et al 2003), although with the advent of large scale nucleotide 
sequencing, SNP analysis has become much more accessible. There have been recent 
developments in SNP analysis which utilise such techniques as MLST to develop 
stiaightforward approaches to SNP-based bacterial typing, whereby computer analysis 
packages can identify highly informative set of SNPs within a database of gene 
sequence variants (Robertson et al 2004). These have the potential to rapidly identify 
and possibly differentiate specific sequence types within a population. This is one 
example where manipulation of sequence data can enable future development of SNP 
analysis tools
Variable Number Tandem Repeats (VNTRs) are represented as repeats, usually 
representing a single locus and show inter-individual length variability and are 
thought to occur due to slipped-strand mispairing. This type of typing scheme has 
been used on a number of different bacteria including, H. influenzae. Staphylococcus 
aureus, and A. meningitidis (van der Ende et al, 2000, van Belkum et al, 1998 and van 
Belkum et al 1997). The selected genes include opacity surface proteins {opa) and 
outer membrane proteins (porA). Within this study porA was used in combination 
with the A. meningitidis MLST scheme to provide a comprehensive profile of each 
organism.
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These approaches have provided high-level discrimination between isolates from the 
same and different species and will no doubt provide the basis for future typing 
methods. These techniques described can be extended to any organism for which 
extensive nucleotide sequence is available. As eluted to previously, these digital 
procedures studying pathogenic related genomic regions may in the future be applied 
to those organisms that are either fastidious or nonculturable. Once whole genome 
sequences of bacterial organisms become available, both diagnostic information and 
data on the evolutionaiy status of the strains involved can be obtained and in some 
cases obtained with the use of a single PCR or multiplex PCR test.
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Apftfendix
XXIII
Figure 6.1 List of all porin A variable region 1 (VRl) types. These aie
represented in peptide sequence format.
VARIANT NAME VR l PEPTIDE SEQUENCE
P1.5 FAMILY
5 PLQNIQPQVTKR
5-1 PLQNIQQPQVTKR
5-2 PLPNIQPQVTKR
5-3 PLQNIKQPQVTKR
5-4 PLQNIQKPQVTKR
5-5 PLQNIQPSYTKR
5-6 LLQNIQQPQVTKR
5-7 PLSNIQPQVTKR
5-8 PIQNIQQPQYTKR
5-9 PLLNIQPQVTKR
5-10 PFQNIQPQVTKR
P1.7 FAMILY
7 AQAANGGASGQVKVTKVTKA
7-1 AQAANGGAGASGQVKVTKVTKA
7-2 AQAANGGASGQVKVTKA
7-3 AQAANGGARASGQVKVTKYTKA
7-4 AQAANGGAGASGQVKVTKA
7-5 AQAANGGAVASGQVKVTKVTKA
7-6 AQAANGGASDQVKVTKA
7-7 AQSANGGASGQVKVTKVTKA
7-8 AQAANGGAGASGQVKVTKVTKVTKA
7-9 AQAANGGASGANGGASGQVKVTKA
7-10 AQAANGGVSGQVKVTKVTKA
7-11 AQAANGGASGQYKVTKVTKVTKA
7-12 AQAANGGARGQVKVTKYTKA
7-13 AQAANGGARGQVKVTKVTKVTKA
7-14 AQAVNGGASGQVKVTKA
7-15 AQAANGGAGASGQVKVTKVTKY
7-16 AQAANDGASGQVKVTKVTKA
P1.12 FAMILY
12 KLSSTNAKTGNKVEVTKA
12-1 KPSSTNAKTGNKVEVTKA
12-2 KPSSTKAKTGNKVEVTKA
12-3 KPSSTNAKTGNKVKVTKA
12-4 KSSNTNAKTSNKVEVTKA
12-5 KPSSTNPKTGNKVEVTKA
12-6 QPSNTNGKTGNKYEVTKA
12-7 KPSSTNANSSTNAKTGNKVEVTKA
12-8 KPSSTNAKTSNEYEVTKA
12-9 KPSSTNATTGNKVEVTKA
12-10 KPSSTNAKTDNKVEVTKA
XXIV
VARIANT NAME VR l PEPTIDE SEQUENCE
P1.17 FAMILY
17 
17-1
17-2
P1.18 FAMILY
18
18-1 
18-2 
18-3 
18-4 
18-5 
18-6 
18-7 
18-8
18-9 
18-10 
18-11
P1.19 FAMILY
19
19-1 
19-2 
19-3 
19-4 
19-5 
19-6 
19-7 
19-8 
19-9 
19-10 
19-11 
19-12 
19-13 
19-14 
19-15 
19-16 
19-17
P1.20 FAMILY
20
PPQKNQSQPVVTKA
PPPKNQSQPWTKA
PPQKNQSQPLVTKA
PPSKGQTGNKVTKG
PPSQGQTGNKVTKG
PPSKSQTGNKVTKG
PPSKGQTGNKVTKA
PPSKGQTGNKVIKG
PPSKGQVGNKVTKG
QLSKGQVGNKVTKG
QPSKGQVGNKVTKG
PPSKGQTGNKVTNG
PPPKDQTGNKVTKG
PPSEGQTGNTVTKA
PPSQGQTGNKYTKA
PPSKSQPQYKYTKA
PPSKSQSQYKYTKA
PPSKSQLQYKYTKA
PRSKSQPQYKYTKA
PPSNSQPQYKYTKA
PLSKSQPQYKYTKA
PPLKSQPQYKYTKA
PSSKSQPQYKYTKA
PPPKSQPQYKYTKA
PPSKSQPQYKYTQYKYTKA
PRSKSQPQYKYTKA
PPSRSQPQYKYTKA
PSSKSQSQYKYTKA
PPSKSQTQYKYTKA
PPSKSQHQYKYTKA
PPSESQPQYKYTKA
PLSKSQSQYKYTKA
PLSKSQHQYKYTKA
QPQTANTQQGGKYKYTKA
XXY
VARIANT NAME VR l PEPTIDE SEQUENCE
P1.21 FAMILY
21
21-1
21-2
21-3
21-4
21-5
21-6
21-7 
21-8
P1.22 FAMILY
22
22-1 
22-2 
22-3 
22-4 
22-5 
22-6 
22-7
P1.31 FAMILY
31
QPQVTNGVQGNQVKVTKA
QPNGVQGNQVKVTKA
QPQATNGVQGGQQGNQVKVTKA
QPQVTKGVQGNQYKVTKA
QPQYPNGYQGNQYKYTKA
QPQYPNSYQGNQYKYTKA
QPQATNGYQGGRQGNQYTYTKA
QLQYTNGYQGNQYKYTKA
QPQYTTGYQGNQVKYTKA
QPSKAQGQTNNQYKYTKA
QPSRTQGQTSNQYKYTKA
QPSRTQAQTSNQYKYTKA
QPSKAKGQTNNQYKYTKA
QLSKAQGQTNNQYKYTKA
QPSKAQGQTNNQYKYTKR
QPSRTQGQTRNQYKYTKA
QPSKAQGQTNNQYEYTKA
PPSSNQGKNQAQTGNTYTKA
XXYI
Figure 6.2 List of all porin A variable region 2 (VR2) types. These are
represented in peptide sequence format.
VARIANT NAME VR2 PEPTIDE SEQUENCE
P l.I FAMILY
1 YVAYENGVAKKVA
1-1 YYAYENGATKKYA
1-2 YYAYENGYYKKYA
1-3 YYAYENGYAKKYT
P1.2 FAMILY
2 HFYQQTPKSQPTLYP
2-1 HFYQQPPKSQPTLYP
2-2 HFYQQTPQSQPTLYP
2-3 HFYQQPPKSQLTLYP
2-4 HFYQQTPQSRPTLYP
2-5 HFYQQIPQSQPTLYP
2-6 HFYQQTPTLYP
2-7 HFYQQTSKSQPTLYP
2-8 HFYQQTTKSQPTLYP
2-9 HFYQQTPQSKPTLYP
2-10 HFYQQAPQSQSTLYP
2-11 HFYLQTPQSQPTLYP
2-12 HFYQQIPKSQPTLYP
2-13 YFYQQTPQSQPTLYP
2-14 HFYQQKLASKPTLYP
2-15 HFYQQKSTSKPTLYP
2-16 HFYQQKPTSKPTLYP
2-17 HFYQQQPTSEPTLYP
2-18 HFYQQIPKSQPILYP
2-19 HFYQQTSQSQPTLYP
2-20 HFYQQTPIYQQTPKSQPTLYP
2-21 HFYQQTHQSQPTLYP
2-22 HSYQQTPKSQPTLYP
2-23 HFYQQTPKSQPPLYP
2-24 HFYQQTPTHFYQQTPKSQPTLYP
2-25 HFYQQTPKSYP
2-26 HFYQQTPQRQPTLYP
2-27 HFYQQTPNSQPTLYP
2-28 PQSQPTLYP (MISSING HFYQQ MOTIF)
2-29 HFYQQTPQSQTPQSQPTLYP
P1.3 FAMILY
3 TLANGANNTIIRYP
3-1 TYANGANNTIIRYP
3-2 TLANGANDTIIRYP
3-3 TLANGADNTIIRYP
3-4 TPANGANNTIIRYP
XXVII
VARIANT NAME VR2 PEPTIDE SEQUENCE
3-5 TLAKGANNTIIRVP
3-6 TLANGATNTIIRVP
3-7 TLATLANGANNTIÏRVP
P1.4 FAMILY
4 HVVVNNKVATHVP
4-1 HVVVNNNVATHVP
4-2 HVVVNNKVATHVPAKVATHVP
4-3 HVVVNNKYTTHYP
4-4 HYYYNNKYATPHYP
4-5 HYYYNNKY ( MISSING THYP MOTIF)
4-6 HYYYNNRYATHYP
P1.9 FAMILY
9 YYDEQSKYHA
9-1 YYDSKYHA
9-2 YYGEQSKYHA
9-3 YYDEQSKDHA
9-4 YYDKQSKYHA
9-5 YYDEQSEYHA
9-6 YYDEQSQYHA
Pl.lO FAMILY
10 HFYQNKQNQRPTLYP
10-1 HFYQNKQNQPPTLYP
10-2 HFYQDKKGQPPTLYP
10-3 HFYQNKQNQQPTLYP
10-4 HFYQNKQNKQNQPPTLYP
10-5 ITFYQNKQSQRPTLVP
10-6 HFYQNKQNQQNQQNQPPTLYP
10-7 HFYQNKQNKPPTLYP
10-8 HFYQNKQNQQNQPPTLYP
10-9 HFYQNKQNKQNQLPTLYP
10-10 HFYQNKQNKQNKQNQPPTLYP
10-11 HFYQNKQNQRSTLYP
10-12 HFYQNKQNQLPTLYP
10-13 HFYQNKQNKKNQPPTLYP
10-14 HFYQNKQHQPPTLYP
10-15 HFYQNKQNQPSTLYP
10-16 HFYQNKQNQWSTLYP
10-17 HFYQNKQNQTPTLYP
10-18 HFYQNKQSQPPTLYP
10-19 HFYQNKQNKQKQPPTLYP
10-20 HFYQNKQNQWLTLYP
10-21 HFYPDKKGQPPTLYP
10-22 HFYQNKQNKQNQQNQPPTLYP
10-23 HFYQNKQNQWPTLYP
10-24 HFYKNKQNQRPTLYP
10-25 HFYQDKKGQP (missing PTLYP motif)
10-26 HFYQNKQNKPNQPPTLYP
XXVIII
VARIANT NAME VR2 PEPTIDE SEQUENCE
10-27 HFVRNKQNQRPTLYP
10-28 HFYQNQNKQNQPPTLYP
10-29 HFYQNKQNQSPTLYP
10-30 HYPNKQNQRPTLYP
10-31 HFYQNKQDQRPTLYP
10-32 HFYQNKQNKQPTLYP
10-33 YFYQNKQNKQNQPPTLYP
10-34 HFYQNKQNQQNQQPTLYP
10-35 HFYQNKQNQQNQQPTLYP
10-36 HFYQDKKGQLPTLYP
P1.13 FAMILY
13 YWTTYNTGSATTTTTFYP
13-1 YWTTYNTGSATTTTFYP
13-2 YWTTYNTGSATTTFYP
13-3 YWTTYNTGSATITTFYP
13-4 YYTTYTQGSATTTTFYP
13-5 YWTTYNTGSATTTTTTTTTFYP
13-6 YWTTYNTGSATTTTTTTTFYP
13-7 YWTTYNTGSATTTTTTFYP
13-8 YWITYNTGSATTTTFYP
13-9 YWTTYNTGSATTFYP
13-10 YWTTYNTGSYTTTTFYP
13-11 YWTTYNTGSAATTTTFYP
13-12 YWTAYNAGSATTTFYP
13-13 YWTTYNNGNATTTTFYP
13-14 YWTTYNTSSATTTTTFYP
13-15 YWTTYNTGSATTTTTTTFYP
13-16 YNTGSATTTFYP (MISSING YWT MOTIF)
13-17 YWTTYNTGNATTTTFYP
P1.14 FAMILY
14 YYDEKKMYHA
14-1 YYDEKKKMYHA
14-2 YYDEKKKYHA
14-3 YYDEKNMYHA
14-4 YYDENKMYHA
14-5 YYDKEQYSHA
14-6 YYDEKQYSHA
14-7 YYDETKMYHA
14-8 YYDEKKMYHA
14-9 YYDAKKMYHA
14-10 YYDEKGMYHA
14-11 YYDEKRYSH
14-12 YYNEKKMYHA
XXIX
VARIANT NAME VR2 PEPTIDE SEQUENCE
PL15 FAMILY
15 HYTRQNNADVFVP
15-1 HYTRQNNTDVFVP
15-2 HYTRQNNNNTDVFVP
15-3 HYTRPNNTDVFVP
15-4 HYNTRQNNADVFVP
15-5 HYTRQNSADVFVP
15-6 HYTRQNYADVFVP
15-7 HYTRQNNANVFYP
15-8 HYTRQNNAGYFYP
15-9 HYTRQNNTRQNNADYFYP
15-10 HYTGQNNADYFYP
15-11 HYTRQNNIDYFYP
15-12 HYNTRQNNIDYFYP
15-13 HYTRQNNQNNIDYFYP
15-14 HYTNTRQNNIDYFYP
15-15 HYTRQSNTDYFYP
15-16 HYTRQNNADFYP
15-17 HYTRQNNAYYFYP
15-18 HYTRQNNDTRQNNADYFYP
15-19 HTRQNNIDYFYP
15-20 HYTRQNNAAYFYP
15-21 HYTRQNDADYFYP
P1.16 FAMILY
16 YYTKDTNNNLTLYP
16-1 YYTKGKNNALTLYP
16-2 YYTKNTNNNLTLYP
16-3 YYTKDKNDNLTLYP
16-4 YYTKDKNDKLTLYP
16-5 YYTKDTNNKNNLTLYP
16-6 YYTKHTNNNLTLYP
16-7 YYTKDTNTKDTNNNLTLYP
16-8 YYTKDKNNALTLYP
16-9 YYTKDTNDLTLYP
16-10 YYTNNNLTLYP
16-11 YYTTDTNNNLTLYP
16-12 YYTKDTNDNLTLYP
16-13 YYTEDTNNNLTLYP
16-14 YYTKDTNTNLTLYP
16-15 YYNTKDTNNNLTLYP
16-16 YYTKDTNNNPTLYP
16-17 YYTKDTNNTNNNLTLYP
16-18 YYTKDTNTNNNLTLYP
16-19 YYTKDTNNNLTHTKDTNNNLTLYP
16-20 KDTNNNLTLYP
16-21 YYTKDTKNNLTLYP
16-22 YYTKDTNNILTLYP
XXX
VARIANT NAME VR2 PEPTIDE SEQUENCE
16-23 YYTKDNKNDNLTLVP
16-24 YYTKYENDNLTLVP
16-25 YYTKDTNNNLNLTLYP
16-26 YYTNTNNNLTLVP
16-27 YYTKDTNNNLTLVS
16-28 YYTKVKNDNLTLVP
16-29 YYTKGTNNDLTLVP
16-30 YYTKDKNDNRTLYP
16-31 YYTKTNNNPTLVP
16-32 YYTKVTNNNLTLVP
16-33 YYTNTKDTNNNLTLVP
16-34 YYTKDTNNNLKDTNNNLTLVP
16-35 YYTKHANNNLTLVP
16-36 YYTKGTNNNPTLYP
16-37 YYTKVTDNNLTLVP
16-38 YYTKDTNNNLPLYP
16-39 YYTKDTTNNNLTLYP
16-40 YYNTKDTKNNLTLVPA
16-41 YYTKDTNNKLTLYP
16-42 YYTKDTNYTKDTNNNLTLVP
16-43 YYTKDTNNNLTNNNLTLVP
16-44 YYTNTNDNLTLVP
16-45 YYTNYTKDTNNNLTLVP
P1.23 FAMILY
23 HWNTVYNTNGTTTTFVP
23-1 HWNTVYNTNGTTTTTTTFVP
23-2 HWNTVYNTNGTTTTTFVP
23-3 HWNTVYNTNGTTTTTTFVP
23-4 HWTTVYNTNGTTTFVP
P1.25 FAMILY
25 TYTVDSSGVVTPVP
25-1 TYTVDSSGYFTPVP
25-2 TYTEGSSGVFTPVP
25-3 TYTVDSSGVVTPLP
25-4 TYTVGSRDVVTPVP
25-5 TYTVDSSNVVTPVP
25-6 TYTVDSGVVTPVP
25-7 YTVDSSGVVTPVP
25-8 TYTVDSSGVP
25-9 TYTVDNSSVVTPVP
25-10 TYTVDSSRVVTPVP
25-11 TYTVDSSDVVTPVP
25-12 TYTVDSSSVVTVPV
25-13 TYTVDSMDSSGVVTPVP
XXXI
VARIANT NAME VR2 PEPTIDE SEQUENCE
P1.26 FAMILY
26
26-1
26-2
P1.28 FAMILY
28
P1.30 FAMILY
30
30-1
30-2
30-3
30-4
30-5
30-6
30-7
P1.34 FAMILY
34
34-1
P1.42 FAMILY
42 
42-1
P1.43 FAMILY
43
HFVADSQGKITRVP
HFVADSQGEITRVP
YFTADPNDQNKITRVP
YYYTTATNSSTSTTFVP
HYTTVYNATTTTTTFVP
HYTTVYNATTTTTFVP
HYTTVYNATTTTTTTFVP
HYTTVYNATTTTTTTTFVP
HYTTVYNATTTTTTTTTFVP
HYTTVYNATTTTTTTTTTFVP
HYTTVYNATTTTTTTTTTTFVP
HYTTVYNATTTTTTTTTTTTTFVP
YVDDQGKVKGP
YYDDQKVKGP
HLVLDGQGKITQVP
HLVSDGQGKITQYP
TFTLESNQMKPVP
XXXII
Figure 6.3 List of all porin A variable region 3 (VR3) types. These are
represented in peptide sequence format.
VARIANT NAME VR3 PEPTIDE SEQUENCE
35 FAMILY
35 
35-1
35-2
36 FAMILY
36
36-1 
36-2
36-3
37 FAMILY
37
37-1
38 FAMILY
38
38-1
39 FAMILY
39
40 FAMILY
40
41 FAMILY
41
LIGSGSDQ
LLGSGSDQ
SLGSGSDQ
LLGSTSDE
LLGSTSDQ
LLGSGSDE
LLGSASDE
LIGSATSDQ
LIGSATSDE
LLGRIGDDDE
LLGRIGEDDE
LLGSGSDG
LLGRSGDDDE
LLGRGSDE
XXXIII
Figure 6.4 Polymorphic sites associated with each allelic variant within each 
housekeeping gene from meningococci isolated in 1999 (year 1). Each 
housekeeping gene is represented by its abbreviated initials followed by the total 
number of different alleles characterised followed by the number of polymorphic 
sites. These are displayed within the nucleotide sequence following this information. 
A consensus sequence is displayed for each housekeeping gene and if a variation 
within the sequence is identified the alternative base pair is displayed directly below 
the consensus nucleotide sequence base pair.
abcZ
14 alleles, 60 polymorphic sites
1 10 20  30  40 50
TTTGATACCGTTGCCGAAGGTTTGGGTGAAATTCGCGATTTATTGCGCCG 
T CA T
51 60 70 80  90 1 0 0
TTACCACCGCGTCGGCCATGAGTTGGAAAACGGTTCGGGTGAGGCTTTGT 
T T AT A T  T GC TAA AAAC C TC A
1 0 1  1 1 0  1 2 0  1 3 0  140  1 5 0
T GAAAGAACTCAACGAATTACAACTTGAAATCGAAGCGAAGGACGGCTGG 
A G  G C CG T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAGCTGGATGCGGCAGTCAAGCAGACTTTGGGGGAACTCGGTTTGCCGGA 
AT G G C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
AAACGAAAAAATCGGCAACCTTTCCGGCGGTCAGAAAAAGCGTGTCGCCT 
T C C
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGCAGGCTTGGGTGCAGAAGCCCGACGTATTGCTGCTGGACGAACCG 
T A C T G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
ACCAACCATTTGGATATCGACGCGATTATTTGGCTGGAAAATCTGCTCAA 
C T C T C
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
AGCGTTTGAAGGCAGCTTGGTTGTGATTACCCACGACCGCCGTTTTTTGG 
G C C T
4 0 1  4 1 0  4 2 0  4 3 0
ACAATATCGCCACGCGGATTGTCGAACTCGATC 
T T C C T T C
XXXIV
adk
8 alleles, 14 polymorphic sites
1 10 20  30 40  50
GAAGCGAAAAAAATCATTGACGAAGGCGGCTTGGTGCGCGACGACATCAT
T
51 60 70 80 90 1 0 0
TATCGGCATGGTC7\7\AGAACGCATCGCGCAAGACGACTGCAAAAACGGTT
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
TCCTGTTCGACGGTTTCCCGCGCACATTGGCACAAGCCGAAGCGATGGTT 
T T GC G
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GAAGCAGGCGTGGATTTGGATGCAGTCGTTGAAATCGACGTGCCTGACAG
T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGTGATTGTCGACCGTATGAGCGGCCGCCGCGTGCATTTGGCTTCCGGCC 
C
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
GTACTTACCACGTTACCTACAACCCGCCCAAAGTTGAAGGCAAAGACGAC
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GTAACCGGCGAAGATTTGATTCAGCGCGACGACGACAAAGAAGAAACCGT 
A
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
GAAAAAACGCCTTGCCGTTTACCACGAGCAAACCGAAGTTTTGGTCGATT
T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
TTTACAGCAAACTGGAAGGCGAACACGCGCCTAAATACATCAAAGTTGAC
4 5 1  4 6 0
GGCACTCAGCCGGTA 
C AG A
XXXV
aroE
18 alleles, 122 polymorphic sites
1 10 20  30  40 50
TATCGGTTTGGCCAACGACATCACGCAGGTCAAAAACATTGCCATCGTy^G 
T G AT GG T AGT A GC C T CA AA T G
T
51 60 70  80 90 100
GCAAAACCATCTTGCTTTTGGGCGCGGGCGGCGCGGTGCGCGGCGTGATT 
AT TC AT GC C A T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CCTGTTTTGAAAGAACACCGTCCTGCCCGTATCGTCATTGCCAACCGCAC 
G C A T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCACGCCAAAGCCGAAGAATTGGCGCGGCTTTTCGGCATTGAAGCCGTCC 
GT G T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGATGGCGGATGTGAACGGCGGTTTTGATATCATCATCAACGGCACGTCC 
CT A A G
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
GGCGGCTTGAGCGGTCAGCTTCCTGCCGTCAGTCCTGAAATTTTCCTCGG 
TC A A A G ATA TCAG GC T T GAAA
C CC A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
CTGCCGCCTTGCCTACGATATGGTTTACGGCGACGCGGCGCAGGAGTTTT 
GCG G A TGA AA ACC
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
, TGAACTTTGCCCAAAGCAACGGTGCGGCCGAAGTTTCAGACGGACTGGGT 
AG T A GGCAATCG C T AAAA ACCG C G C
C
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
ATGCTGGTCGGTCAAGCGGCGGCTTCCTACGCCCTCTGGCGCGGATTTAC 
A G T C C CATA T G
4 5 1  4 6 0  4 7 0  4 8 0  4 9 0
GCCCGATATCCGCCCTGTTATCGAATACATGAAAGCCATG 
TA CA C A
XXXVI
fumC
14 alleles, 36 polymorphic sites
1 10 20  30 40 50
GAAGCCTTGGGCGGACGCGATGCCGCCGTTGCCGCTTCGGGCGCATTGTV^ 
AC A T C
51 60 70 80  90 1 0 0
AACGCTGGCGGCAAGCCTGAATAAAATCGCCAACGACATCCGCTGGCTGG 
AT C T T
1 0 1  1 1 0  1 2 0  1 3 0  140  150
CAAGCGGCCCGCGCTGCGGTTTGGGCGAAATCAAAATCCCCGAAAACGAG 
T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCGGGTTCGTCCATCATGCCGGGCAAAGTCAACCCGACCCAATGCGAAGC 
T T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
GATGACCATGGTGTGCTGCCAAGTGTTCGGCAACGACGTTACCATCGGCA 
A G T  T
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGGGCGCGTCGGGCAATTTCGAGCTGAACGTCTATATGCCCGTTATC 
A A C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCTACAACCTCTTGCAATCCATCCGCCTGTTGGGCGACGCGTGCAACAG
AT C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CTTCAACGAACACTGCGCCGTCGGCATCGAACCCGTACCGGAAAAAATCG
A T  G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
ACTATTTCCTGCACCATTCCCTGATGCTGGTTACTGCGTTAAACCGTAAA
C C AC G C
4 5 1  4 6 0
ATCGGCTACGAAAAC
T
XXXVII
gdh
13 alleles, 25 polymorphic sites
1 10 20  30  40 50
ATGTTCGAGCCGCTGTGGAACAATAAATACATCGAAAGCGTGCAGTTGAC 
T T C
51 60 70 80 90 100
CATCGCCGAACAGCTCGGTGTGGAAGAGCGCGGCGAGTTTTACGACATTA 
G T G C A T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CTGGCGCCTTGCGCGATATGGTGCAAAACCACTTGATGCAAATGCTGTGC 
C G T T G T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
ATGACTGCGATGGAAGCCCCCGCCAGCTTGGATGCCGACGCGGTGCGCGA
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGAAAAAGTCAAAGTCATCAAGTCATTGAAGCCGCTGACCGTCGAGTCTG
A
2 5 1  260 2 7 0  2 8 0  2 9 0  300
TCAATGAAAACGTCGTGCGCGGACAATATACCGCCGCCAGAGGCATGAAC 
T A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GGCTATCTTGAAGAAATCAACGTTCCGCAAGACAGCTTTACCGAAACCTA
3 5 1  360 3 7 0  3 8 0  3 9 0  4 0 0
CGTCGCCATTAAAGCCGAAATCGAAAACG7W\CGCTGGAAGGGCGTTCCCT
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
TCTACCTGCGTACCGGCAAACGCATGGCGGGCAAAGTGGCGGAAATCGTT
G A T
4 5 1  460 4 7 0  4 8 0  49.0 500
TTGAACTTCAAAGATTTGAACAGCCATATTTTTGAAGGCAGCCGCACCGC
A T G
5 0 1
G
XXXVIII
pdhC
16 alleles, 71 polymorphic sites
1 10 20  30  40 50
ATGCCCGAAGGTGCGGAACAAGACATCTTGAAAGGTATGTACCTGCTGAA 
C A C T
51  60 70  80 90 1 0 0
AGCCGGCGGCAAAGGCGACAAGAAAGTCCAACTGATGGGTTCCGGTACGA
T T T C C
1 0 1  1 1 0  1 2 0  1 3 0  140  1 5 0
TTTTGCAAGAAGTGATTGCCGGTGCCGAGCTGCTGAAAGCCGACTTCGGC 
CC CG A A AT
T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GTGGAAGCAGACATTTGGTCTTGCCCATCTTTCAACCTGTTGCATCGCGA 
T A  C G C C C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGCTATCGAAGCAGAACGTTTCAACCGCCTGAATCCTTTGGAAACTGCAA 
C CG GATC C C GC G C A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGTACCGTTTGTTACTTCTCAACTGCAAGGTCATGACGGCCCGGTGATT 
G T C  C CA T T T C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GCCGCTACCGACTATATCCGTAGCTATGCTGACCGCATCCGTGCCTACAT 
C C G T C
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
CCCTAACGACTACCACGTCTTGGGTACTGACGGCTTCGGCCGCTCCGACA 
G C T T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCCGTGCCAACCTGCGTAGCTTCTTCGAAGTTGACCGCTACAACGTTGCC 
T C CC T G TT
4 5 1  4 6 0  4 7 0  4 8 0
GTTGCTGCATTGAGCGCATTGGCCGATCAA 
G A GC G A
A C
XXXIX
pgm
12 alleles, 59 polymorphic sites
1 10 20  30 40 50GTGGTTACCAAAGACGGCAACATTATTTATCCCGACCGCCAACTGATGCT 
G A G  C C G  T A T
A
51 60 70  80  90 1 0 0
GTTCGCCCAAGACGTTTTGAACCGCAATCCCGGCGCGAAAGTCATTTTCG 
T G G A G  TAAA A G C
C A
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
ACGTGAAGTCCACCCGCCTGCTTGCGCCTTGGATTAAAGAACACGGCGGC 
T G A  T G A T G  C
C
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAAGCCATAATGGAAAAAACCGGCCACAGCTTTATCAAATCCGCCATGAA 
G C TG G T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
AGAAACCGGCGCGCCGGTTGCCGGCGAAATGAGCGGACACATCTTCTTCA 
A T
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGAACGCTGGTTCGGCTTCGACGACGGTCTGTACGCCGGCGCACGCCTC
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
TTGGAAATCCTGTCTGCCTCCGATAATCCGTCCGAAGTGTTAAACAACCT 
C G
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
GCCGCAAAGCATTTCCACGCCCGAACTCAACATCGCCCTGCCCGAAGGCA 
A T G T A G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
GCAACGGCCATCAGGTTATCGACGAACTCGCCGCCAAAGCCGAATTTGAA 
C A A G T A G G T  T A G C
XL
Figure 6.5 Polymorphic sites associated with each allelic variant within each 
housekeeping gene from meningococci isolated in 2000 (year 2). Each 
housekeeping gene is represented by its abbreviated initials followed by the total 
number of different alleles characterised followed by the number of polymorphic 
sites. These are displayed within the nucleotide sequence following this information. 
A consensus sequence is displayed for each housekeeping gene and if a variation 
within the sequence is identified the alternative base pair is displayed directly below 
the consensus nucleotide sequence base pair.
abcZ
14 alleles, 69 polymorphic sites
1 10 20  30 40 50
TTTGATACTGTTGCCGAAGGTTTGGGCGAAATTCGCGATTTATTGCGCCG 
C TA G T A
51  60 70 80 90 1 0 0
TTATCATCATGTCAGCCATGAGTTGGAAAATGGTTCGAGTGAGGCCTTAT 
C C GC G T T GC GAA AGAC C TT G
1 0 1  110  1 2 0  1 3 0  1 4 0  1 5 0
TGAAAGAGCTCAACGAATTGGAACTTGAGATCGAAGCGAAGGACGGCTGG 
A A T A C CA T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAGTTGGATGCGGGGGTGAAGCAGACTTTGGGCGAACTCGGTTTGCGGGA 
AC A C  G
201 210 220 230 240 250
AAAGGAAAAAATGGGGAACCTCTCGGGGGGTGAGAAAAAGCGGGTGGGGT
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGCAGGCTTGGGTGCAGAAGCCGGACGTATTGCTGCTCGATGAACCG 
T A G C G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
ACCAACCATTTGGACATCGACGCGATTATTTGGTTGGAAAACCTGCTCAA 
T T T C C T T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
AGCGTTTGAAGGCAGCCTGGTTGTGATTACCCACGACCGCCGTTTTTTGG 
G T C T C
4 0 1  4 1 0  4 2 0  4 3 0
ACAATATCGCCACGCGGATTGTCGAACTCGATC 
T C T T A C C T  T C
XLI
adk
10 alleles, 23 polymorphic sites
1 10 20  30 40 50
GAAGCGAAAAAAATCATTGACGAAGGCGGCTTGGTGCGCGACGACATCAT
T
51  60 70 80  90 100
TATCGGCATGGTCAAAGAACGCATCGCGCAAGACGACTGCAAAAACGGTT
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
TCCTGTTTGACGGTTTCCCGCGCACGCTGGCACAGGCCGAAGCGATGGTT 
T C AT A
1 5 1  160 1 7 0  1 8 0  1 9 0  2 0 0
GAAGCAGGCGTGGATTTGGATGCAGTCGTTGAAATCGACGTGCCTGACAG
T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGTGATTGTCGACCGCATGAGCGGCCGCCGCGTGCATTTGGCTTCCGGCC 
T
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  300
GTACTTACCACGTTACCTACAACCCGCCCAAAGTTGAAGGCAAAGACGAC
T G C T
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GTAACCGGCGAAGATTTGATTCAGCGCGACGACGACAAAGAAGAAACCGT 
A C
3 5 1  360 3 7 0  3 8 0  3 9 0  4 0 0
GAAAAAACGCCTTGCCGTTTACCACGAGCAAACCGAAGTTTTGGTTGATT
G GC C
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
TTTACAGCAAACTGGAAGGCGAACACGCGCCTAAATACATCAAAGTTGAC
G
4 5 1  460
GGCACTCAGCCGGTA 
C AG A
XLII
aroE
18 alleles, 127 polymorphic sites
1 10 20  30 40 50
TATCGGTTTGGCCAACGACATCACGCAGGTCAAAAACATTGCCATCGAAG 
T G AT GG T AGT A GC C T CA AA T G
T
51 60 70  80  90 1 0 0
GCAAAACCATCTTGCTTTTGGGCGCGGGCGGCGCGGTGCGCGGCGTGATT 
AT TC AT GC C A T A
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
CCTGTTTTGAAAGAACACCGTCCTGCCCGTATCGTCATTGCCAACCGCAC 
G G G C A G  T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCACGCCAAAGCCGAAGAATTGGCGCGGCTTTTCGGCATTGAAGCCGTCC 
TGT G T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGATGGCGGATGTGAACGGCGGTTTTGATATCATCATCAACGGCACGTCC 
CT A C A G
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
GGCGGCTTGAGCGGTCAGCTTCCTGCCGTCAGTCCTGAAATTTTCCTCGG 
TC A A A G ATA TCAG GC T T GAAA
C CC A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
CTGCCGCCTTGCCTACGATATGGTTTACGGCGACGCGGCGCAGGAGTTTT 
GCG G A TGA AA ACC
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
TGAACTTTGCCCAAAGCAACGGTGCGGCCGAAGTTTCAGACGGACTGGGT 
AG T A GGCAATCG C AAAA ACCG C G C
C
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
ATGCTGGTCGGTCAAGCGGCGGCTTCCTACGCCCTCTGGCGCGGATTTAC 
A G T C C TATA T G
C
4 5 1  4 6 0  4 7 0  4 8 0  4 9 0
GCCCGATATCCGCCCTGTTATCGAATACATGAAAGCCATG 
TA CA C A
XLIII
fumC
13 alleles, 36 polymorphic sites
1 10  2 0  30  40  50
GAAGCCTTGGGCGGACGCGATGCCGCCGTTGCCGCTTCGGGCGCATTGAA 
AC A T C
51  60 70  80  90 100AACGCTGGCGGCAAGCCTGAATAAAATCGCCAACGACATCCGCTGGCTGG 
AT C T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
CAAGCGGCCCGCGCTGCGGTTTGGGCGAAATCAAAATCCCCGAAAACGAG 
T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCGGGTTCGTCCATCATGCCGGGCAAAGTCAACCCGACCCAATGCGAAGC 
T T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
GATGACCATGGTGTGCTGCCAAGTGTTCGGCAACGACGTTACCATCGGCA 
A G T  T
251 260 270 280 290 300
TGGCGGGCGCGTCGGGCAATTTCGAGCTGAACGTCTATATGCCCGTTATC 
A A C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GCCTACAACCTCTTGCAATCCATCCGCCTCTTGGGCGACGCGTGCAACAG
AT G T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CTTCAACGAACACTGCGCCATCGGCATCGAACCCGTACCGGAAAAAATCG
G T G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
ACTATTTCCTGCACCATTCCCTGATGCTCGTTACCGCGTTAAACCGCAAA
G T AC G T
4 5 1  4 6 0
ATCGGTTACGAAAAC
C
XLIV
gdh
15 alleles, 32 polymorphic sites
1 10 20  30 40 50
ATGTTCGAGCCGCTGTGGAACAATAAATACATCGAAAGCGTGCAGTTGAC 
T C
51  60 70 80  90 100
CATCGCCGAACAGCTCGGTGTGGAAGAGCGCGGCGAGTTTTACGACATTA 
G T G C A T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CTGGCGCCTTGCGCGATATGGTGCAAAACCACTTGATGCAAATGCTGTGC 
C G  T T  G T T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
ATGACTGCGATGGAAGCCCCCGCCAGCTTGGATGCCGACGCGGTGCGCGA
A TT A T T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGAAAAAGTCAAAGTCATCAAGTCATTGAAGCCGCTGACCGTCGAGTCTG
A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TCAATGAAAACGTCGTGCGCGGACAATATACCGCCGCCAGAGGCATGAAC 
T A G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GGCTATCTTGAAGAAATCAACGTTCCGCAAGACAGCTTTACCGAAACCTA
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
CGTCGCCATTAAAGCCGAAATCGAAAACGAACGCTGGAAGGGCGTTCCCT
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
TCTACCTGCGTACCGGCAAACGCATGGCGGGCAAAGTGGCGGAAATCGTT
G A T
45 1  4 6 0  4 7 0  4 8 0  4 9 0  500
TTGAACTTCAAAGATTTGAACAGCCATATTTTTGAAGGCAGCCGCACCGC
A T G
5 0 1
G
XLV
pdhC
17 alleles, 78 polymorphic sites
1 10 20  30 40 50
ATGCCCGAAGGTGCGGAACAAGACATCTTGAZ\AGGTATGTACCTGCTGAA 
G C TA C C TT
T
51  60 70  80 90 1 0 0
AGCCGGCGGCAAAGGCGACAAGAAAGTCCAACTGATGGGTTCCGGTACGA
T T T C C
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
TTTTGCAAGAAGTGATTGCCGGTGCCGAGCTGCTG7W\GCCGACTTCGGC 
CC CG A A AT T
T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GTGGAAGCAGACATTTGGTCTTGCCCATCTTTCAACCTGTTGCATCGCGA 
T A  C G C C C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGCTATCGAAGCAGAACGTTTCAACCGCCTGAATCCTTTGGAAACTGCAA 
C CG GATC C C GC A G C A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGTACCGTTTGTTACTTCTCAACTGCAAGGTCATGACGGCCCGGTGATT 
G T C  C CA T T A T C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCGCTACCGACTATATCCGTAGCTATGCTGACCGCATCCGTGCCTACAT
C C T C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CCCTAACGACTACCACGTCTTGGGTACTGACGGCTTCGGCCGCTCCGACA
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCCGTGCCAACCTGCGTAGCTTCTTCGAAGTTGACCGCTACAACGTTGCC 
T C CC T G T
4 5 1  4 6 0  4 7 0  4 8 0
GTTGCTGCATTGAGCGCATTGGCCGATCAA 
G A GC G A
A C
XLVI
pgm
12 alleles, 67 polymorphic sites
1 10 20  30  40 50
GTGGTTACCAAAGACGGCTVACATTATTTATCCCGACCGCCAACTGATGCT 
G A G  C C G  T A T
A
51 60 70 80  90 1 0 0
GTTCGCCCAAGACGTTTTGAACCGCAATCCCGGCGCGAAAGTCATTTTCG 
T G G A G  C TAAA A G C
C A
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
ACGTGAAGTCCACCCGCCTGCTTGCGCCTTGGATTAAAGAACACGGCGGC 
T C A  T G A T G  C
C
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAAGCCATAATGGAAAAAACCGGCCACAGCTTTATCAAATCCGCCATGAA 
G C TG G C GA
T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
AGAAACCGGCGCGCCGGTTGCCGGCGAAATGAGCGGACACATCTTCTTCA 
A A TC C
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  300
AAGAACGCTGGTTCGGCTTCGACGACGGTCTGTACGCCGGCGCACGCCTC
A C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
TTGGAAATCCTGTCTGCCTCCGATAATCCGTCCGAAGTGTTAAACAACCT 
C G
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
GCCGCAAAGCATTTCCACGCCCGAACTCAACATCGCCCTGCCCGAAGGCA 
A T G T A G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCAACGGCCATCAGGTTATCGACGAACTCGCCGCCAAAGCCGAATTTGAA 
C A A G T A G G T  T A G C
XLvn
Figure 6.6 Polymorphic sites associated with each allelic variant within each 
housekeeping gene from meningococci isolated in 2001 (year 3). Each 
housekeeping gene is represented by its abbreviated initials followed by the total 
number of different alleles characterised followed by the number of polymorphic 
sites. These are displayed within the nucleotide sequence following this information. 
A consensus sequence is displayed for each housekeeping gene and if a variation 
within the sequence is identified the alternative base pair is displayed directly below 
the consensus nucleotide sequence base pair.
abcZ
16 alleles, 66 polymorphic sites
1 10 20  30  40 50
TTTGATACCGTTGCCGAAGGTTTGGGTGAAATTCGCGATTTATTGCGCCG 
T A CA T A
51 60 70 80  90 1 0 0
TTACCACCGCGTCGGCCATGAGTTGGAAAACGGTTCGGGTGAGGCTTTGT 
T T AT TA T T GC TAA AAAC C TC A
1 0 1  110  1 2 0  1 3 0  1 4 0  1 5 0
TGAAAGAACTCAACGAATTACAACTTGAAATCGAAGCGAAGGACGGCTGG 
A G  G C CG T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAGCTGGATGCGGCAGTCAAGCAGACTTTGGGGGAACTCGGTTTGCCGGA 
AT G G A C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
AAACGAAAAAATCGGCAACCTTTCCGGCGGTCAGAAAAAGCGTGTCGCCT 
T C C T
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGCAGGCTTGGGTGCAGAAGCCCGACGTATTGCTGCTGGACGAACCG 
T A C T G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
ACCAACCATTTGGATATCGACGCGATTATTTGGCTGGAAAATCTGCTCAA 
C T C T C
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
AGCGTTTGAAGGCAGCTTGGTTGTGATTACCCACGACCGCCGTTTTTTGG 
G C C T
4 0 1  4 1 0  4 2 0  4 3 0
ACAATATCGCCACGCGGATTGTCGAACTCGATC 
T C  T C C T  T C
XL VIII
adk
13 alleles, 26 polymorphic sites
1 10 20  30  40 50
GAAGCGAAAAAAATCATTGACGAAGGCGGCTTGGTGCGCGACGACATCAT
T
51  60 70  80  90 1 0 0
TATCGGCATGGTCAAAGAACGCATCGCGCAAGACGACTGCAAAAACGGTT
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
TCCTGTTCGACGGTTTCCCGCGCACATTGGCACAAGCCGAAGCGATGGTT 
T T GC G
1 5 1  1 6 0  1 7 0  1 8 0  190  2 0 0
GAAGCAGGCGTGGATTTGGATGCAGTCGTTGAAATCGACGTGCCTGACAG
T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGTGATTGTCGACCGTATGAGCGGCCGCCGCGTGCATTTGGCTTCCGGCC 
T C
251 260 270 280 290 300
GTACTTACCACGTTACCTACAACCCGCCCAAAGTTGAAGGCAAAGACGAC
T G C T
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GTAACCGGCGAAGATTTGATTCAGCGCGACGACGACAAAGAAGAAACCGT 
A C
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
GAAAAAACGCCTTGCCGTTTACCACGAGCAAACCGAAGTTTTGGTCGATT
G GC T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
TTTACAGCAAACTGGAAGGCGAACACGCGCCTAAATATATCAAAGTTGAC 
G G C
4 5 1  4 6 0
GGCACTCAGCCGGTA 
C AG A
XLIX
aroE
17 alleles, 123 polymorphic sites
1 10 20  30  40  50
TATCGGTTTGGCCAACGACATCACGCAGGTCAAAAACATTGCCATCGAAG 
T G AT GG T AGT A GC C T CA AA T G
T
51  60 70  80  90 1 0 0GCAAAACCATCTTGCTTTTGGGCGCGGGCGGCGCGGTGCGCGGCGTGATT 
AT TC AT GC C A T A
1 0 1  1 1 0  1 2 0  1 3 0  140  150
CCTGTTTTGAAAGAACACCGTCCTGCCCGTATCGTCATTGCCAACCGCAC 
G G C  G T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCACGCCAAAGCCGAAGAATTGGCGCGGCTTTTCGGCATTGAAGCCGTCC 
GT G T A
201 210 220 230 240 250
CGATGGCGGATGTGAACGGCGGTTTTGATATCATCATCAACGGCACGTCC 
CT A A G
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
GGCGGCTTGAGCGGTCAGCTTCCTGCCGTCAGTCCTGAAATTTTCCTCGG 
TC A A A G ATA TCAG GC T T GAAA
C CC A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
CTGCCGCCTTGCCTACGATATGGTTTACGGCGACGCGGCGCAGGAGTTTT 
GCG G A TGA AA ACC
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
TGAACTTTGCCCAAAGCAACGGTGCGGCCGAAGTTTCAGACGGACTGGGT 
AG T A GGCAATCG C AAAA ACCG C G C
C
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
ATGCTGGTCGGTCAAGCGGCGGCTTCCTACGCCCTCTGGCGCGGATTTAC 
A G T C C CATA T G
4 5 1  4 6 0  4 7 0  4 8 0  4 9 0
GCCCGATATCCGCCCTGTTATCGAATACATGAAAGCCATG 
TA CA C A
L
fumC
17 alleles, 37 polymorphic sites
1 10 20  30  40 50
GAAGCCTTGGGCGGACGCGATGCCGCCGTTGCCGCTTCGGGCGCATTGAA 
AC A T C
51  60 70 80 90 1 0 0
AACGCTGGCGGCAAGCCTGAATAAAATCGCCAACGACATCCGCTGGCTGG 
AT C T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CAAGCGGCCCGCGCTGCGGTTTGGGCGAAATCAAAATCCCCGAAAACGAG 
T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCGGGTTCGTCCATCATGCCGGGCAAAGTCAACCCGACCCAATGCGAAGC
T T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
GATGACCATGGTGTGCTGCCAAGTGTTCGGCAACGACGTTACCATCGGTA 
A G T  C
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGGGCGCGTCGGGCAATTTCGAGCTGAACGTCTATATGCCCGTCATC 
A A T
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCTACAACCTCTTGCAATCCATCCGCCTGTTGGGCGACGCGTGCAACAG 
T AT C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CTTCAACGAACACTGCGCCGTCGGCATTGAACCCGTACCGGAAAAAATCG
A C  G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
ACTATTTCCTGCACCATTCCCTGATGCTCGTTACCGCGTTAAACCGCAAA
G T AC G T
4 5 1  4 6 0
ATCGGTTACGAAAAC
C
LI
gdh
16 alleles, 34 polymorphic sites
1 10 20  30  40 50
ATGTTCGAGCCGCTGTGGAACAATAAATACATCGAAAGCGTGCAGTTGAC 
T T C
51 60 70  80  90 100CATCGCCGAACAGCTCGGTGTGGAAGAGCGCGGCGAGTTTTACGACATTA 
G T G C A T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150CTGGCGCCTTGCGCGATATGGTGCAAAACCACTTGATGCAAATGCTGTGC 
C G  T T  G T T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
ATGACTGCGATGGAAGCCCCCGCCAGCTTGGATGCCGACGCGGTGCGCGA
A TT A T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGAAAAAGTCAAAGTCATCAAGTCATTGAAGCCGCTGACCGTCGAGTCTG
A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TCAATGAAAACGTCGTGCGCGGACAATATACCGCCGCCAGAGGCATGAAC 
T A G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GGCTATCTTGAAGAAATCAACGTTCCGCAAGACAGCTTTACCGAAACCTA
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CGTCGCCATTAAAGCCGAAATCGAAAACGAACGCTGGAAGGGCGTTCCCT
T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
TCTACCTGCGTACCGGCAAACGCATGGCGGGCAAAGTGGCGGAAATCGTT
G T A T
4 5 1  4 6 0  4 7 0  4 8 0  4 9 0  5 0 0
TTGAACTTCAAAGATTTGAACAGCCATATTTTTGAAGGCAGCCGCACCGC
A T
5 0 1
G
LII
pdhC
16 alleles, 75 polymorphic sites
1 10 20  30 40 50ATGCCCGAAGGTGCGGAACAAGACATCTTGAAAGGTATGTACCTGCTGAA 
G O A  C C T
51 60 70  80  90 1 0 0
AGCCGGCGGCAAAGGCGACAAGAAAGTCCAACTGATGGGTTCCGGTACGA
T T T C C
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
TTTTGCAAGAAGTGATTGCCGGTGCCGAGCTGCTGT^ AAGCCGACTTCGGC 
CC C A AT T
T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GTGGAAGCAGACATTTGGTCTTGCCCATCTTTCAACCTGTTGCATCGCGA 
T A  C G C C C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGCTATCGAAGCAGAACGTTTCAACCGCCTGAATCCTTTGGAAACTGCAA 
C CG GATC C C GO A G C A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  300
AAGTACCGTTTGTTACTTCTCAACTGCAAGGTCATGACGGCCCGGTGATT 
G T C  C C A T  T A T C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCGCTACCGACTATATCCGTAGCTATGCTGACCGCATCCGTGCCTACAT 
C C C T C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
CCCTAACGACTACCACGTCTTGGGTACTGACGGCTTCGGCCGCTCCGACA 
G T C T T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
GCCGTGCCAACCTGCGTAGCTTCTTCGAAGTTGACCGCTACAACGTTGCC 
T C CC T G T
4 5 1  4 6 0  4 7 0  4 8 0
GTTGCTGCATTGAGCGCATTGGCCGATCAA 
G A GC G A
A C
LIII
pgm
14 alleles, 68 polymorphic sites
1 10 20  30 40 50GTGGTTACCAAAGACGGCAACATTATTTATCCCGACCGCCAACTGATGCT 
A C  C C G  T A  AT
A
51 60 70 80  90 100GTTCGCCCAAGACGTTTTGAACCGCAATCCCGGCGCGAAAGTCATTTTCG 
T G G A G  C TAAA A G C
C A
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
ACGTGAAGTCCACCCGCCTGCTTGCGCCTTGGATTAAAGAACACGGCGGC 
T C A  T G A T G  C
C
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0AAAGCCATAATGGAAAAAACCGGCCACAGCTTTATCAAATCCGCCATGAA 
G C TG G C GA
T
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0AGAAACCGGCGCGCCGGTTGCCGGCGAAATGAGCGGACACATCTTCTTCA 
A A TC C
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGAACGCTGGTTCGGCTTCGACGACGGTCTGTACGCCGGCGCACGCCTC
A A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
TTGGAAATCCTGTCTGCCTCCGATAATCCGTCCGAAGTGTTAAACAACCT 
C G
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
GCCGCAAAGCATTTCCACGCCCGAACTCAACATCGCCCTGCCCGAAGGCA 
A T G T A G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCAACGGCCATCAGGTTATCGACGAACTCGCCGCCAAAGCCGAATTTGAA 
CA A G TA A G G T T A G C
LIV
Figure 6.7 Polymorphic sites associated with each allelic variant within each 
housekeeping gene from meningococci isolated in 2002 (year 4). Each 
housekeeping gene is represented by its abbreviated initials followed by the total 
number of different alleles characterised followed by the number of polymorphic 
sites. These are displayed within the nucleotide sequence following this information. 
A consensus sequence is displayed for each housekeeping gene and if a variation 
within the sequence is identified the alternative base pair is displayed directly below 
the consensus nucleotide sequence base pair.
abcZ
17 alleles, 74 polymorphic sites
1 10  20  30  40 50
TTTGATACCGTTGCCGAAGGTTTGGGTGAAATTCGCGATTTATTGCGCCG 
T A CA G T A
51 60 70 80 90 1 0 0
TTACCACCGCGTCGGCCATGAGTTGGAAAACGGTTCGGGTGAGGCTTTGT 
T T AT TA T T GC TAA AAAC CATC A
101 110 120 1 3 0 140 150TGAAAGAACTCAACGAATTACAACTTGAAATCGAAGCGAAGGACGGCTGG
A T
1 5 1 16 0 1 7 0
C CG
1 8 0 1 9 0 200
AAGCTGGATGCGGCAGTCAAGCAGACTTTGGGGGAACTCGGTTTGCCGGA
AT
201 210
G
220
A
2 3 0 2 4 0 2 5 0
AAACGAAAAAATCGGCAACCTTTCCGGCGGTCAGAAAAAGCGTGTCGCCT
C
2 5 1 2 6 0 270 280 290 300
TGGCGCAGGCTTGGGTGCAGAAGCCCGACGTATTGCTGCTGGACGAACCG
A C T
301 3 1 0 3 2 0 3 3 0 3 4 0 350
ACCAACCATTTGGATATCGACGCGATTATTTGGCTGGAAAATCTGCTCAA
T C C
351 360 370 3 8 0 390 4 0 0
AGCGTTTGAAGGCAGCTTGGTTGTGATTACCCACGACCGCCGTTTTTTGG 
G C C A  T C
4 0 1  4 1 0  4 2 0  4 3 0
ACAATATCGCCACGCGGATTGTCGAACTCGATC 
T T T A C C T  T C
LV
adk
10 alleles, 32 polymorphic sites
1 10 20  30  40 50
GAAGCGAAA7y\AATCATTGACGAAGGCGGCTTGGTGCGCGACGACATCAT
C T
51 60 70 80 90 100
TATCGGCATGGTCAAAGAACGCATCGCGCAAGACGACTGCAAAAACGGTT 
T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
TCCTGTTCGACGGTTTCCGGCGCACATTGGCACAAGCCGAAGCGATGGTT 
T T GC G
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GAAGCAGGCGTGGATTTGGATGCAGTCGTTGAAATCGACGTGCCTGACAG 
C T  C G C  T A C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
CGTGATTGTCGACCGTATGAGCGGCCGCCGCGTGCATTTGGCTTCCGGCC 
A T A  
C
251 260 270 280 290 300
GTACTTACCACGTTACCTACAACCCGCCCAAAGTTGAAGGCAAAGACGAC
T C T
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GTAACCGGCGAAGATTTGATTCAGCGCGACGACGACAAAGAAGAAACCGT 
A
3 5 1  3 6 0  3 7 0  3 8 0  390 400
GAAAAAACGCCTTGCCGTTTACCACGAGCAAACCGAAGTTTTGGTCGATT
GC T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  450
TTTACAGCAAACTGGAAGGCGAACACGCGCCTAAATACATCAAAGTTGAC 
G
4 5 1  4 6 0
GGCACTCAGCCGGTA 
C AG A
LVI
aroE
20 alleles, 128 polymorphic sites
1 10 20 30 40 50TATCGGTTTGGCCAACGACATCACGCAGGTCAAAAACATTGCCATCGAAG
T G AT GG T AGT A GCT
C T CA AA T
51 60 70  80 90 1 0 0
GCAAAACCATCTTGCTTTTGGGCGCGGGCGGCGCGGTGCGCGGCGTGATT 
AT TC AT GC C A T
101 110 120 1 30 1 4 0
G A G
1 5 1 1 6 0 1 7 0 180 190
GT A
150
CCTGTTTTGAAAGAACACCGTCCTGCCCGTATCGTCATTGCCAACCGCAC
200
CCACGCCAAAGCCGAAGAATTGGCGCGGCTTTTCGGCATTGAAGCCGTCC
201 210 220 2 3 0 2 4 0
CT A
2 5 0
CGATGGCGGATGTGAACGGCGGTTTTGATATCATCATCAACGGCACGTCC
A
2 5 1 2 6 0 2 7 0 2 8 0 2 9 0
A TC A A A G ATA TCAG GC 
C CC
3 0 0
GGCGGCTTGAGCGGTCAGCTTCCTGCCGTCAGTCCTGAAATTTTCCTCGG
T G AAA 
A
3 0 1 310 320 3 3 0 3 4 0
GCG
3 5 1 360 370
A TGA
3 8 0
AA ACC
3 9 0
AG T A GGCAATCG AAAA
C
ACCG C C
350
CTGCCGCCTTGCCTACGATATGGTTTACGGCGACGCGGCGCAGGAGTTTT
400
TGAACTTTGCCCAAAGCAACGGTGCGGCCGAAGTTTCAGACGGACTGGGT
C
4 0 1 410
A
4 2 0 4 3 0 440
T C C CATA T
450
ATGCTGGTCGGTCAAGCGGCGGCTTCCTACGCCCTCTGGCGCGGATTTAC
4 5 1 460
TA
4 7 0 4 8 0 490
GCCCGATATCCGCCCTGTTATCGAATACATGAAAGCCATG
CA C A
LVII
ftimC
17 alleles, 46 polymorphic sites
1 10 20  30  40  50
GAAGCCTTGGGCGGACGCGATGCCGCCGTTGCCGCTTCGGGCGCATTGAA 
AC A T A  C
51  60 70  80 90 1 0 0
AACGCTGGCGGCAAGCCTGAATAAAATCGCCAACGACATCCGCTGGCTGG 
AT C T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CAAGCGGCCCGCGCTGCGGTTTGGGCGAAATCAAAATCCCCGAAAACGAG 
T T T A
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
CCGGGTTCGTCCATCATGCCGGGCAAAGTCAACCCGACCCAATGCGAAGC 
T T A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
GATGACCATGGTGTGCTGCCAAGTGTTCGGCAACGACGTTACCATCGGCA 
A G T  A T
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TGGCGGGCGCGTCGGGCAATTTCGAGCTGAACGTCTATATGCCCGTTATC 
A A C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCTACAACCTCTTGCAATCCATCCGCCTGTTGGGCGACGCGTGCAACAG 
T C G AT C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
CTTCAACGAACACTGCGCCGTCGGCATCGAACCCGTACCGGAAAAAATCG 
A AC T T G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
ACTATTTCCTGCACCATTCCCTGATGCTGGTTACTGCGTTAAACCGTAAA
C C AC G C
4 5 1  4 6 0
ATCGGCTACGAAAAC
T
Lvin
gdh
16 alleles, 36 polymorphic sites
1 10 20  30 40 50
ATGTTCGAGCCGCTTTGGAACAATAAATACATCGAAAGCGTGCAGCTGAC 
G T A T
51  60 70  80 90 1 0 0
CATCGCCGAGCAGTTGGGCGTGGAAGAACGCGGCGAGTTTTACGACATTA 
A C C T G T T
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
CCGGCGCGTTGCGCGATATGGTGCAAAACCACTTGATGCAAATGCTGTGC 
T C  T T  G T T T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
ATGACTGCGATGGAAGCCTCCGCCAGCTTGGATGCCGACGCGGTGCGCGA
AC TT A
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGAAAAAGTCAAAGTCATCAAGTCATTGAAGCCGCTGACCGTCGAATCTG
G G
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
TCAATGAAAATGTCGTGCGCGGACAATATACCGCCGCCAAAGGCATGAAC 
C G
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  350
GGCTATCTTGAAGAAATCAACGTTCCGCAAGACAGCTTTACCGAAACCTA
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
CGTCGCCATTAAAGCCGAAATCGAAAACGAACGCTGGAAGGGCGTTCCCT
T
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
TCTACCTGCGTACCGGCAAGCGCATGGCGGGCAAAGTGGCGGAAATCGTT
A T  A T
4 5 1  4 6 0  4 7 0  4 8 0  4 9 0  500
TTGAACTTCAAAGATTTGAACAGCCATATTTTTGAAGGCAGTCGCACCGC
A C G
501
G
LIX
pd/tC
16 alleles, 77 polymorphic sites
1 10 20  30 40 50
ATGCCCGAAGGTGCGGAACAAGACATCTTGAAAGGTATGTACCTGCTGAA 
G C TA C C TT
T
51 60 70 80  90 1 0 0
AGCCGGCGGCAAAGGCGACAAGAAAGTCCAACTGATGGGTTCCGGTACGA
T T T C  C
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  150
TTTTGCAAGAAGTGATTGCCGGTGCCGAGCTGCTGAAAGCCGACTTCGGC 
CC C A AT T
T
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
GTGGAAGCAGACATTTGGTCTTGCCCATCTTTCAACCTGTTGCATCGCGA 
T A  C G C C C
2 0 1  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0
TGCTATCGAAGCAGAACGTTTCAACCGCCTGAATCCTTTGGAAACTGCAA 
C CG GATC C C GC A G C A
2 5 1  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
AAGTACCGTTTGTTACTTCTCAACTGCAAGGTCATGACGGCCCGGTGATT 
G T C  C C A T  T A T C
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
GCCGCTACCGACTATATCCGTAGCTATGCTGACCGCATCCGTGCCTACAT 
C C C T C T
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  400
CCCTAACGACTACCACGTCTTGGGTACTGACGGCTTCGGCCGCTCCGACA
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCCGTGCCAACCTGCGTAGCTTCTTCGAAGTTGACCGCTACAACGTTGCC 
T C CC T G T
4 5 1  4 6 0  4 7 0  4 8 0
GTTGCTGCATTGAGCGCATTGGCCGATCAA 
G A GC G A
A C
LX
pgm
'■71 
!  
V
15 alleles, 64 polymorphic sites
■f
1 10 20  30  40 50GTGGTTACCAAAGACGGCAACATTATTTATCCCGACCGCCAACTGATGCT 
A C  C C G  T A T
A
51  60 70  80 90 1 0 0
GTTCGCCCAAGACGTTTTGAACCGCAATCCCGGCGCGAAAGTCATTTTCG 
T G G A G  C TAAA A G C
C A
1 0 1  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
ACGTGAAGTCCACCCGCCTGCTTGCGCCTTGGATTAAAGAACACGGCGGC 
T C A  T GA C G C
1 5 1  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0
AAAGCCATAATGGAAAAAACCGGCCACAGCTTTATCAAATCCGCCATGAA 
G C TG G C GA
T
201 210 220 230 240 250
AGAAACCGGCGCGCCGGTTGCCGGCGAAATGAGCGGACACATCTTCTTCA 
A A TC C
. '
251 260 270 280 290 300
AAGAACGCTGGTTCGGCTTCGACGACGGTCTGTACGCCGGCGCACGCCTC
A A
3 0 1  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0
TTGGAAATCCTGTCTGCCTCCGATAATCCGTCCGAAGTGTTAAACAACCT
C
3 5 1  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0
GCCGCAAAGCATTTCCACGCCCGAACTCAACATCGCCCTGCCCGAAGGCA
T G T A  G
4 0 1  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0
GCAACGGCCATCAGGTTATCAACGAACTCGCCGCCAAAGCCGAATTTGAA 
CA A G TG A G G T T AG
LXI
Figure 6.8 Genbank nucleotide submission of a Neisseria meningitidis 
shikimate dehydrogenase {aroE) gene allele 225,
LOCUS
20-AÜG-2003
DEFINITION
partial
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AY348556 4 90 bp DNA linear BCT
Neisseria meningitidis AroE (aroE) gene, aroE-225 allele.
cds.
AY348556
AY348556.1 GI:33694224
Neisseria meningitidis 
Neisseria meningitidis 
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria.
REFERENCE 1 (bases 1 to 4 90)
AUTHORS Lawie,D.I., Diggle,M.A. and Clarke,S.C.
TITLE Neisseria meningitidis aroE allele 225
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 4 90)
AUTHORS Lawie,D.I., Diggle,M.A. and Clarke,S.C.
TITLE Direct Submission
JOURNAL Submitted (23-JUL-2003) SMPRL, Stobhill Hospital, 
Balornock Road,
Glasgow, Lanarkshire G21 3UW, Scotland 
FEATURES Location/Qualifiers
source 1..4 90
/organism^"Neisseria meningitidis"
/mol_type="genomic DNA"
/db_xref="taxon:4 87"
<1..>490 
/gene="aroE"
/allele="225"
<1..>490 
/gene="aroE"
/allele-"225"
/codon_start=2 
/transi table=ll 
/product= "AroE"
/protein id="AAQ24851.1"
/db xref="GI:33694225"
gene
CDS
LXII
Figure 6.9 Genbank nucleotide submission of a Neisseria meningitidis porin A
class 1 outer membrane protein variable region 3 (VR3) variant 35.
LOCUS AF4 8 94 96 90 9 bp DNA linear BCT
27-MAR-2002
DEFINITION Neisseria meningitidis strain 590-60 class 1 outer 
membrane protein
(porA) gene, partial cds.
ACCESSION AF489496
VERSION AF489496.1 GI:19744840
KEYWORDS
SOURCE Neisseria meningitidis
ORGANISM Neisseria meningitidis
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria.
REFERENCE 1 (bases 1 to 909)
AUTHORS Clarke,S.C., Diggle,M.A., Moiling,P., Unemo,M. and 
Olcen,P.
TITLE Analysis of PorA variable region 3 in meningococci has
implications
for vaccine policy 
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 909)
AUTHORS Moiling,P. and Unemo,M.
TITLE Direct Submission
JOURNAL Submitted (Ol-MAR-2002) National Reference Laboratory for
Pathogenic Neisseria, Department of Clinical
Microbiology, Orebro
University Hospital, Orebro SE-701 85, Sweden 
FEATURES Location/Qualifiers
source 1..909
/organism^"Neisseria meningitidis"
/mol_t ype="genomi c DNA"
/strain="590-60"
/db_xref="taxon: 487"
/note="genosubtype Pi.7,16-29,35 
isolated in 2001 
serogroup: C" 
gene 1..>909
/gene="porA"
CDS 1..>909
/gene="porA"
/note="porin; PorA; variable regions 1,2,3"
/codon_start=l
/transi tableau
/product="class 1 outer membrane protein"
/protein id="AAL96679.1"
/db xref="GI:19744841"
LXIII
Figure 6.10 Genbank nucleotide submission of a Neisseria meningitidis porin A
class 1 outer membrane protein variable region 3 (VR3) variant 37.
LOCUS AF4894 97 885 bp DNA linear BCT
27-MAR-2002
DEFINITION Neisseria meningitidis strain 90-108 class 1 outer 
membrane protein
(porA) gene, partial cds.
ACCESSION AF4 8 94 97
VERSION AF489497.I GI:19744842
KEYWORDS
SOURCE Neisseria meningitidis
ORGANISM Neisseria meningitidis
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria.
REFERENCE 1 (bases 1 to 885)
AUTHORS Clarke,S.C., Diggle,M.A., Moiling,P., Unemo,M. and 
Olcen,P.
TITLE Analysis of PorA variable region 3 in meningococci has
implications
for vaccine policy 
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 885)
AUTHORS Moiling,P. and Unemo,M.
TITLE Direct Submission
JOURNAL Submitted (Ol-MAR-2002) National Reference Laboratory for
Pathogenic Neisseria, Department of Clinical
Microbiology, Orebro
University Hospital, Orebro SE-701 85, Sweden 
FEATURES Location/Qualifiers
source 1.,885
/organism="Neisseria meningitidis"
/mol type="genomic DNA"
/strain^"90-108"
/db_xref="taxon: 487"
/note="genosubtype Pi.7-2,4,37 ; former
PI.7b,4,37
isolated in 1997 
serogroup: B" 
gene 1..>885
/gene="porA"
CDS 1..>885
/gene="porA"
/note="porin; PorA; variable regions 1,2,3"
/codon_start=l
/transi table=ll
/product^"class 1 outer membrane protein" 
/protein_id="AAL9668 0 .1"
/db xref="GI:19744843"
LXIV
Figure 6.11 Genbank nucleotide submission of a Neisseria meningitidis porin A
class 1 outer membrane protein variable region 3 (VR3) variant 39.
LOCUS AF481699 4 93 bp DNA linear BCT
21-MAR-2002
DEFINITION Neisseria meningitidis strain 00-1008 outer membrane 
porin (porA)
gene, partial cds.
ACCESSION AF481699
VERSION AF481699.I GI:19568837
KEYWORDS
SOURCE Neisseria meningitidis
ORGANISM Neisseria meningitidis
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria,
REFERENCE 1 (bases 1 to 4 93)
AUTHORS Clarke,S.C., Diggle,M.A. and Edwards,G,F.S.
TITLE Semiautomation of multilocus sequence typing for the
characterization of clinical isolates of Neisseria
meningitidis
JOURNAL J. Clin. Microbiol. 39 (9), 3066-3071 (2001)
MEDLINE 21417403
PUBMED 11526130
REFERENCE 2 (bases 1 to 4 93)
AUTHORS Diggle,M.A. and Clarke,S,C ,
TITLE Direct Submission
JOURNAL Submitted (05-FEB-2002) SMPRL, Stobhill Hospital, 
Balornock Road,
Glasgow G21 3UW, Scotland 
FEATURES Location/Qualifiers
source 1,.4 93
/organism="Neisseria meningitidis" 
/mol_type="genomic DNA"
/strain="00-1008"
/db_xref="taxon: 487"
/note=:"subgroup : C"
gene <1..>493
/gene="porA"
CDS <1,,>493
/gene="porA"
/codon_start=l
/transi table^^ll
/product="outer membrane porin"
/protein__id= "AAL91932 .1 "
/db xref="GI:19568838"
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Figure 6.12 Genbank nucleotide submission of a Neisseria meningitidis porin A
class 1 outer membrane protein variable region 3 (VR3) variant 40,
LOCUS AY192543 156 bp DNA linear BCT
04-FEB-2003
DEFINITION Neisseria meningitidis porin A variable region 3 variant 
4 0 gene,
partial cds.
ACCESSION AY192543
VERSION AY192543.1 01:28207736
KEYWORDS
SOURCE Neisseria meningitidis
ORGANISM Neisseria meningitidis
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria.
REFERENCE 1 (bases 1 to 156)
AUTHORS Diggle,M.A. and Clarke,S.C.
TITLE Novel porin A variable region three
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 156)
AUTHORS Diggle,M.A. and Clarke,S.C.
TITLE Direct Submission
JOURNAL Submitted (lO-DEC-2002) SMPRL, Stobhill Hospital, 
Balornock Road,
Glasgow G21 3UW, Scotland 
FEATURES Location/Qualifiers
source 1..156
/organism^"Neisseria meningitidis"
/mol_type="genomic DNA"
/db_xref="taxon: 487"
CDS <1..>156
/codon_start=l 
/transi table=ll
/product^"porin A variable region 3 variant 40" 
/protein i d = " A A 0 3 1 9 7 8 . 1 "
/db xref="GI:28207737"
LXVI
Figure 6.13 Genbank nucleotide submission of a Neisseria meningitidis porin A
class 1 outer membrane protein variable region 3 (VR3) variant 41.
LOCUS AY192542 150 bp DNA linear BCT
04-FEB-2003
DEFINITION Neisseria meningitidis porin A variable region 3 variant 
41 gene,
partial cds.
ACCESSION AYI92542
VERSION AYI92542.1 GI:28207734
KEYWORDS
SOURCE Neisseria meningitidis
ORGANISM Neisseria meningitidis
Bacteria; Proteobacteria; Betaproteobacteria; 
Neisseriales;
Neisseriaceae; Neisseria.
REFERENCE 1 (bases 1 to 150)
AUTHORS Diggle,M.A. and Clarke,S.C.
TITLE Novel porin A variable region three
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 150)
AUTHORS Diggle,M.A. and Clarke,S.C.
TITLE Direct Submission
JOURNAL Submitted (lO-DEC-2002) SMPRL, Stobhill Hospital, 
Balornock Road,
Glasgow G21 3UW, Scotland 
FEATURES Location/Qualifiers
source 1. .150
/organism^"Neisseria meningitidis" 
/mol_type="genomic DNA"
/db__xref="taxon: 487 "
CDS <1..>150
/codon_start=l 
/transi tableau
/product="porin A variable region 3 variant 41" 
/protein i d = " A A 0 3 1 9 7 7 . 1 "
/db xref="GI:28207735"
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